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Abstract 
 
TBX3 is a transcriptional regulator involved in embryonic development and in 
tumorigenesis of several cancer types. There are two isoforms of TBX3 (TBX3iso1 and 
TBX3iso2) with different DNA binding domains. The large-scale functional roles of TBX3iso1 
and TBX3iso2 were characterized in a breast cancer context. Both TBX3 isoforms induced 
invasiveness and an epithelial-to-mesenchymal (EMT) phenotype. Coupling data from 
genome-wide ChIP-array and RNA-Seq studies provided a novel list of genes regulated by 
each isoform. Both TBX3 isoforms regulate expression of several EMT-related genes, 
including SLUG and TWIST1. Importantly, TBX3 is a direct regulator of SLUG, and SLUG 
expression is required for TBX3-induced migration and invasion. 
Assessing TBX3 expression in early stage breast cancers by immunohistochemistry 
(IHC) revealed high expression in low-grade lesions. Within a second non-high-grade cohort, 
there was an association between TBX3 expression in the pre-invasive ductal carcinoma in 
situ (DCIS) and size of the invasive focus. Additionally, there was a positive correlation 
between TBX3/SLUG, and TBX3/TWIST1 expression by IHC in the invasive carcinoma. 
Pathway analysis of transcriptomics data revealed altered expression of several proteases 
and their inhibitors, consistent with the ability of tumor cells to degrade basement membrane. 
These findings strongly suggest the involvement of TBX3 in the promotion of invasiveness 
and progression of early stage pre-invasive DCIS to invasive carcinoma through the low-
grade molecular pathway. 
Interestingly, only TBX3iso1 overexpressing cells exhibited increased tumorigenic 
potential in mouse xenograft experiments. Transcriptomics data and functional studies 
revealed that TBX3iso1 overexpression promotes angiogenesis and secretion of cancer-
associated cytokines (including osteopontin) which is able to induce tubule formation by 
endothelial cells in vitro. Tumorigenic TBX3iso1 overexpressing cells also had elevated 
hyaluronan synthase 2 (HAS2) levels and high levels of hyaluronan retention. These factors 
may contribute to the survival of cells and promote angiogenesis, allowing the formation of 
primary tumors in vivo. 
 ii 
 
In conclusion, I have found evidence for a role of TBX3iso1 and TBX3iso2 in direct 
modulation of EMT and invasiveness, and a role for TBX3iso1 in inducing angiogenesis. 
Together these, along with previous work showing anti-senescence and pro-proliferative 
activities of TBX3, suggest multiple potential activities for promotion of malignancy of breast 
cancer.  
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Chapter 1 
 
Introduction 
 1 
1 
1.1 Breast Cancer 
Recent statistics from the Canadian Cancer Society has revealed that 1 in 2 
Canadians will develop cancer in their lifetime, and 1 in 4 Canadians will die of cancer 
(Canadian Cancer Society, 2017). Leading the list of cancer prevalence for Canadian women 
is breast cancer, with 1 in 8 women expected to develop breast cancer in their lifetime 
(Canadian Cancer Society, 2017). This accounted for 10,100 diagnoses of breast cancer in 
2017, of which 1,900 succumbed to the disease (Canadian Cancer Society, 2017). While 
breast cancer incidence rates rose in the 1990s (likely due to increased opportunistic 
mammography screenings), mortality rates have been declining at a rate of approximately 
2.3% per year between 1992 and 2012 (Canadian Cancer Society, 2017). This decline is 
likely due to a combination of screening mammograms and more effective adjuvant systemic 
therapies (Canadian Cancer Society, 2017). Similar reductions in mortality rates have been 
observed in the United States, United Kingdom, and Australia (Bray et al., 2004). 
The current public health strategy for breast cancer is one of early detection; at this 
early stage, treatment generally has a high success rate compared to metastatic diagnosis. 
In addition to surgical management, treatment for patients with early-stage breast cancer can 
include systemic therapy, such as chemotherapy (i.e. taxanes, anthracyclines) and/or 
hormone therapy (i.e. tamoxifen, aromatase inhibitors), which are tailored to the 
characteristics of the tumour (Esteva and Hortobagyi, 2004). Once the cancer has spread to 
distant organs, however, survival is greatly reduced.  
Molecular profiling of breast cancers has revealed the presence of distinct breast 
cancer subtypes with different clinical outcomes, including luminal A, luminal B, basal-like 
and human epidermal growth factor receptor 2 (HER2)-enriched (Perou et al., 2000). In 
general, age-standardized survival rates for breast cancers are 97% (1-year), 91% (3-year), 
86% (5-year) and 82% (10-year) for the specified number of years post-diagnosis (Canadian 
Cancer Society, 2017), although basal-like and HER2-enriched breast cancers are 
associated with lower survival rates (Sørlie et al., 2001).  Additional prognostic factors that 
may help predict patient outcome include tumor size, lymph node status, and nuclear and 
histologic grade of the tumor (Esteva and Hortobagyi, 2004).  
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 Histopathology of breast cancer progression 
 
Figure 1.1.1 – Histology of normal breast epithelium.  
Obtained from breast histology slides in The Human Protein Atlas, available at 
www.proteinatlas.org/learn/dictionary/normal/breast 
Normal breast histology (depicted in Figure 1.1.1) must be appreciated in order to 
diagnose pathological conditions. Histologically, the breast is made up of several ductal-
lobular structures. The lactiferous duct is located beneath the nipple, and branches out into 
several progressively smaller ductal structures, eventually terminating at the terminal 
ductules and lobules (Mills, 2007). The epithelium within these ductal-lobular structures 
consists of two distinct cell layers. The inner (luminal) layer is composed of cuboidal to 
columnar epithelial cells, with an outer (basal) layer composed of flattened myoepithelial cells 
(Mills, 2007). The terminal ducts and their corresponding lobules are collectively referred to 
as the terminal duct lobular unit (TDLU), and represents the structural and functional unit of 
the breast (Mills, 2007). A layer of type IV collagen and laminin surrounds the ductal-lobular 
structures, separating them from the surrounding stroma (Mills, 2007). The stroma 
immediately adjacent to the mammary glands is composed of loose fibrovascular tissue, with 
dense interlobular stroma composed of collagen, fibroblasts, and adipose tissue surrounding 
the aforementioned structures (Mills, 2007). 
Most breast pathologies, including atypical ductal hyperplasia (ADH), ductal 
carcinoma in situ (DCIS), and invasive breast carcinoma, originate in the TDLUs (Mills, 2007). 
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The two most common histological subtypes of invasive breast cancer include infiltrating 
ductal carcinoma (IDC) and infiltrating lobular carcinoma (ILC). While both arise from the 
TDLUs, they present quite different histologically (Wellings and Jensen, 1973, Wellings et 
al., 1975). A majority of breast cancers have the morphology of ductal epithelial cells (DCIS, 
IDC), representing approximately 80% of diagnoses (Kumar et al., 2013). Lobular 
morphologies, including atypical lobular hyperplasia (ALH), lobular carcinoma in situ (LCIS), 
and invasive lobular carcinoma (ILC), are less common than their ductal counterparts (Kumar 
et al., 2013). The more common pathways, related to IDC, are discussed below. 
The IDC breast cancer progression model is often simplified into a series of phenotypic 
histological stages, beginning with benign epithelial cells and sometimes transitioning to 
columnar cell lesions including flat epithelial atypia (FEA), atypical ductal hyperplasia (ADH), 
ductal carcinoma in situ (DCIS), and ultimately invasive and metastatic breast carcinoma 
(Burstein et al., 2004, Bombonati and Sgroi, 2011). FEA, ADH and DCIS are considered to 
be non-obligate precursors for the development of invasive breast cancer, meaning that not 
all cases exhibiting the aforementioned precursor lesions will progress to invasive carcinoma 
(Bombonati and Sgroi, 2011). Epidemiological, histological, immunohistochemical, loss of 
heterozygosity (LOH), comparative genomic hybridization (CGH), and later high-throughput 
mutational studies have shed light on the intricacies of this process, and highlighted the 
presence of divergent low-grade and high-grade pathways (Thorat et al., 2007, Formenti et 
al., 2011, Bombonati and Sgroi, 2011, Sagara et al., 2015).  
Low-grade (LG) breast lesions usually contain near-diploid chromosomal content, with 
frequent loss of 16q and gain of 1q (Bombonati and Sgroi, 2011). High-grade (HG) breast 
lesions are typically aneuploid and associated with a collection of more complex mutational 
alterations including recurrent loss of 8p, 11q, 13q, 1p and 18q, and recurrent gain of 8q, 
17q, 20q and 16p (Buerger et al., 1999, Roylance et al., 1999, Bombonati and Sgroi, 2011). 
Intermediate grade (IG) breast lesions possess a combination of LG and HG genetic 
alterations (Buerger et al., 2001). When loss of 16q is observed in HG lesions, the remaining 
underlying genetic alterations are distinct; while LG lesions demonstrate physical loss of 16q, 
HG lesions are missing small regions of 16q and undergo mitotic recombination, leading to 
shuffling of these genetic components (Cleton-Jansen et al., 2004, Abdel-Fatah et al., 2008). 
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These findings suggest that high-grade breast cancers (basal-like and HER2-enriched) do 
not arise from low-grade breast cancers (Bombonati and Sgroi, 2011). 
Immunohistochemical studies of FEA, ADH and LG DCIS has revealed high 
expression levels of estrogen receptor (ER) and progesterone receptor (PR), along with lack 
of HER2 expression (Buerger et al., 2001). Additionally, these precursor lesions frequently 
express high levels of the proliferation marker Ki67, luminal cytokeratins CK8/18/19, B-cell 
lymphoma 2 (Bcl2), cyclin D1, and are negative for basal cytokeratins CK5/6 (Schnitt, 2003, 
Abdel-Fatah et al., 2008, Ahmad, 2013). Genetic analysis of FEA, ADH and LG DCIS has 
revealed comparable loss of 16q, which is an early hallmark genetic change in LG lesions; 
the degree of genomic instability, however, increases with further progression (O'Connell et 
al., 1998, Moinfar et al., 2000, Simpson et al., 2005, Larson et al., 2006, Gao et al., 2009). 
Genes which may function as tumor suppressors that are subsequently lost with 16q 
deletions have been assessed, and include E-cadherin (CDH1) and CCCTC-binding factor 
(CTCF), with reduced expression reported in LG lesions, as assayed by PCR and 
immunohistochemistry (Bürger et al., 2013). The detailed breast cancer progression 
pathways of the LG and HG molecular pathways is depicted in Figure 1.1.2. 
 
Figure 1.1.2 – Detailed breast cancer progression pathway of LG and HG breast cancers. 
Adapted from Bombonati & Sgroi, 2011. 
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 Columnar cell lesions (CCLs) 
 
Figure 1.1.3 – Columnar cell lesions (CCLs) of the breast. 
Columnar cell change (CCC), columnar cell hyperplasia (CCH), and flat epithelial atypia 
(FEA) of the breast (left to right). 
Columnar cell lesions (CCLs) are among the most common abnormalities observed 
in breast biopsies (Turashvili et al., 2008). CCLs are generally divided into columnar cell 
change (CCC) and columnar cell hyperplasia (CCH), consisting of one or several layers of 
pseudostratified ductal epithelial cells, respectively, which have taken on a columnar 
phenotype (depicted in Figure 1.1.3) (Dabbs et al., 2006). CCLs present with frequent 
exaggerated apical blebs or snouts, often resulting in intraluminal secretions that can calcify, 
and are thus often detected as abnormalities on mammographic screening (Lerwill, 2008). 
CCC and CCH with the aforementioned histological patterns can be further subdivided, 
depending on the presence or absence of atypia (Turashvili et al., 2008, Go et al., 2012). 
Genetic analysis of CCLs without atypia has revealed infrequent mutations relative to 
the background of normal ductal epithelial cells (Dabbs et al., 2006), although more recently, 
phosphatidylinositol-3-kinase catalytic subunit alpha (PIK3CA) mutations have been 
documented in CCLs with or without atypia (Troxell et al., 2012). The atypical CCL variant 
FEA is often considered to be the earliest neoplastic lesion within the breast (Dabbs et al., 
2006, Turashvili et al., 2008). FEA lesions show slightly enlarged columnar epithelial cells, 
frequently consisting of several layers, and low-grade cytologic atypia (Turashvili et al., 
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2008). Interestingly, CCLs with HG atypia tend to progress to comedo DCIS (associated with 
necrosis and higher rates of invasive recurrence), whereas FEA with LG cytologic atypia is 
thought to progress to LG DCIS (Azzopardi et al., 1979), further providing evidence for the 
divergent LG and HG progression pathways. Additionally, CCLs were reported to coexist in 
76% of LG and 10% of HG breast cancers (Abdel-Fatah et al., 2008). Coexisting CCLs, ADH 
and DCIS lesions often exhibit near identical cytological morphologies, with the differences 
typically being size and architecture-related (Go et al., 2012).  
Little is known regarding the clinical significance of the presence of CCLs and FEA in 
a biopsy. The risk of invasive recurrence for patients with FEA is unclear – some studies 
suggest that the associated risk is slightly increased relative to that of the general population, 
up to a risk similar to ADH (4-5 fold) (Schnitt, 2003, Kunju and Kleer, 2007, Martel et al., 
2007, Lerwill, 2008, Ahmad, 2013). Longitudinal studies examining rates of invasive 
recurrence revealed that 7.4% of patients with CCLs without atypia, and 18.3% of patients 
with CCLs with atypia (diagnosed as FEA) developed invasive breast cancer over a period 
of 5 years (Guerra-Wallace et al., 2004). Upon analysis of 1,000 FEA lesions, it was reported 
that 7% and 26% of cases had coexisting invasive carcinoma and lobular neoplasia, 
respectively (Bratthauer and Tavassoli, 2004). The presence of FEA in a biopsy should 
therefore prompt for potential identification of coexisting precursor lesions and invasive 
carcinoma (Lerwill, 2008). Although these studies demonstrate that the risk of progression to 
invasive carcinoma after FEA diagnosis by biopsy is higher than the general population, the 
relative risk of invasive recurrence is quite low. Clinical management of patients with FEA on 
biopsy usually consists of close follow-up with repeat mammograms to detect cases of occult 
carcinoma within the vicinity that were missed by biopsy (Turashvili et al., 2008), or surgical 
excision if there is any residual abnormality (i.e. indeterminate calcifications) (Calhoun et al., 
2015). Larger studies with extended follow-up times are required for critical evaluation of 
long-term risk of progression to invasive cancer for these patients, as well as time course for 
progression (Lerwill, 2008). A more thorough understanding of clinicopathologic 
characteristics would allow for optimal management of patients with CCL lesions, including 
the FEA variant. 
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 Atypical ductal hyperplasia (ADH) 
  
Figure 1.1.4 – Atypical ductal hyperplasia (ADH) of the breast. 
Normal breast ductal epithelial cells are lined by two layers of cells consisting of a 
luminal and myoepithelial cell layer (Kumar et al., 2013). The presence of hyperplasia 
signifies an excess of two layers of epithelial cells, and can range from mild to florid ductal 
epithelial hyperplasia without atypia, to atypical ductal hyperplasia (ADH) (Kumar et al., 
2013). The pattern observed in ADH is consistent with the presence of two different cell 
populations: a low-grade neoplastic cell population and a benign ductal epithelial cell 
population, observed within the same duct cross-section (Kumar et al., 2013). The non-
neoplastic cell population contains cells showing random placement and streaming patterns, 
with nuclei of varying shape and size (Pinder and Ellis, 2003). Conversely, the atypical (LG 
neoplastic) cells contain enlarged, hyperchromatic nuclei, with uniformity in shape and size 
and even cell placement, suggestive of a clonal population (Pinder and Ellis, 2003).  
The atypical cells are often arranged in various architectural patterns, including solid, 
cribriform, papillary or micropapillary (Kader et al., 2018). Cribriform pattern ADH is shown in 
Figure 1.1.4. 
ADH is frequently described as having some but not all features of DCIS (Fitzgibbons 
et al., 1998). ADH and DCIS are distinguished from each other by the degree of atypia and 
the extent of atypical epithelial proliferation (Tavassoli and Norris, 1990, Page and Rogers, 
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1992, Ahmad, 2013). Additionally, ADH is usually small and focal, measuring less than 2 
mm; if larger and more extensive, a diagnosis of DCIS is typically made (Pinder and Ellis, 
2003). LOH and CGH-based studies of ADH have revealed frequent loss of the 16q 
chromosomal region (Lakhani et al., 1995, O'Connell et al., 1998, Amari et al., 1999). 
Additionally, microsatellite analysis has revealed that 60% of IDC and DCIS showed 
concurrent ADH that was clonal in origin (Larson et al., 2006), with copy number alterations 
and documented at early stages of ADH (Crissman et al., 1990, Eriksson et al., 1992, 
Stomper et al., 1992, Ruiz et al., 1999, Niu et al., 2013, Kader et al., 2018).  
Marked transcriptional changes have been identified at the ADH stage relative to 
adjacent benign ductal epithelium (Ma et al., 2003), including up-regulation of several 
oncogenes such as FOXA1 and GATA3 (Brunner et al., 2014). Several studies have 
therefore proposed that alteration in expression of genes at the early stages of progression, 
including ADH and DCIS, may be critical for progression to invasive breast cancer, as 
expression of several transcripts is maintained throughout progression (van de Vijver et al., 
2002, Paik et al., 2004). In fact, transcriptional studies have shown that ADH and LG DCIS 
possess near-identical gene expression profiles (Bombonati and Sgroi, 2011).  
Epidemiological studies estimate that an ADH diagnosis is associated with a 4-5 fold 
increased risk of developing invasive breast cancer relative to the general population (Page 
et al., 1985, Page and Dupont, 1993, Fitzgibbons et al., 1998). If an immediate family member 
has previously been diagnosed with breast cancer, the risk of upgrade from an ADH 
diagnosis becomes about 10-fold (Page et al., 1985, Tavassoli and Norris, 1990, Page and 
Dupont, 1992, Pinder and Ellis, 2003). A recent study showed that approximately 20% 
(142/698) of women with ADH lesions had an upgrade in diagnosis (typically to DCIS) without 
surgical intervention (Hartmann et al., 2015). Clinical management of patients with ADH upon 
needle core biopsy thus includes surgical excision to rule out concomitant malignancy 
(Morrow et al., 2015, Rageth et al., 2016).  
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 Ductal carcinoma in situ (DCIS) 
  
 
Figure 1.1.5 – Ductal carcinoma in situ (DCIS) of the breast. 
Low-grade DCIS, intermediate-grade DCIS, and high-grade DCIS (left to right); all neoplastic 
cells of the DCIS are confined to the duct and possess an intact basement membrane. 
 
1.1.4.1 Histopathology of DCIS  
The presence of pure ductal carcinoma in situ (DCIS) is observed in approximately 
15-20% of breast biopsies, compared to 5% before the introduction of mammography 
screening (van Dongen et al., 1989, Lagios, 1990, Faverly et al., 1994). DCIS is referred to 
as “Stage 0” breast cancer, with the cancer cells located within the confines of the basement 
membrane. Relative to ADH, DCIS contains further expansion of tumor volume through the 
ductal system, along with elevated histological and biological diversity (Allred et al., 2008). 
Clinically significant parameters which are reported for DCIS include nuclear grade, size, 
architecture, positive margins, and presence or absence of comedo necrosis (presence of 
necrosis is an independent prognostic indicator for invasive recurrence) (Lester et al., 2009). 
The expanded volume of cells within DCIS can exhibit a wide spectrum of histological 
patterns (Allred et al., 2001). LG DCIS is composed of small uniform cells, with nuclei subtly 
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larger than those of adjacent normal epithelial cells (Figure 1.1.5, left panel) (Pinder and 
Ellis, 2003). HG DCIS is associated with an increase in the nuclei to cytoplasm ratio, coarse 
chromatin, prominent nucleoli, loss of polarization, frequent mitoses, and pleomorphism from 
cell to cell (Figure 1.1.5, right panel) (Lester et al., 2009). The architecture is variable (i.e. 
solid, cribriform, micropapillary, and/or papillary), although solid is frequently observed, often 
with central zone necrosis which may undergo calcification (Pinder and Ellis, 2003). The 
diagnosis of IG DCIS is quite subjective, and is made if nuclear pleomorphism exhibits an 
intermediate between LG and HG DCIS with some degree of polarization (Pinder and Ellis, 
2003). On this note, a recent study using integrative bioinformatic analysis of the Cancer 
Genome Atlas (TCGA) breast cancer cohort reported that patients with IG IDC could be re-
classified into LG-like and HG-like IDC based on a 22 gene tumor aggressiveness classifier 
(Aswad et al., 2015), suggesting that this subgroup consists of both LG and HG lesions 
(Bombonati and Sgroi, 2011). 
The distinguishing factor between DCIS and IDC is the dissolution of the myoepithelial 
cell layer in IDC, with neoplastic cells invading beyond the basement membrane and into the 
adjacent stroma. Previous studies have shown that myoepithelial cells possess tumor-
suppressor functions through their secretion of protease inhibitors and continuous synthesis 
and maintenance of the basement membrane (Barsky and Karlin, 2005, Polyak and Hu, 
2005, Hu et al., 2008). During progression of DCIS to IDC, the myoepithelial cell layer 
gradually disappears, and their associated tumor suppressive function is thus lost (Hu et al., 
2008). This can be tracked immunohistochemically using molecular markers such as smooth 
muscle myosin heavy chain (cytoplasmic) and/or p63 (nuclear), which are characteristically 
expressed by myoepithelial cells. Staining for these markers is lost with dissolution of the 
myoepithelial layer. This event results in loss of organization and polarity of breast epithelial 
cells, paving the way for tumor progression to invasion (Hu et al., 2008).  
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1.1.4.2 Clinical Management of DCIS 
It is estimated that 25-50% of DCIS (depending on the DCIS characteristics) will 
progress to invasive carcinoma during the lifetime of the patient, generating potentially life-
threatening disease (Page and Dupont, 1993, Fitzgibbons et al., 1998, Sanders et al., 2005, 
Ahmad, 2013, Sagara et al., 2015). Local recurrence rates for patients with DCIS are 5-25% 
with lumpectomy (Fisher et al., 1993, Warneke et al., 1995, Ernster et al., 1996, Fowble et 
al., 1997, Habel et al., 1998, Boyages et al., 1999, Hetelekidis et al., 1999), and 1-2% for 
mastectomy in the absence of radiation therapy (Silverstein et al., 1995a, Warneke et al., 
1995, Boyages et al., 1999). This risk of non-invasive or invasive recurrence further depends 
on characteristics of the DCIS, including the nuclear grade, extent and presence or absence 
of necrosis.  
The natural history of DCIS is for the most part unknown since routine treatment 
includes surgical excision (Bartlett et al., 2014). Prior to the 1980s, most patients with DCIS 
underwent a mastectomy (Waldman et al., 2000). Such radical surgical practices have been 
replaced by breast-conserving surgery (lumpectomy), often combined with radiation therapy, 
regardless of grade (Waldman et al., 2000, Mokbel and Cutuli, 2006). The higher rates of 
local recurrence for DCIS patients treated with lumpectomy suggest that the recurrent DCIS 
arises from residual tumor cells missed by surgery (Waldman et al., 2000). Work by Waldman 
et al. reported that recurrent DCIS lesions exhibited the same histologic architecture as the 
initial DCIS, and CGH analysis revealed that the initial and recurrent DCIS were clonally 
related (Waldman et al., 2000). 
In a retrospective longitudinal cohort study examining 57,222 patients with 
documented DCIS and surgery status, Sagara et al. reported a significant survival benefit 
when comparing the surgery vs. non-surgery arm of patients with IG and HG DCIS (Sagara 
et al., 2015). In contrast, there was no survival benefit for patients with LG DCIS that 
underwent surgical excision (Sagara et al., 2015). In the only existing study assessing the 
natural history of LG DCIS, however, Sanders et al. identified 28 women in which DCIS was 
not initially diagnosed upon biopsy, but was detected upon examination of archival samples 
(Sanders et al., 2005). In their median follow-up time of 31 years, 11/29 (39.3%) women 
developed IDC, and 5/28 (17.9%) died of metastatic breast cancer (Sanders et al., 2005). 
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They noted that the risk of invasive recurrence is greatest within the first fifteen years after 
diagnosis (Sanders et al., 2005). Omission of surgical excision for patients with LG DCIS 
therefore leaves a percentage of women at risk for recurrence. 
Randomized control trials have concluded that the addition of radiation therapy to 
lumpectomy reduces recurrence rates for early breast cancers by approximately 50%, similar 
to that of mastectomy (Fisher et al., 1998, Bijker et al., 2001, Fisher et al., 2001, Fisher et 
al., 2002, Bijker et al., 2006, Holmberg et al., 2008, Correa et al., 2010, Cuzick et al., 2011, 
Wapnir et al., 2011). Clinical records, however, show that only half of women treated by 
lumpectomy receive radiation therapy (Baxter et al., 2004, Jackson et al., 2008, Hughes et 
al., 2009). Several studies have also reported that approximately 30% of patients do not 
receive any significant benefit from radiation therapy (Lagios et al., 1989, Schwartz et al., 
1992, Zafrani et al., 1994, Silverstein et al., 1995b, Silverstein et al., 1996).  
DCIS represents a heterogeneous spectrum of lesions with several treatment 
approaches. Some DCIS may require local surgical excision, while others require radiation 
therapy or mastectomy. While the benefit of lumpectomy and radiation therapy results in 
great survival benefits to early breast cancer patients as a whole, we are unable to identify 
which patients are over-treated and do not benefit from these interventions (Bartlett et al., 
2014). Paradoxically, we are uncertain of which DCIS lesions have an intrinsically higher 
propensity to progress to invasive cancer, such that some patients may be under-treated 
(Bartlett et al., 2014). Most patients therefore receive identical treatment, even though the 
risk, particularly of over-diagnosis and treatment, is well-recognized (Miller et al., 2014). The 
exception to this is patients with small, localized, non-high grade DCIS, for whom surgery 
without radiation is sometimes considered (Hetelekidis et al., 1999, Wong et al., 2014). Due 
to this important clinical problem, the 2009 National Institutes of Health State-of-the-Science 
Conference recommended that a focus on development and validation of risk stratification 
models and/or biomarkers is vital in order to optimize treatment strategies based on the 
underlying biology of each patient’s DCIS (Allegra et al., 2010).  
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 Biomarkers for progression to invasive carcinoma 
Breast cancers are now being diagnosed earlier, but this lead-time has not resulted in 
significant reductions in diagnosis of invasive carcinoma after DCIS (Kerlikowske, 2010, 
Miller et al., 2014). While up to 50% of DCIS lesions are expected to progress to IDC in the 
lifetime of the patient (Sagara et al., 2015), there is a high degree of variability in terms of 
latency (Muggerud et al., 2010). Indeed, some patients with DCIS progress to invasion 
quickly, while others remains relatively unchanged over 20 years (Porter et al., 2003, Schuetz 
et al., 2006). Previous studies have reported that traditional clinical and pathologic criteria 
are not sufficient to consistently and accurately define DCIS risk groups (Porter et al., 2003, 
Solin et al., 2013, Rakovitch et al., 2015). Conventional markers which are routinely assessed 
by immunohistochemistry in invasive breast cancers (ER, PR) are also of limited value in 
DCIS (Bartlett et al., 2014). The lack of reliable markers for risk stratification of patients 
diagnosed with DCIS results in identical treatment for almost all patients (Bartlett et al., 2014). 
There is therefore a pressing need for the development of novel diagnostic approaches for 
risk stratifications of patients with DCIS in order to optimize treatment strategies.  
The majority of examined IDCs possess non-invasive DCIS components; histological 
analysis of both lesion types in these instances has revealed near identical histological and 
biological features (Allred et al., 2008). A more thorough understanding of molecular 
alterations within precursor lesions has been made possible through the use of tissue 
microdissection technologies and high throughput genomic analyses. Diversity has been 
shown to emerge at the DCIS stage, with very similar histology and transcriptional profiles in 
the IDC portions within the same patient (Perou et al., 2000, Ma et al., 2003, Porter et al., 
2003, Schuetz et al., 2006, Allred et al., 2008). Analysis of pure DCIS, IDC, and mixed DCIS 
and IDC has revealed that by conducting hierarchical clustering based on the most variably 
expressed genes, DCIS cluster by “intrinsic subtype” and not by diagnosis (DCIS vs. IDC) 
(Muggerud et al., 2010). This suggests that genes that confer the ability to invade are active 
in some pre-invasive lesions (Muggerud et al., 2010). Additionally, they showed that not all 
HG DCIS exhibit the potential for invasion (Muggerud et al., 2010). Importantly, several 
studies have demonstrated that most gene expression changes characteristic of invasive 
breast cancers, including genes which confer invasive growth, are already present at the pre-
invasive stage (ADH, DCIS, and persist in IDC) (Ma et al., 2003, Porter et al., 2003, Abba et 
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al., 2015). These findings are consistent with early LOH and CGH-based studies showing 
that similar genetic abnormalities associated with DCIS and IDC are already present at the 
ADH stage (Zhuang et al., 1995, Deng et al., 1996, O'Connell et al., 1998, Allred et al., 2001). 
Van’t Veer et al. established a poor-prognosis signature associated with a 28-fold 
increased risk for the development of metastasis over a 5-year period (van 't Veer et al., 
2002). Based on their 70-gene approach, they concluded that even small primary tumors 
displaying a poor prognosis signature are already programmed for a metastatic phenotype 
(van 't Veer et al., 2002). Taken together, these studies suggest that since DCIS and IDC 
possess very similar transcriptional profiles, and a poor prognosis signature can be 
established from the primary IDC, the same may hold true for DCIS. 
The assessment of biomarkers for DCIS is still in its infancy. As highlighted by Bartlett 
et al., 60 DCIS biomarker studies were published during the 2004-2014 period, with 90% of 
the published studies regarded as statistically under-powered (Bartlett et al., 2014). 
Additionally, several of these studies remain un-validated (Bartlett et al., 2014). 
One DCIS biomarker that has been validated by several groups, however, is HER2 
expression (as assessed by immunohistochemistry (IHC) and fluorescence in situ 
hybridization (FISH)). High HER2 expression in DCIS is associated with non-invasive 
recurrence (Provenzano et al., 2003, Kepple et al., 2006, Nofech-Mozes et al., 2008, Holmes 
et al., 2011, Ringberg et al., 2001, Han et al., 2012). Additionally, joint assessment of HER2 
and Ki67 expression in DCIS was associated with a 3.22-fold increased risk of non-invasive 
recurrence (Rakovitch et al., 2012). Kerlikowske et al. reported that patients with DCIS which 
are ER- and HER2+ with high expression of Ki67 possess the greatest risk (Kerlikowske et 
al., 2010). The conclusions regarding HER2 expression and invasive recurrence post-
lumpectomy are variable. This discrepancy was discussed by Kerlikowske et al. and 
Rakovitch et al., where they suggested this outcome was dependent on subtype (Kerlikowske 
et al., 2010, Rakovitch et al., 2012, Bartlett et al., 2014). 
 Biomarkers which have been assessed by immunohistochemistry include HER2, ER, 
PR, Ki67, cyclooxygenase 2 (COX2), p16 and p53 (Kerlikowske et al., 2010, Rakovitch et al., 
2012, Bartlett et al., 2014). Noteworthy examples include studies examining the co-
expression of p16, COX2 and Ki67. High expression of p16 and COX2 in the absence of the 
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proliferation marker Ki67 is indicative of a normal stress response, and protective against 
progression of DCIS (Gauthier et al., 2007). High p16, and COX2 with elevated Ki67 
expression, however, is associated with a 2-fold higher rate of invasive recurrence (Gauthier 
et al., 2007, Kerlikowske et al., 2010). 
The usage of one biomarker for risk stratification will likely result in limited predictive 
power, so multiple markers are likely needed (van 't Veer et al., 2002). Multi-parameter gene 
expression approaches for risk stratification of patients with DCIS has also been reported in 
the literature. Oncotype Dx, a qRT-PCR based assay consisting of a panel of 16 breast-
cancer related genes and 5 housekeeping genes, possesses significant prognostic value in 
predicting recurrence of patients with early-stage, node-negative invasive breast cancers 
treated with adjuvant tamoxifen (Paik et al., 2004). The Oncotype Dx assay was adapted for 
assessment of DCIS recurrence risk after treatment by surgical excision without radiation 
therapy, and referred to as the DCIS Score (Solin et al., 2013). The DCIS Score is calculated 
through assessment of a 12-gene panel (including the previously-used 5 housekeeping 
genes), with an emphasis on genes involved in proliferation (Solin et al., 2013). The DCIS 
score of low, intermediate, and high-risk was associated with a 10.6% (3.7%), 26.7% 
(12.3%), and 25.9% (19.2%) risk of non-invasive (and invasive) recurrence over 10-years in 
the absence of radiation therapy (Solin et al., 2013). Interestingly, the DCIS Score was not 
associated with existing clinical or pathologic factors (Solin et al., 2013). These findings have 
been validated in an independent cohort of 718 patients, with 12.7% (low-risk), 33.0% 
(intermediate-risk), 27.8% (high-risk) local recurrence rates for the specified risk group over 
a 10-year follow-up period (Rakovitch et al., 2015). These findings may therefore be used to 
provide predictive information in order to determine which patients may be spared radiation 
therapy due to their low intrinsic risk of developing invasive breast cancer.  
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 Experimental Models of Breast Cancer Progression 
The development of breast cancer is a multi-step process, and our understanding of 
the underlying molecular events has been hindered due to a lack of suitable models of 
progression (Liu et al., 1994). Previous studies have demonstrated that mouse-derived pre-
malignant lesions are histologically different from those of humans, particularly in transgenic 
mouse models where the cellular origin of hyperplastic lesions is more often associated with 
the promoter rather than the transgenes used (Cardiff et al., 2000). The standard method 
used to determine malignant potential of cells within precursor lesions is transplantation 
(Cardiff et al., 2000). As described by Cardiff et al., this is similar to “Koch’s Postulates” of 
tumor biology, including “identification [of cells representing the precursor stage], isolation, 
transplantation and characterization” (Cardiff et al., 2000). Most human cells lines 
representing pre-malignant stages do not form any discernible histologic lesions in nude 
mice, and the majority of existing cell lines used for xenograft assays are of metastatic origin 
(Band et al., 1990, Miller, 2000). Importantly, only the 21T, HMT-3522, and MCF10AT breast 
epithelial cell line series have been reported to recapitulate the various histological 
characteristics of human breast carcinoma within a xenograft model (Santner et al., 2001, 
Rizki et al., 2008, Souter et al., 2010).  
The 21T series cell lines were isolated from a single patient with invasive ductal 
carcinoma through selective trypsinization and expanding of polygonal tumor-like cells from 
spindle-shaped epithelial cells and fibroblasts (Band et al., 1989, Band et al., 1990). The 
21PT and 21NT cells were isolated from the primary tumor, and 21MT-1 cells were isolated 
from a pleural effusion (Band and Sager, 1989, Band et al., 1989, Souter et al., 2010). 
Importantly, the isolated cell lines represent distinct stages of progression: 21PT cells mimic 
ADH (non-tumorigenic), 21NT cells mimic DCIS (tumorigenic, non-metastatic), and 21MT-1 
mimic IDC (tumorigenic, metastatic) when injected into the mammary fat pad of nude mice 
(Band et al., 1990, Souter et al., 2010). Karyotyping of the 21T series cell lines has previously 
been conducted by our laboratory (Xu et al., 2008), indicating that all three cell lines have 
common chromosomal aberrations, potentially reflecting a common origin within the same 
tumor (Xu et al., 2008). Additionally, these cells are weakly ER and PR positive, HER2 
amplified, and possess a mutated form of p53 (Band et al., 1990, Liu et al., 1994, Biswas et 
al., 1998, Biswas et al., 2001).  
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The HMT-3522 human breast epithelial cell lines were derived from a reduction 
mammoplasty, with the S1 cells isolated from a sample with fibrocystic breast disease 
(Madsen et al., 1992, Rizki et al., 2008). The S2, S3(A-B) and T4-2 cell lines were established 
through sub-culturing of cells (in 2D or 3D Matrigel), isolation of colonies with distinct 
phenotypes characteristic of aggressiveness, along with inoculation of cells into mice and 
passaging of xenograft cells for T4-2 cells (Madsen et al., 1992, Rizki et al., 2008). The cells 
represent a model of spontaneous transition and exhibit differential growth patterns and 
phenotypes in 3D Matrigel, along with varying tumorigenicity in nude mouse xenograft assays 
(Rizki et al., 2008). The S3 cell lines represent the pre-invasive stage of the human breast 
cancer progression series, but give rise to a metaplastic phenotype (Rizki et al., 2008). 
Human metaplastic breast cancers are rare, but also extremely aggressive, sharing similar 
clinical behavior and markers with basal-like breast carcinomas (Kenny et al., 2007, Rizki et 
al., 2008).  
There are several variants of the MCF10A cell line, all previously isolated from a 
sample consisting of fibrocystic breast disease, most notably the pre-malignant MCF10AT 
and malignant MCF10CA variants both of which are Ras transformed (Miller, 2000, Miller et 
al., 2000). In mouse xenograft assays, MCF10AT cells initially form simple ducts and lead to 
a wide spectrum of pre-malignant lesions, including ADH and DCIS, with approximately 25% 
of mice developing invasive carcinoma (Miller, 2000). Lesions formed by MCF10AT cells are 
highly heterogeneous, giving rise to several different and distinct histological subtypes as 
well as differential immunoreactivity (Strickland et al., 2000, Santner et al., 2001). 
Additionally, these cells are able to give rise to a myoepithelial cell layer (Tait et al., 1996), 
indicating the presence of precursor stem cells and likely explaining the unstable and 
heterogeneous phenotype (Miller, 2000). The MCF10DCIS.com cell variants were isolated 
from a xenograft lesion formed by MCF10AT cells (Miller et al., 2000). The MCF10DCIS.com 
cells are highly proliferative and form comedo DCIS (high nuclear grade with zonal necrosis) 
in vivo (Miller, 2000). These cells have high rates of spontaneous progression to invasive 
carcinoma, although the DCIS component is retained (Miller et al., 2000). The MCF10CA cell 
line was isolated through serial transplantation of spontaneous tumors formed by MCF10AT 
cells, and is malignant and highly metastatic (Miller, 2000, Santner et al., 2001). The 
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tumorigenic MCF10AT cell line variants are ER and PR positive, and possess wildtype p53 
(Shekhar et al., 1998, Miller, 2000, Hevir et al., 2011). 
A major advantage of utilizing a series of cell lines derived from a single patient to 
study progression is the minimal genetic variability. This allows for the mining of biologically 
relevant driver mutations and gene expression changes directly related to a subset of genetic 
alterations, independent of individual variability. Genetic manipulation of cell lines 
representing various stages of progression can be used to examine the relative functional 
impacts of genes on transitions between distinct stages (ADH, DCIS, IDC) (Souter et al., 
2010). This can often be done through the use of in vitro techniques, which can be modified 
for high-throughput screens for identification of genes important in functional and phenotypic 
transitions, or for identification of therapeutically effective chemical agents in preclinical 
screens (Miller, 2000). Souter et al. described a 3D in vitro Matrigel culture in which cells 
were seeded on Matrigel and the resultant colonies were phenotypically assessed (Souter et 
al., 2010). Through the use of this 3D culture system, the 21PT, 21NT and 21MT-1 cells were 
shown to exhibit differential phenotypes and display features of distinct stages of the breast 
cancer progression pathway (Souter et al., 2010). Less aggressive cell lines (including the 
21PT cells) typically show more polarized cells and higher rates of lumen formation, along 
with more spherical colonies and a lower frequency of single, dispersed cells (Souter et al., 
2010) (depicted in Figure 1.1.6). 
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Figure 1.1.6 – Characteristic growth patterns of 21T cell lines in 2D, 3D, and in mouse 
xenografts.  
H&E images were obtained from Souter et al., 2010.  
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1.2 TBX3 
TBX3 is a member of the highly conserved family of T-box transcription factors. The 
18 T-box genes within mammals are believed to have evolved from tandem duplication of a 
primordial gene, followed by cluster dispersion (Agulnik et al., 1996, DeBenedittis and Jiao, 
2011). Several of the T-box genes are expressed throughout development, with tight 
temporal and spatial regulation (DeBenedittis and Jiao, 2011). The identification of T-box 
family members generally occurred through experiments designed to identify genes involved 
in embryonic development, with lack of expression resulting in developmental defects (Bollag 
et al., 1994, Bamshad et al., 1999).  
The first T-box transcription factor identified was the Brachyury (TBXT) gene 
(Gruneberg, 1958). In mice, homozygous mutations in Brachyury are embryonic lethal due 
to insufficient formation of mesodermal cells in the developing embryo, while heterozygous 
mutations result in a variable short tail phenotype (Gluecksohn-Schoenheimer, 1938, 
Gruneberg, 1958, Yanagisawa et al., 1981, Stott et al., 1993). Several decades later, TBX3 
was discovered by Bollag et al., who postulated its role in development after observing highly 
specific patterns of expression in the developing mouse embryo (Bollag et al., 1994). It was 
later discovered that TBX3 plays an important role in limb, heart, and mammary gland 
development (Wilson and Conlon, 2002). In mice, homozygous TBX3 mutations are 
embryonic lethal, and most embryos die by E12.5 due to yolk sac defects (Davenport et al., 
2003). Limb defects, along with lack of mammary glands was also documented (Davenport 
et al., 2003), similar to the conditions observed in human patients. In humans, mutations or 
haploinsufficiency of TBX3 results in Ulnar-Mammary Syndrome (UMS, OMIM 181450). UMS 
is fully penetrant although it presents with highly variable clinical characteristics, mainly 
consisting of mammary gland hypoplasia, apocrine gland, dental, and genital defects 
(Bamshad et al., 1997, Bamshad et al., 1999, Davenport et al., 2003). These observed 
phenotypes are consistent with the broad expression profile of TBX3 (Figure 1.2.2). 
Complete loss of TBX3 expression is predicted to be fatal, as patients lacking both copies of 
TBX3 have not been identified (Rowley et al., 2004). 
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Figure 1.2.1 – Full-length TBX3 protein structure. Adapted from Willmer et al., 2017. 
The full-length TBX3 protein is 743 residues in length, containing the T-box domain 
(residues 105-305), nuclear localization sequence (NLS; residues 312-317), activation 
domain (residues 443-520) and repression domains (residues 123-200, 587-643) (Smith, 
1999, Carlson et al., 2001, Papaioannou, 2001, Willmer et al., 2017) (Figure 1.2.1). Two 
TBX3 isoforms exist through alternative splicing: TBX3iso1 and TBX3iso2 (which contains 
the 2a exon). TBX3 isoforms are described in Section 2.3.1. 
All T-box transcription factors possess the highly conserved DNA binding domain 
known as the T-box domain which shares no sequence similarity to other known DNA binding 
motifs (Wilson and Conlon, 2002). Most of the described T-box domains are approximately 
180 amino acids in length (Coll et al., 2002). T-box transcription factors bind to DNA 
sequences containing the T-box element (TBE) (Wilson and Conlon, 2002). To date, all T-
box transcription factors examined are able to bind to the TBE consisting of bases 
TCACACCT (Wilson and Conlon, 2002). Coll et al. have proposed a less stringent consensus 
sequence (5’-xTxxCACxx’-3’; x signifies a less conserved base) for identification of new T-
box binding sites (Coll et al., 2002).  
T-box proteins function as transcriptional activators or repressors depending on the 
promoter context (Wilson and Conlon, 2002, Lu et al., 2010). TBX2 is the most closely related 
T-box gene to TBX3, sharing ~95% sequence homology in the T-box domain and ~70% 
homology in the repression domain (Bamshad et al., 1999). Interestingly, TBX2 and TBX3 
are the only T-box transcription factors that function as transcriptional repressors (Carlson et 
al., 2001, Lu et al., 2010). Sequence analysis of the repression domain of TBX2 and TBX3 
revealed no conserved sequence or motifs shared with other known repression domains (Lu 
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et al., 2010). While TBX2 and TBX3 exhibit overlapping and complementary expression 
patterns in the developing mouse embryo, they were found to have non-redundant roles in 
developmental processes (Rowley et al., 2004).  
TBX3 possesses both activation and repression domains. Most of the existing cancer-
related literature focuses on transcriptional repression of target genes by TBX3, while 
transcriptional activation of target genes has been further characterized in heart development 
(Boogerd et al., 2011, Lu et al., 2011). The effect of TBX3 on transcription likely depends on 
interacting partners and target genes (Willmer et al., 2017). Several domains which facilitate 
protein-protein interaction likely reside outside of the T-box domain, since this area has 
undergone rapid diversification between T-box genes (Bamshad et al., 1999, Coll et al., 
2002). The effect of TBX3 on transcription of downstream target genes as they relate to the 
process of tumorigenesis is discussed in the next section. 
 
Figure 1.2.2 – TBX3 mRNA expression by tissue type.  
Graphical representation of TBX3 mRNA expression across tissue types was obtained from 
Jensen TISSUES database (tissues.jensenlab.org), depicting Genotype Tissue Expression 
(GTEx) dataset (histogram plot on upper right). TBX3 mRNA expression in normal tissue is also 
shown from the Human Protein Atlas (HPA) dataset. 
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 Mechanisms of transcriptional regulation by TBX3 
TBX3 is able to bind several target genes through recognition of the conserved TBE 
sequence by the DNA binding domain (Wilson and Conlon, 2002). X-ray crystallography 
studies of TBX3 and Brachyury indicate that there are only two specific contacts within the 
DNA binding domain per TBE (Müller and Herrmann, 1997, Coll et al., 2002). The binding of 
TBX3 to the phosphatase and tensin homolog (PTEN) promoter, however, occurs in the 
absence of a TBE sequence (Burgucu et al., 2012), thereby suggesting that the binding of 
TBX3 to target sites is likely dependent on: i) DNA specificity and binding to a conserved 
TBE, ii) interaction with specific DNA binding proteins, iii) interaction with chromatin 
determinants (Lingbeek et al., 2002, Rodriguez et al., 2008). TBX3 is able to interact with 
chromatin, and directly binds to histone H2A (Kumar P et al., 2014b), histone deacetylases 
(HDACs), and DNA methyltransferases (DNMTs) (Yarosh et al., 2008, Dan et al., 2013), 
leading to transcriptional up-regulation or down-regulation of target genes. Additionally, 
TBX2, TBX4, TBX5 and TBX6 are able to bind to histone H3 N-terminal tails (Demay et al., 
2007), the primary location of histone post-translational modifications (Mersfelder and 
Parthun, 2006). 
Acetylation of histones is associated with active chromatin (Lewin et al., 2011). 
Histone deacetylases (HDACs) are involved in the removal of acetyl groups from histones, 
which results in tighter histone-DNA interactions and reduced levels of transcription (Yarosh 
et al., 2008). As HDACs do not contain a DNA binding domain, they are recruited by DNA-
binding transcription factors (Cress and Seto, 2000). TBX3 is able to recruit and directly 
interact with histone deacetylases (HDACs) in order to epigenetically silence gene promoters 
(Willmer et al., 2017). This includes direct interaction with HDAC1, HDAC2, HDAC3, and 
HDAC5 to transcriptionally repress p14ARF in MCF7 cells (Yarosh et al., 2008). HDACs are 
often overexpressed in breast cancers (Zhang et al., 2005, Glozak and Seto, 2007), and it is 
suggested that each HDAC plays a specific role in the process of breast tumorigenesis (Puri 
et al., 2001, Dokmanovic and Marks, 2005, Glozak et al., 2005). The association between 
TBX3 and HDACs may therefore play an important role in breast cancer progression (Yarosh 
et al., 2008). Additionally, in a recent study in hepatocellular carcinoma (HCC), TBX3 was 
found to directly interact with HDAC5, resulting in down-regulation of E-cadherin; 
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administration of HDAC inhibitor was able to block TBX3-induced repression of E-cadherin 
and TBX3-induced migration in HCC cell lines (Dong et al., 2018). 
DNA methylation is associated with transcriptionally inactive DNA (Lewin et al., 2011). 
ChIP-Seq analysis revealed that TBX3 binds upstream of the DNA methyltransferases 
DNMT3A and DNMT3B genes, leading to their transcriptional repression (Han et al., 2010). 
TBX3 overexpression results in a reduction in the global DNA methylation levels, likely 
through down-regulation of DNMT3B (involved in DNA methylation) and up-regulation of 
TET2 (involved in DNA de-methylation) (Dan et al., 2013).  
Not only is TBX3 able to modify epigenetic profile of target genes, the physical 
interaction of TBX3 with several RNA-binding proteins and splice factors has revealed that 
TBX3 is also able to bind to TBEs within mRNA transcripts and directly regulate splicing 
(Kumar P et al., 2014b). These studies show that not only does TBX3 regulate gene 
expression through activation/repression of genes through various means including 
alterations of histone modifications, but is also able to modulate splicing of target mRNA 
sequences. In fact, there is an over-representation of TBEs in sequences flanking alternative 
exons (Kumar P et al., 2014b). Alternative splicing is an important post-transcriptional 
mechanism of gene regulation, and changes in alternative splicing profiles has been 
observed in several cancers (Venables, 2004, Pajares et al., 2007, Venables et al., 2008, 
Shapiro et al., 2011, Oltean and Bates, 2014). The study by Kumar et al. sheds light on other 
potential mechanisms in which TBX3 overexpression in several cancer types may lead to 
tumorigenesis (Kumar P et al., 2014b). 
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 TBX3 in Cancer 
TBX3 levels are up-regulated in several cancers, including breast (Fan et al., 2004, 
Lomnytska et al., 2006, Yarosh et al., 2008, Souter et al., 2010), melanoma (Rodriguez et 
al., 2008), pancreatic (Hansel et al., 2004, Cavard et al., 2009, Begum and Papaioannou, 
2011), cervical (Lyng et al., 2006), ovarian (Lomnytska et al., 2006), gastric (Miao et al., 
2016), and prostate cancers (Gudmundsson et al., 2010, Witte, 2010). TBX3 expression 
levels in normal tissues, tumor tissues, and plasma samples have been assessed in several 
studies described below, using methods ranging from IHC, microarray analysis, qRT-PCR, 
western blot, and 2D gel electrophoresis coupled to mass spectrometry. 
TBX3 PROTEIN IN CANCERS – Assessment of TBX3 expression in pancreatic cancer by 
IHC revealed that elevated TBX3 expression within tumor samples was an independent 
prognostic factor for reduced overall survival (Wang et al., 2015). In gastric cancers, elevated 
TBX3 expression by IHC was significantly associated with advanced TNM (tumor, node, 
metastasis) stage and higher incidence of relapse (Miao et al., 2016). In colorectal cancer, 
elevated TBX3 expression by IHC was an independent predictor of poor outcome, and was 
correlated with tumor size, differentiation, TNM stage and lymph node metastasis (Shan et 
al., 2015).  
Lomnytska et al. assessed differential protein expression within plasma samples of 
breast and ovarian cancer patients through the use of 2D gel electrophoresis coupled to 
matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TOF-
MS) (Lomnytska et al., 2006). This study revealed significantly higher levels of TBX3 in 
plasma of both early stage and advanced stage breast cancer and ovarian cancer patients 
relative to healthy control patients (Lomnytska et al., 2006).  
Examination of TBX3 expression by western blot in a diverse subset of cell lines 
representing normal human fibroblasts, transformed fibroblasts, and several soft tissue and 
bone sarcoma cell lines reported high levels of TBX3 in transformed fibroblasts and sarcoma 
cell lines relative to normal human fibroblast controls (Willmer et al., 2016a). Willmer et al. 
suggested clinical assessment of TBX3 expression to differentiate benign soft tissue masses 
from sarcomas (Willmer et al., 2016a).  
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TBX3 mRNA IN CANCERS – TBX3 is overexpressed in a variety of different cancer types 
(Figure 1.2.3). Microarray analysis revealed that elevated TBX3 mRNA expression was 
associated with advanced tumor stage, chemo-resistance and an unfavorable prognosis in 
patients with hepatoblastoma (Renard et al., 2007). Assessment of TBX3 expression by qRT-
PCR and western blot in non-small cell lung cancer (NSCLC) patient samples revealed that 
overexpression of TBX3 was associated with tumor size, TNM stage, differentiation, and 
recurrence, and was an independent prognostic marker for overall survival (Wu et al., 2017). 
Additionally, up-regulation of TBX3 has been documented with chronic exposure to 
carcinogens, including a positive correlation with tobacco smoking status (Wu et al., 2017) 
and exposure to the environmental toxin DE-71 and liver tumorigenesis (Shimbo et al., 2017). 
 
 
Figure 1.2.3 – TBX3 mRNA expression by cancer type.  
Graphic obtained from CCLE (Cancer Cell Line Encyclopedia).  
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The single published transgenic TBX3-inducible mouse model used a doxycycline-
inducible TBX3iso2 expression system under the control of the mouse mammary tumor virus 
(MMTV) promoter (Liu et al., 2011). Their results showed that overexpression of TBX3iso2 
in murine mammary glands resulted in mild focal hyperplasia and importantly no tumor 
formation (Liu et al., 2011). The effect of inducible overexpression of TBX3iso1 was not 
examined. Few xenograft studies have been conducted overexpressing either TBX3iso1 or 
TBX3iso2 (or knockdown of total TBX3 levels) in various cell line backgrounds in order to 
assess resultant tumorigenicity. TBX3iso1 was overexpressed in SWI1353 chondrosarcoma 
cells and exhibited enhanced tumor growth (Willmer et al., 2016a). Injection of TBX3-
overexpressing non-tumorigenic WM1650 melanoma cells into the flank of nude mice 
resulted in 6/6 of mice forming tumors compared to 0/6 in the parental control cells (Peres 
and Prince, 2013). Overexpression of TBX3 in pancreatic cancer cell lines resulted in 
significantly larger tumors than controls (Perkhofer et al., 2016). The latter two examples did 
not state which TBX3 isoform was overexpressed. The shRNA-mediated knockdown of TBX3 
in tumorigenic ME1402 melanoma cells abolished their ability to form tumors when injected 
into the flank of nude mice (Peres et al., 2010).  
The use of TBX3 as a potential biomarker in various cancer subtypes has been 
examined through the use of several methodologies, as has its role in chemically-induced 
carcinogenesis. In all documented cancer cases aside from fibrosarcoma, overexpression of 
TBX3 has led to increased migration and invasion (Rodriguez et al., 2008, Peres et al., 2010, 
Krstic et al., 2016, Willmer et al., 2016a). Although the contribution of TBX3 in tumorigenesis 
is not fully understood, accumulating evidence suggests that several pathways may be 
involved (summarized in Figure 1.2.4). More research is needed for further identification of 
upstream activators of TBX3 signaling, its target genes, along with co-factors required for its 
proper functioning (Willmer et al., 2017). Some of the cancer-associated pathways in which 
TBX3 is involved are described in the next sections.  
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Figure 1.2.4 – Cancer-related TBX3 signaling pathways.  
Green lines represent direct transcriptional interactions, while red lines represent direct  
post-translational interactions. 
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 TBX3 and Cellular Senescence – p14ARF / p53 / p21CIP1 Pathway 
The cyclin-dependent kinase inhibitor 2A (CDKN2A) gene encodes the p16INK4A and 
p14ARF proteins in humans, with differential promoters and partially overlapping reading 
frames (Ruas and Peters, 1998). Both proteins act as tumor suppressors and are important 
regulators of cellular senescence (Ruas and Peters, 1998). While p14ARF is primarily involved 
in stabilization of p53, p16INK4A inhibits the enzymatic activity of cyclin-dependent kinases 4 
and 6 (CDK4/6) (Rayess et al., 2012). CDK4/6 binds cyclin D, which then phosphorylates the 
Retinoblastoma (Rb) protein, resulting in dissociation of Rb and the E2F transcription factor, 
thereby promoting the G1 to S phase transition (Rayess et al., 2012). 
Cellular senescence is a protective mechanism of irreversible growth-arrest resulting 
in permanent exit from the cell cycle. Senescence can be induced by cellular stresses 
(accelerated senescence) or telomere shortening (replicative senescence) (Lu et al., 2010). 
One of the most well described pathways of accelerated senescence is through activation of 
p14ARF, whereby p14ARF binds to and sequesters mouse double minute 2 (MDM2), preventing 
MDM2 from targeting p53 for destruction (Tao and Levine, 1999). High expression of p14ARF 
thus stabilizes p53, leading to expression of p53 target genes (Lu et al., 2010). Early studies 
reported that TBX3 overexpression leads to impaired functioning of the p53-pathway, 
suppression of apoptosis and facilitation of cell transformation (Carlson et al., 2002). TBX3 
was later identified in a senescence screen and described as a potent inhibitor of senescence 
through inhibition of p14ARF (and p19ARF mouse ortholog), explaining the previously reported 
effect on p53 (Brummelkamp et al., 2002). After this initial identification of the powerful anti-
senescence effect of TBX3, both TBX3 and TBX2 have been shown to bind to a variant TBE 
in the human p14ARF promoter matching 13 of 20 nucleotides within the consensus TBE 
(Lingbeek et al., 2002). Specifically, TBX3 is able to interact with HDACs 1, 2, 3 and 5, leading 
to local changes in histone acetylation and subsequent down-regulation of p14ARF expression 
in breast cancer cell lines (Yarosh et al., 2008).  
Overexpression of several oncogenes and activation of mitogenic signaling pathways 
induces p14ARF expression, and subsequent p53-dependent cell cycle arrest (Rowley et al., 
2004). Overexpression of MYC or oncogenic H-RasVal17 with TBX3 (but not by themselves), 
however, protects cells from apoptosis through inhibition of p14ARF (Carlson et al., 2002). On 
a similar note, knockdown of TBX3 was shown to sensitize cells to doxorubicin in rat bladder 
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carcinoma and human colorectal cancer, later attributed to activation of the p14ARF / p53 
pathway (Renard et al., 2007, Zhang et al., 2011a).  
The cyclin-dependent kinase inhibitor p21CIP1 is essential for p53-induced cellular 
senescence (Waldman et al., 1995). TBX3 was shown to directly bind to the p21CIP1 promoter 
and repress gene transcription in a dose-dependent manner in melanoma cell lines 
(Hoogaars et al., 2008, Willmer et al., 2016b). This was shown by electromobility shift assays 
(EMSA), luciferase assays, and ChIP qRT-PCR validation (Hoogaars et al., 2008, Willmer et 
al., 2016b). Repression of both p14ARF and p21CIP1 by TBX3 produces a powerful synergistic 
effect, leading to a strong inhibition of senescence (Lu et al., 2010).  
Lastly, TBX3 is also able to bypass senescence through down-regulation of p16INK4A 
through formation of a co-repressor complex, leading to destabilization of p16INK4A and 
inhibition of the Rb pathway (Kumar P et al., 2014a). 
 
 TBX3 and the TGF-ß Pathway 
The transforming growth factor beta (TGF-ß) signaling pathway is involved in 
development, along with the processes of homeostasis, proliferation and differentiation in 
adult tissues (Massagué, 2012). TGF-ß proteins bind their cognate receptors, and the signal 
is mediated through the canonical suppressor of mothers against decapentaplegic (SMAD) 
proteins that control the expression of hundreds of genes (Massagué, 2012). The TGF-ß 
signaling pathway is constitutively activated in several breast cancers, leading to a promotion 
of migration but inhibition of proliferation of cancer cells (Tian et al., 2003, Moses and 
Barcellos-Hoff, 2011). Treatment of epithelial cell lines with TGF-ß results in up-regulation of 
TBX3 (Kang et al., 2003). Later it was discovered that TGF-ß1 is able to up-regulate TBX3 
through cooperative binding of Smad3/4 and JunB in the TBX3 promoter, with subsequent 
TBX3-dependent repression of the pro-proliferative family member TBX2 in melanoma cell 
lines (Li et al., 2013, Li et al., 2014). While overexpression of TBX3 results in an increased 
proliferation rate in several cell lines, TBX3 has an anti-proliferative effect in melanoma cell 
lines while still maintaining its pro-tumorigenic properties (Peres et al., 2010). TBX3 was 
therefore proposed to mediate the anti-proliferative, pro-migratory effect associated with 
TGF-ß signaling in melanoma cells (Li et al., 2013, Li et al., 2014).  
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 TBX3 and the FGF Pathway 
The fibroblast growth factor (FGF) signaling pathway is comprised of a group of 
developmentally-important secreted signaling proteins. Binding of FGF ligands to their 
signaling receptors (FGFRs) results in activation of their intracellular tyrosine kinase domain, 
which can activate several intracellular signaling pathways involved in maintenance, repair, 
regeneration and metabolism of adult tissues (Ornitz and Itoh, 2015).  
During development in the mouse, TBX3 is initially expressed in the mammary lineage 
prior to mammary bud formation at E10.25, which is followed by the first signs of the 
mammary gland at E10.5 to E11, and expression of several Wnts and FGF ligands (Eblaghie 
et al., 2004). Eblaghie et al. soaked beads in various FGF proteins, and implanted them into 
the flank of mice in order to assess expression of downstream genes of interest (Eblaghie et 
al., 2004). They reported that FGF8 induces expression of TBX3 in an FGFR1-dependent 
manner (Eblaghie et al., 2004). These early studies showed that TBX3 and FGF ligands are 
able to interact and influence expression of one another within a developmental context 
(Eblaghie et al., 2004). Several other studies have reported autoregulation of expression 
between T-box and FGF family members (Isaacs et al., 1994, Schulte-Merker and Smith, 
1995, Casey et al., 1998, Eblaghie et al., 2004). 
In a breast cancer context, Fillmore et al. reported that estrogen leads to an expansion 
of breast cancer stem cells (CSCs) through the FGF and TBX3-mediated signaling pathways 
(Fillmore et al., 2010). The binding of estrogen to the estrogen receptor results in 
transcriptional up-regulation of FGF proteins (Fillmore et al., 2010). Specifically, FGF9 binds 
to FGFR3, which induces TBX3 expression (Fillmore et al., 2010). Elevated TBX3 expression 
is important for further production of FGF proteins and signal propagation, eventually 
resulting in an increase in an expansion of the breast CSC population (Fillmore et al., 2010). 
It was therefore shown that due to this TBX3-mediated expansion of CSCs in MCF7 cells 
treated with estrogen, TBX3 overexpression resulted in a 100-fold increase in tumor initiation 
rates in ovariectomized NOD/SCID mice (Fillmore et al., 2010). 
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 TBX3 and the Wnt / ß-Catenin Pathway 
The Wingless (Wnt) signaling pathway is involved in cellular proliferation and 
differentiation, and plays a crucial role in development and tissue homeostasis (Giles et al., 
2003). Several Wnt proteins are overexpressed in breast cancer cell lines, leading to 
activation of the canonical Wnt/ß-catenin signaling pathway (Howard and Ashworth, 2006). 
ß-catenin directly binds to the TBX3 promoter through a T-cell specific (TCF)-binding site, 
leading to increased proliferation and survival of liver cancer cells (Renard et al., 2007).  
TBX3 and Wnt signaling have been extensively studied in the processes of 
development. Within the developing mammary gland, TBX3 is required for the induction of 
Wnt signaling, as homozygous TBX3 mutant transgenic mice showed an inability to initiate 
mammary gland development and lack expression of the earliest markers of this 
developmental process (Lef1 and Wnt10b) (Davenport et al., 2003, Rowley et al., 2004). 
Additionally, induction of TBX3 expression in the developing mammary gland requires Wnt 
signaling (Eblaghie et al., 2004, Douglas and Papaioannou, 2013), suggesting the presence 
of a feedback loop (Davenport et al., 2003, Eblaghie et al., 2004, Cho et al., 2012). TBX3 
overexpression in mammary epithelial cells was additionally reported to coordinate 
expansion of progenitor cells through induction of Wnt signaling (Arendt et al., 2014). 
 
 TBX3 and the PTEN / PI3K / AKT Pathway  
The phosphoinositide 3-kinase (PI3K) and protein kinase B (AKT) signaling pathway 
has been described as an upstream mediator of TBX3 expression in mouse embryonic stem 
cells (Niwa et al., 2009), melanoma, and head and neck squamous cell carcinoma (HNSCC) 
(Burgucu et al., 2012, Boyd et al., 2013, Peres et al., 2015). The PI3K/AKT pathway promotes 
proliferation and cell survival in response to binding of growth factors, cytokines and/or 
hormone ligands to receptor tyrosine kinases (RTKs) (Cantley and Neel, 1999).  
AKT3, the predominant AKT isoform expressed in melanomas, was shown to 
phosphorylate TBX3 at residue Ser-720 in vitro, leading to increased protein stability and 
nuclear localization (Peres et al., 2015). This phosphorylation event resulted in enhanced 
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repression of E-cadherin by TBX3, and increased migration and invasion of melanoma cell 
lines (Peres et al., 2015).  
There is also evidence that TBX3 may function upstream of the PI3K/AKT pathway 
through repression of the tumor suppressor PTEN. PTEN is the main negative regulator of 
PI3K, thus functioning as a tumor suppressor through its PI3K-dependent inhibition of AKT 
(Cantley and Neel, 1999). There is an inverse correlation between TBX3 and PTEN 
expression in HNSCC (Burgucu et al., 2012). TBX3 is able to repress both basal and induced 
expression of PTEN in HNSCC cell lines, through binding a non-canonical TBX3 binding site 
in the PTEN promoter (Burgucu et al., 2012). TBX3 was not able to repress PTEN in muscle 
cells, however, suggesting context-dependent repressive functions (Zhu et al., 2016). 
 
 Regulation of TBX3 by miRNAs 
MicroRNAs (miRNAs) are non-coding RNAs which are able to modulate gene 
expression by binding to complementary nucleotides in the 3’ untranslated region (UTR) of 
target genes (Bartel, 2004). The 3’ UTR of TBX3 extends 1,587 bp beyond the termination 
codon (Bamshad et al., 1999). Binding sites for several microRNAs have been found in the 
3’ UTR of TBX3, including miR-25, miR-32, miR-92, miR-93 (validated), miR-137 (validated), 
miR-206 (validated), miR-363, and miR-367 (Zhang et al., 2011b, Humtsoe et al., 2012, Jiang 
et al., 2013, Cioffi et al., 2015, Amir et al., 2016).  
Most of the in vitro studies assessing miRNA regulation of TBX3 have been conducted 
with miR-137 (Jiang et al., 2013, Peres et al., 2017). The miR-137 is an important regulator 
of differentiation in embryonic stem cells (Szulwach et al., 2010, Sun et al., 2011, Jiang et 
al., 2013), and inhibits anchorage-independent growth and migration of malignant melanoma 
cells (Peres et al., 2017). Expression of miR-137 is down-regulated in several cancers, with 
epigenetic silencing of miR-137 representing an early event in colorectal cancer (Silber et al., 
2008, Balaguer et al., 2010, Chen et al., 2010, Jiang et al., 2013, Peres et al., 2017).  
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1.3 Alternative Splicing in normal and neoplastic cells 
Gene expression changes, on their own, cannot fully account for changes in gene 
functions and cellular phenotype (Venables, 2004). It is estimated that over 90% of human 
genes are alternatively spliced, adding an enhanced layer of complexity and diversification 
to genes encoded in the genome (Matlin et al., 2005, DeBenedittis and Jiao, 2011). Cancer 
cells are able to exploit the process of alternative splicing to produce isoform switches, 
resulting in enhanced survival, proliferation and invasiveness (Oltean and Bates, 2014, Shen 
et al., 2016). 
Genes are transcribed into pre-mRNA, containing long intervening segments called 
introns, and protein-coding segments called exons. Alternative splicing refers to the “cutting” 
of intron-exon boundaries in pre-mRNA and joining the exons together in highly specific 
arrangements, producing structurally and functionally distinct mRNA and protein variants 
(Blencowe, 2006). The majority of alternative splicing events occur simultaneously with 
transcription, with the emergence of pre-mRNA from RNA polymerase II (Bentley, 2005, 
Blencowe, 2006). Additionally, modifiers of chromatin structure, including histone 
modifications and nucleosome positioning, affect transcription kinetics and thus alternative 
splicing decisions (Kornblihtt et al., 2013). This global post-transcriptional mechanism thus 
allows for cell-specific, stage-specific and stimuli-specific responses (Pajares et al., 2007). 
After transcription and pre-RNA processing is completed, mature mRNA is exported 
from the nucleus to the cytoplasm where it is translated into protein. As a precautionary 
quality control mechanism, the nonsense-mediated mRNA decay (NMD) pathway leads to 
cytoplasmic degradation of inappropriately expressed transcripts (Pajares et al., 2007). 
Sometimes an aberrant transcript is not detected by the NMD pathway and is translated into 
protein; this is observed in several diseases including cancers (Pajares et al., 2007). 
Each hallmark of cancer has been associated with changes in alternative splicing 
(Oltean and Bates, 2014). Mutations in cis-regulatory elements (i.e. splicing enhancers and 
silencers), near intron-exon junctions (i.e. creating or disrupting splice sites), or trans-acting 
splicing factors (i.e. involved in assembly of spliceosome) can lead to aberrant splicing 
(Pajares et al., 2007). Additionally, changes in concentration, localization, activity, and/or 
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composition of trans-acting splice factors (even in the absence of mutations) has also been 
documented to alter splicing patterns (Pajares et al., 2007). The documented splicing 
machinery changes during oncogenesis result in cancer-specific patterns of alternative 
splicing, leading to the emergence of previously non-existent transcripts and/or aberrant 
isoform ratios expressed within tumors relative to normal tissues (Pino et al., 2003, Venables, 
2004, Ladomery et al., 2007, Pajares et al., 2007). 
There are numerous examples of alternatively spliced transcripts having diverse and 
antagonistic functions (Pajares et al., 2007). A prominent example includes alternative 
splicing of vascular endothelial growth factor (VEGF); most splice variants are actively pro-
angiogenic (Ladomery et al., 2007). Interestingly, the VEGFb splice variant is actively anti-
angiogenic, and contains only 6 different amino acids relative to its most similar isoform 
(Ladomery et al., 2007). A splicing switch from the anti-angiogenic to pro-angiogenic variant 
is observed both in cancer progression, as well as in diseases such as proliferative diabetic 
retinopathy (Blencowe, 2006, Ladomery et al., 2007, Pajares et al., 2007). As such, 
differential expression of VEGF isoforms is associated with significant differences in survival 
for patients with node-positive breast cancer (Konecny et al., 2004).  
Recent studies have shown that alternative-splicing based analyses consistently 
outperform gene expression-based survival predictors (Shen et al., 2016, Klinck et al., 2008). 
Shen et al. have reported distinct cancer-associated alternative splicing patterns across 6 
different cancer types in the TCGA datasets (Shen et al., 2016). Various strategies are 
currently being employed in an attempt to exploit alternative splicing in diagnosis, prognosis 
and treatment of cancer (Yamaguchi et al., 1998, Venables, 2004). The large number of 
genes encoded in the human genome, along with the many subtypes of cancer in which 
alternative splicing changes have been documented suggests that the current knowledge is 
only the beginning in our understanding of the cause and effect of alternative splicing events 
in cancer, as well as how this knowledge may be used clinically.  
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 Alternative Splicing of T-box genes 
Most of the T-box family members encode a single transcript and few examples of 
alternative splicing have been documented (Wilson and Conlon, 2002, DeBenedittis and 
Jiao, 2011). While TBX3, TBX5 and TBX21 undergo alternative splicing, only TBX3 and 
TBX21 contain an insertion in their T-box domain (DeBenedittis and Jiao, 2011). Alternative 
splicing of TBX3 leads to two distinct transcripts; TBX3iso2 contains an additional 20 amino 
acid sequence in the DNA binding region attributed to the 2a exon, while TBX3iso1 does not 
(Bamshad et al., 1999). Alternative splicing of TBX21 leads to a three amino acid insertion in 
the DNA binding domain corresponding to the exon 2a insertion site in TBX3 (DeBenedittis 
and Jiao, 2011). While alternative splicing of TBX3 in particular is highly conserved within 
mammals (Hoogaars et al., 2008), the functional significance of the 2a exon remains unclear. 
These alternative splicing events may therefore provide a potentially critical differential role 
for TBX3 isoforms in development and tumorigenesis (DeBenedittis and Jiao, 2011). 
Previous studies have reported that isoforms of T-box proteins can differ in subcellular 
localization, expression, protein-protein interaction, and functionality (Wilson and Conlon, 
2002, DeBenedittis and Jiao, 2011). For example, alternative splicing of TBX5 leads to two 
protein products, TBX5a and TBX5b (DeBenedittis and Jiao, 2011). While only TBX5a can 
bind to the natriuretic peptide A (Nppa) promoter, both TBX5a and TBX5b can interact with 
GATA4 (Georges et al., 2008, DeBenedittis and Jiao, 2011). Additionally, TBX5a and TBX5b 
have differential cellular localization, with TBX5a being strictly nuclear localized while TBX5b 
is localized within the cytoplasm and nucleus (Georges et al., 2008). These studies indicate 
that relative levels, along with transcriptional targets and protein-protein interactions of each 
isoform must be examined in order to understand the resultant functions of alternatively 
spliced transcripts. 
The TBX3 isoform ratios were found to be tissue and species specific (Stennard et al., 
1999, Fan et al., 2004). Differing levels of TBX3 isoforms have also been reported in several 
breast cancer cell lines (Bamshad et al., 1999, Fan et al., 2004). Additionally, the ratio of 
TBX3iso2 to TBX3iso1 increased during osteogenic differentiation in human adipose stromal 
cells (Lee et al., 2007), thereby suggesting that isoform ratios are important in differentiation. 
Based on preliminary studies assessing functional differences between TBX3 isoforms, along 
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with details regarding differential properties of alternatively spliced T-box transcription 
factors, DeBenedittis et al. proposed that assessment of TBX3 isoform expression levels is 
of importance for future studies (DeBenedittis and Jiao, 2011).  
Residues Ser224 and Met225 within the DNA binding domain of human TBX3iso1 
have been shown to interact with target DNA sequences with the TBE through polar and 
hydrophobic interactions, respectively (see Figure 1.3.1) (Coll et al., 2002). The transcribed 
2a exon within TBX3iso2 is located at residues 220-240; this alternative splicing event shifts 
the residues that interact with target DNA, while the effect on transcriptional regulation 
remains unclear.  
Conflicting results have been published regarding functionality of the TBX3 isoforms. 
Fan et al. reported that TBX3iso2 did not bind to a sequence containing a previously-
identified TBE in their in vitro oligonucleotide binding assays (Fan et al., 2004), proposing 
that the 20-amino acid addition in the DNA binding domain of TBX3iso2 alters the protein’s 
binding to target sequences (Fan et al., 2004). Other studies have assessed TBX3iso1 and 
TBX3iso2 in various assays and found both isoforms to have similar functions in vitro, 
reporting that both TBX3 isoforms were able to bind to the TBE in the Nppa and p21CIP1 
promoters (Hoogaars et al., 2008). Hoogaars et al. proposed that since the 20-amino acid 
insertion does not make contact with DNA, it may not alter binding (Hoogaars et al., 2008). 
The function of T-box proteins is regulated by protein-protein interactions with other 
transcription factors (Lu et al., 2010), several of which are mediated through the T-box 
domain. Some groups have therefore speculated that there may be differential protein-
protein interactions between TBX3 isoforms. Through glutathione S-transferase (GST) pull 
down assays to examine TBX3iso1 and TBX3iso2 interacting proteins, it was revealed that 
both TBX3 isoforms physically interact with a known T-box interacting protein, NK2 
homeobox 5 (Nkx2-5), via the T-box binding domain (Hoogaars et al., 2008). Additionally, 
while both TBX3 isoforms were able to inhibit transcription of Nanog in luciferase assays, 
only TBX3iso2 was able to directly bind to Nanog in co-immunoprecipitation experiments 
(Zhao et al., 2014). More work is therefore needed in order to evaluate which proteins TBX3 
physically interacts with, and whether differences exist between isoforms. 
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Figure 1.3.1 – TBX3 Protein Sequence Secondary Structure.  
Protein structure of TBX3iso1 (with absence of 2a exon at residue 220-240) is shown above. 
Image was obtained from Protein Data Bank (PDB), available at https://www.rcsb.org.  
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1.4 Epithelial-Mesenchymal Transition (EMT) 
Over 90% of cancer-related deaths are due to the process of metastasis (Luzzi et al., 
1998, Kumar et al., 2013). Incredible phenotypic plasticity is required for malignant cells of 
epithelial origin to leave the primary tumor, intravasate into the blood or lymphatic vessels, 
and then extravasate at a distant secondary site and establish growth (Oltean and Bates, 
2014). The acquisition of an epithelial-mesenchymal transition (EMT) phenotype plays an 
important role in systemic dissemination of cancer cells through the process of metastasis 
(Chaffer and Weinberg, 2011). In breast cancer specifically, the phenomenon of EMT has 
been associated with highly aggressive tumors and therapeutic resistance (Blick et al., 2008, 
Sarrió et al., 2008, Creighton et al., 2009, Polyak and Weinberg, 2009).  
EMT is the process whereby epithelial cells lose apical-basal polarity, tight cell-to-cell 
contacts, and undergo remodelling of the actin cytoskeleton, with the acquisition of a more 
migratory mesenchymal phenotype. The process of EMT is critical in normal processes such 
as embryogenesis and wound healing, and is reactivated in invasive and metastatic tumors 
(Polyak and Weinberg, 2009, Thiery et al., 2009). The most studied transcription factors in 
the promotion of EMT include TWIST1, SNAIL (SNAI1), and SLUG (SNAI2) (Shapiro et al., 
2011). SNAIL, SLUG and TWIST1 are frequently overexpressed in IDC and have been 
associated with histological grade, lymph node metastasis, and reduced survival (Blanco et 
al., 2002, Elloul et al., 2005, Martin et al., 2005, Mironchik et al., 2005, Côme et al., 2006, 
Palena et al., 2014, Alix-Panabières et al., 2017).  
Several studies have shown that expression of EMT markers is associated with poor 
clinical outcome in several epithelial cancers, including breast cancer (Abba et al., 2004, 
Thompson et al., 2005, Sabbah et al., 2008, Shapiro et al., 2011, Sørlie et al., 2001). The 
induction of EMT is associated with alterations in canonical EMT markers, including up-
regulation of the mesenchymal proteins vimentin (VIM) and N-cadherin (CDH2), as well as 
down-regulation of the epithelial protein E-cadherin (CDH1). Both E-cadherin and N-cadherin 
are members of the cadherin superfamily of cell adhesion molecules involved in homophilic 
cell-to-cell interactions. E-cadherin is an integral epithelial membrane protein that mediates 
cell-to-cell adhesion and is widely regarded as a major suppressor of motility and 
invasiveness of cancer cells (Le Bras et al., 2012). Several EMT transcription factors (SNAIL, 
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SLUG, ZEB1, ZEB2, Brachyury) are able to directly down-regulate E-cadherin expression 
(De Craene and Berx, 2013). Combined repression of other junctional proteins, along with 
E-cadherin, facilitates the de-differentiation program and induction of EMT (De Craene et al., 
2005, Vandewalle et al., 2005, Moreno-Bueno et al., 2006, De Craene and Berx, 2013). The 
switch from E-cadherin to N-cadherin expression is associated with malignant progression 
and poor clinical outcome in several cancer types (Gravdal et al., 2007, Polyak and 
Weinberg, 2009). Up-regulation of N-cadherin enhances interaction between cancer cells 
and endothelial/stromal cells, thereby providing a mechanism for endothelial transmigration 
(Tran et al., 1999, Hazan et al., 2000). 
EMT is also associated with suppression of apoptosis, cellular senescence, and 
chemo-resistance (Polyak and Weinberg, 2009, De Craene and Berx, 2013, Nieto et al., 
2016). Additionally, several correlations have been documented relating expression of EMT 
markers and a stem-like phenotype, and response to breast cancer therapy (Mani et al., 
2008, Morel et al., 2008, Aktas et al., 2009, Creighton et al., 2009). This is likely due to an 
enrichment of CSCs after standard breast cancer treatments including letrozole or docetaxel 
(Mani et al., 2008, Creighton et al., 2009). 
Direct in vivo evidence for EMT has been challenging due to its dynamic and transient 
nature, as well as the reverse process, mesenchymal-epithelial transition (MET). The 
process of MET is believed to play a fundamental role once cells have extravasated from the 
vasculature into distant organs, allowing for clonal outgrowth (Alix-Panabières et al., 2017). 
While the process of EMT has been documented in mouse models (Oltean et al., 2008), 
many invasive tumors and metastatic lesions exhibit epithelial morphology and are positive 
for epithelial markers (Christiansen and Rajasekaran, 2006). This is likely attributed to partial 
induction of EMT, a restriction of the occurrence of this process to a small number of cells, 
and the reverse process of MET (Shapiro et al., 2011). The assessment of EMT markers 
would therefore only measure levels at one point in time, and has mostly been reported at 
the invasive front of primary tumors of epithelial origin (Scheel et al., 2007, Brabletz, 2012, 
Puisieux et al., 2014). Interestingly, studies assessing the importance of MET in metastatic 
colonization have reported that tumor cells that have undergone partial EMT possess the 
most malignant features (Nieto et al., 2016, Alix-Panabières et al., 2017). 
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 TBX3 and EMT 
An EMT phenotype is characterized by a cadherin switch, with reduced expression of 
the epithelial marker E-cadherin, and increased expression of the mesenchymal marker  
N-cadherin (Polyak and Weinberg, 2009). Importantly, TBX3 is able to directly repress  
E-cadherin expression levels, which has been documented in HCC and melanoma cell lines 
(Rodriguez et al., 2008, Dong et al., 2018). 
High throughput analyses have linked elevated TBX3 expression with an EMT 
phenotype (Humtsoe et al., 2012). In this study, Humtsoe et al. conducted microarray 
analysis to examine gene expression differences between a panel of squamous cell 
carcinoma (SCC) cell lines displaying either a non-EMT or an EMT-like phenotype (Humtsoe 
et al., 2012). They revealed strong up-regulation of TBX3 in EMT-like SCC cells, as well as 
in a model of Snail-induced EMT (Humtsoe et al., 2012). Additionally, they reported a close 
association between high TBX3 and N-cadherin expression, and low E-cadherin expression 
across twelve SCC cell lines (Humtsoe et al., 2012), which has been recapitulated in 
colorectal cancer samples (Shan et al., 2015), and gastric cancer cell lines (Miao et al., 2016). 
Elevated TBX3 expression is also associated with increased vimentin expression (Krstic et 
al., 2016, Miao et al., 2016). Lastly, TBX3 was shown to drive a pro-EMT phenotype in B-
RAF mutant melanomas (Boyd et al., 2013). These examples show that there is an 
abundance of preliminary studies showing a link between TBX3 and an EMT profile, although 
the molecular mechanisms remain elusive.  
Other T-box transcription factors, including Brachyury and TBX2, are also able to 
induce EMT (Fernando et al., 2010, Wang et al., 2012). Brachyury directly represses  
E-cadherin by binding to a TBE in the transcription start site (De Craene and Berx, 2013, 
Fernando et al., 2010). This binding site in the E-cadherin transcription start site reported for 
Brachyury (Fernando et al., 2010) overlaps with the identified binding site for TBX3 
(Rodriguez et al., 2008). 
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 SLUG 
SLUG (encoded by the SNAI2 gene) is a member of the SNAIL family of zinc-finger 
transcriptional repressors which mediate sequence-specific interactions with DNA (Phillips 
and Kuperwasser, 2014). SLUG contains a conserved SNAG domain in the N-terminus 
region, which is required for protein-protein interactions, transcriptional repression, and 
nuclear localization (Shirley et al., 2010, Chiang and Ayyanathan, 2013, Phillips and 
Kuperwasser, 2014). The zinc finger domain is located in the C-terminus of the protein, which 
facilitates binding to E-box motifs (Nieto, 2002, Phillips and Kuperwasser, 2014).  
The role of SLUG is well characterized in both embryonic development and 
tumorigenesis, with most of the literature focusing on its promotion of EMT (Barrallo-Gimeno 
and Nieto, 2005, Phillips and Kuperwasser, 2014). Physiologically, SLUG has been 
described as an important regulator of mammary epithelial cell differentiation, where it 
maintains cells in a basal-like state and repress luminal lineage differentiation (Proia et al., 
2011, Phillips et al., 2014, Phillips and Kuperwasser, 2014). Additionally, SLUG plays a 
critical role in multiple stages of cancer development (Phillips and Kuperwasser, 2014), and 
has been described as an important early initiator of EMT (Slabáková et al., 2011). 
Within breast cancers, elevated SLUG expression is often associated with basal-like 
tumors and mutations in the breast cancer associated 1 (BRCA1) gene (Foulkes et al., 2004, 
Arnes et al., 2005, Proia et al., 2011). While ER is able to directly repress transcription of 
SLUG (Ye et al., 2008, Ye et al., 2010), elevated estrogen levels are also able to induce 
SLUG expression through ERα; the effects mediated by ER on SLUG expression are 
therefore context-dependent. Elevated expression of SLUG, however, is associated with 
poor prognosis in both ER positive (Chimge et al., 2011), and ER negative breast cancers 
(Storci et al., 2008, Liu et al., 2013), as well as lymph node metastasis and therapy resistance 
(Côme et al., 2006, Alves et al., 2018). Interestingly, elevated SLUG expression in IDC has 
been associated with the presence of tubule structures, which is one of three criteria for the 
Scarff-Bloom-Richardson (SBR) grading system (Côme et al., 2006). This study by Côme et 
al., along with other experimental studies of partial induction of EMT (Dang et al., 2015), 
suggest the involvement of SLUG in collective cell migration. 
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1.5 Angiogenesis 
Solid cancers must form a blood supply through the process of angiogenesis if they 
are to grow beyond 1-2 mm in size (Knowles and Selby, 2005). This value represents the 
distance that oxygen, nutrients, and wastes can diffuse freely between a tumor and adjacent 
blood vessels (Kumar et al., 2013). Angiogenesis is a hallmark of cancer, and the newly-
formed blood vessels allow increased delivery of oxygen and nutrients, further providing a 
growth advantage for the tumor (Hanahan and Weinberg, 2000). Angiogenesis occurs 
through the formation of new micro-vessels from pre-existing vessels. This process also 
allows for systemic spread of cancer cells in the process of metastasis. Early studies 
assessing tumor angiogenesis in breast cancers showed that higher micro-vessel density 
corresponded to increased rates of distant metastasis (Weidner et al., 1991).  
The process of angiogenesis is triggered by tissue hypoxia and/or injury. Angiogenic 
factors are then released in the microenvironment, which diffuse in the extracellular millieu 
and are then able to activate endothelial cells (Nishida et al., 2006). Endothelial cells then 
migrate to the hypoxic area, proliferate, and form vessel structures (Nishida et al., 2006). The 
process may continue to be influenced through the balance of pro- and anti-angiogenic 
signaling molecules present within the microenvironment, which dictate the degree of 
angiogenesis (Knowles and Selby, 2005). 
 The use of anti-angiogenic therapies for cancer treatment was first proposed by 
Folkman in 1971 (Folkman, 1971), and this initial proposal has paved the way to a large body 
of work investigating the role of angiogenesis in tumor growth, along with the effect of its 
inhibition (Knowles and Selby, 2005). The emerging conclusion from several studies was that 
anti-angiogenics would be given as an adjuvant therapy in combination with cytotoxic drugs 
(Knowles and Selby, 2005). To date, the best characterized pro-angiogenic factor has been 
VEGF. Other notable pro-angiogenic regulators include FGF, the transforming growth factor 
(TGF) superfamily, hypoxia inducible factor alpha (HIF1α) and osteopontin (OPN; described 
in Section 1.5.1). 
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 Osteopontin and Angiogenesis  
OPN is a secreted phosphoprotein that is involved in both cell attachment to the 
extracellular matrix (ECM) through interaction with integrins and CD44, and induction of cell 
signaling pathways (Rittling and Chambers, 2004). Following binding and receptor activation, 
a series of signaling pathways are initiated, ultimately resulting in gene expression changes 
which modulate tumor cell behaviour. Elevated OPN expression has been associated with 
all six initially-described hallmarks of cancer in several different cancer subtypes (Cook et al., 
2005). For breast cancer specifically, elevated OPN expression is associated with early 
metastasis and poor outcome (Bellahcène and Castronovo, 1995, Rudland et al., 2002, 
Bramwell et al., 2006, El-Tanani et al., 2006, Tuck et al., 1998, Singhal et al., 1997).  
OPN modulates cell migration, invasion, and survival; this is mainly accomplished 
through interaction with integrins through its arginine-glycine-aspartate (RGD) integrin 
binding domain (Denhardt and Chambers, 1994, Tuck et al., 1999, Sodek et al., 2000, Lin 
and Yang-Yen, 2001, Geissinger et al., 2002). Integrins are transmembrane molecules 
comprised of a heterodimeric α and ß subunits that function by mediating adhesion between 
cells and interactions with the ECM (Knowles and Selby, 2005). OPN binds to the integrin 
heterodimers αvß1, αvß3, αvß5, α4ß1, α5ß1, α8ß1, and α9ß1 (Wai and Kuo, 2004, El-Tanani et 
al., 2006). Several of the aforementioned integrins are associated with metastasis and poor 
outcome, with much of the literature focusing on αvß3 (El-Tanani et al., 2006). In breast 
cancers, up-regulation of αvß3 is correlated with extent of disease and presence of bone 
metastasis (Liapis et al., 1996, Gasparini et al., 1998). OPN binds to the transmembrane 
protein CD44 in an RGD-independent manner (Sodek et al., 2000), resulting in up-regulation 
of CD44 and increased migration of breast cancer cell lines (Khan et al., 2005). A schematic 
of OPN protein structure and interactions is shown in Figure 1.5.1. 
Several studies have also reported crucial roles for tumor-derived OPN on 
angiogenesis (Pröls et al., 1998, Shijubo et al., 1999, Takano et al., 2000, Asou et al., 2001, 
Takahashi et al., 2002, Hirama et al., 2003, Leali et al., 2003, Cook et al., 2005, Chakraborty 
et al., 2006, Chakraborty et al., 2008). While integrins are minimally expressed on the surface 
of endothelial cells, their expression is significantly up-regulated during angiogenesis 
(Knowles and Selby, 2005). Binding of OPN within the tumor microenvironment to integrin 
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receptors (and/or CD44) on endothelial cells promotes angiogenesis through stimulation of 
endothelial cell migration, survival and lumen formation (Brooks et al., 1994, Senger et al., 
1996, Arap et al., 1998, Scatena et al., 1998, Bayless et al., 2000). OPN-induction of VEGF 
has also been reported (Chakraborty et al., 2008), as well as the reciprocal instance of VEGF-
induced OPN expression (Senger et al., 1996). Moreover, OPN, in cooperation with VEGF, 
has been shown to mediate αv integrin endothelial cell migration (Senger et al., 1996).  
Microarray analysis of transcripts altered upon constitutive OPN overexpression in 
breast cancer cells detected up-regulation of several genes, including hyaluronan synthase 
2 (HAS2) and increased production of hyaluronan (HA), which also mediates the process of 
angiogenesis (discussed in the Section 1.5.2) (Cook et al., 2005).  
 
 
 
Figure 1.5.1 – OPN protein structure and interactions. 
OPN contains many protein domains which facilitate interactions with receptor proteins, 
including the integrin binding domains (amino acid sequence for the domains is shown), 
along with the heparin binding domains which facilitates binding to CD44. OPN can be 
cleaved by two classes of proteases, including thrombin and MMPs, with the cleavage 
exposing new active domains. Adapted from (Musso et al., 2013). 
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 Hyaluronan and Angiogenesis 
The ECM plays a critical role in tumor development, providing cells with a scaffold 
which can be used for attachment, migration, and growth. An important ECM component that 
is up-regulated by OPN is HA, via up-regulation of HAS2 (Cook et al., 2006). HA is an 
unbranched polysaccharide consisting of repeating disaccharide subunits and constitutes a 
major portion of the ECM, particularly in tissues undergoing high rates of proliferation (West 
and Kumar, 1989). HA regulates the processes of adhesion, migration, proliferation, and 
differentiation (Itano et al., 1999, Tammi et al., 2002, Toole, 2004, Cook et al., 2006). HA is 
also able to up-regulate expression of OPN (Kim et al., 2005). Interestingly, both HA and 
OPN mediate several overlapping functions, and are frequently co-expressed across cancer 
subtypes (Kim et al., 2005, Lee et al., 2007).  
HA is produced at the intracellular face of the plasma membrane by hyaluronan 
synthase enzymes (HAS1-3) (Weigel and DeAngelis, 2007). The HAS enzymes are distinct 
in their stability, elongation rate, and size of HA synthesized, along with distinct expression 
patterns (Itano et al., 1999). Once synthesized by HAS enzymes, HA is then extruded from 
the cell and either released into the microenvironment, or retained in pericellular coats 
through interaction with cell surface receptors (Tammi et al., 1998, Evanko et al., 2007, 
Weigel and DeAngelis, 2007). High levels of synthesis and retention of HA in pericellular 
coats has an important role in malignant progression (Cook et al., 2006) and is an indicator 
of poor prognosis in epithelial cancers (Auvinen et al., 2000, Misra et al., 2006, Tammi et al., 
2008, Auvinen et al., 2014). HAS2 is the highest expressed among the HAS enzymes in 
breast cancer tissues and cell lines (Udabage et al., 2005b, Auvinen et al., 2014). Elevated 
HAS2 expression in breast cancer is associated with invasiveness (Udabage et al., 2005b, 
Udabage et al., 2005a), induction of EMT (Zoltan-Jones et al., 2003, Porsch et al., 2013), 
induction of angiogenesis (Koyama et al., 2007), and promotion of metastasis through 
increased interaction with stromal cells (Cook et al., 2006, Okuda et al., 2012).  
The effect of HA on angiogenesis is dependent on its molecular weight, which imparts 
unique biochemical properties; high molecular weight HA suppresses angiogenesis, while 
low molecular weight HA (4-20 disaccharides) stimulates endothelial cell migration, 
proliferation and angiogenesis (West et al., 1985, West and Kumar, 1989). The effect of HA 
within a tumor is thought to be dynamic; the leading edge of a tumor possesses large 
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amounts of high molecular weight HA, which aids in invasion via hydration of tissues and 
expansion of areas through which cancer cells can migrate (Iozzo and Müller-Glauser, 1985, 
Knudson et al., 1989, Rooney et al., 1995). As the tumor cells invade adjacent tissues, new 
HA is synthesized, while the remaining HA is degraded by hyaluronidase (HAse) enzymes, 
creating pro-angiogenic low molecular weight fragments (Rooney et al., 1995).  
CD44 is a transmembrane glycoprotein and the principal receptor for HA (Toole, 2009, 
Auvinen et al., 2013). CD44 is also able to bind several other ligands including OPN, 
collagens, and MMPs (Goodison et al., 1999, Senbanjo and Chellaiah, 2017). CD44 is 
ubiquitously expressed in adult and fetal tissues, with elevated expression levels in several 
cancers (Basakran, 2015). In breast cancer, elevated expression of standard CD44 as well 
as its splice variants is associated with disease progression and metastasis (McFarlane et 
al., 2015). Interaction between HA and CD44 results in activation of several signaling 
pathways (Misra et al., 2006, Toole, 2009). Additionally, HA is able to regulate the activity of 
several RTKs (most notably HER2) through stabilization of oncogenic CD44/RTK cell surface 
complexes (Bourguignon et al., 2001, Turley et al., 2002, Ghatak et al., 2005, Misra et al., 
2005, Bourguignon et al., 2006, Misra et al., 2006, Slomiany et al., 2009).  
The tumor stroma of breast cancer patients is associated with high HA expression 
near carcinoma cells, which is associated with several clinicopathological features including 
tumor size, lymph node positivity, and poor differentiation (Auvinen et al., 2013). CD44 is 
expressed on endothelial cells (Liesveld et al., 1994, Xu et al., 1994), and binding of HA to 
CD44 on endothelial cells promotes their migration (Trochon et al., 1996, Griffioen et al., 
1997, Savani et al., 2001). This provides a mechanism for HA- as well as OPN-induced 
angiogenesis, as OPN is able to promote elevated HA levels and itself bind CD44 on 
endothelial cells (Trochon et al., 1996, Griffioen et al., 1997, Savani et al., 2001, Kim et al., 
2005, Cook et al., 2006, Lee et al., 2007). 
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1.6 Summary of Objectives 
I hypothesized that the transcriptional regulatory proteins TBX3iso1 and TBX3iso2 
have distinct roles in breast cancer progression. This activity is mediated by their 
downstream transcriptional targets.  
To address my hypothesis, I had four main aims which are described over three chapters of 
my thesis: 
 
Aim 1: Examination of functional and phenotypic changes associated with modulation 
of TBX3 levels at various stages of breast cancer progression (Chapter 2). 
While TBX3 is overexpressed in several cancer types, the full scope of TBX3-associated 
functional changes in breast cancer was unclear due to the focus on melanoma cell lines 
within several prominent studies. Initial studies were therefore important in order to 
characterize the functional and phenotypic changes associated with modulation of TBX3 
levels at various stages of breast cancer progression, in an isoform-specific context. The 
majority of my work has focused on non-invasive DCIS-like 21NT cells and invasive IDC-
like 21MT-1 cells, in which increased TBX3 expression was identified in the DCIS to IDC 
transition (Souter et al., 2010). These findings have been corroborated through functional 
overexpression studies in 21PT, MCF7, T-47D, SKBR3, and MDA-MB-468 cells. Several 
prominent TBX3iso1 and TBX3iso2-dependent changes were observed, including 
alterations in growth, survival, invasiveness, and prominently, the acquisition of an EMT 
phenotype. 
 
Aims 2 & 3: Elucidation of the molecular mechanism of TBX3-induced EMT, and 
assessment of identified downstream targets (SLUG, TWIST1) in clinical samples of 
DCIS and early invasive breast cancer (Chapter 3). 
As a follow-up to Aim 1, the molecular mechanism of TBX3-induced EMT was investigated 
in Aim 2. High throughput studies, including ChIP-array and RNA-Seq, were conducted in 
order to gain a thorough understanding of both direct and indirect transcriptional changes 
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mediated by TBX3 isoform overexpression, with a focus on genes similarly altered with 
both TBX3 isoforms. SLUG was identified as a direct target up-regulated by both TBX3iso1 
and TBX3iso2, and an important downstream mediator of TBX3-induced migration and 
invasion. Another important regulator of EMT indirectly up-regulated by both TBX3 
isoforms was TWIST1. For Aim 3, the expression of TBX3 by IHC was assessed in two 
independent cohorts consisting of early stage breast cancers. Within the second cohort, 
expression of downstream targets identified in the high-throughput screens (SLUG and 
TWIST1) was also assessed by IHC. My findings from Aims 2 and 3 are reported together 
in Chapter 3, with a working schematic on the mechanism whereby TBX3 promotes 
progression by inducing EMT in low-grade, pre-invasive lesions, which is representative 
of luminal A breast cancers. 
 
Aim 4: Examination of the effects of TBX3 isoforms in vivo in nude mice (Chapter 4). 
As overexpression of TBX3 was previously identified in the DCIS to IDC transition, the 
effect of altered TBX3 expression on in vivo tumorigenesis was assessed in nude mice via 
mammary fat pad xenograft assays. Surprisingly, TBX3iso1 and TBX3iso2 differentially 
altered tumorigenicity, with overexpression of TBX3iso1 (but not TBX3iso2) in 21NT cells 
associated with high rates of invasive carcinoma. The mechanism of TBX3iso1-induced 
tumorigenicity was assessed through further mining and enrichment analysis of RNA-Seq 
data obtained in Aim 2. Interestingly, TBX3iso1 overexpression was associated with a pro-
angiogenic gene signature, with elevated expression of OPN and HAS2, increased 
hyaluronan retention, and thus increased rates of angiogenesis through in vitro assays. 
These changes likely explain the differential tumorigenicity between TBX3 isoforms in vivo.  
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 Examination of functional and phenotypic changes associated 
with modulation of TBX3 levels at various stages of breast 
cancer progression 
 
 
 
 
SUMMARY OF FINDINGS 
 
TBX3 is abundant in the invasive 21MT-1 cell line, while being minimally expressed in the 
non-invasive 21NT and 21PT cell lines. Overexpression of either TBX3iso1 or TBX3iso2 in 
21NT cells resulted in increased cell survival/colony forming ability, growth vs. apoptosis and 
invasion in Matrigel. In contrast, short hairpin RNA-mediated knockdown of TBX3 in the 
21MT-1 cells resulted in smaller colonies, with a more regular, less dispersed (less infiltrative) 
morphology. Array profiling of the 21NT TBX3iso1 and TBX3iso2 transfectants showed that 
there are common alterations in expression of several genes involved in signal transduction, 
cell cycle control/cell survival, epithelial-mesenchymal transition (EMT) and invasiveness. 
Overall, these results indicate that TBX3 expression can promote progression in a model of 
early breast cancer by altering cell properties involved in cell survival/colony formation and 
invasiveness, as well as key regulatory and EMT/invasiveness-related gene expressions. 
 
 
 
 
 
 
 
Chapter 2 in this dissertation has been published (Krstic et al. 2016, BMC Cancer).   
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2.1 Introduction 
Arguably the most critical stage of early breast cancer progression is the transition 
from DCIS to invasive mammary carcinoma (IMC). Although a number of molecular changes 
have been identified that accompany invasive breast cancer (Page et al., 1985, Page and 
Dupont, 1993, Lakhani et al., 1995, Allred et al., 2001, Arpino et al., 2005, Allred et al., 2008), 
those which may directly control the transition from DCIS to IMC remain elusive.  
Using microarray analysis, we previously identified TBX3 as a potential regulator of 
progression from DCIS to IMC, using the 21T cell lines which represent distinct stages of 
breast cancer progression (Souter et al., 2010). Specifically, we found that invasive and 
metastatic 21MT-1 cells expressed higher levels of TBX3 than non-invasive DCIS-like 21NT 
cells and non-invasive ADH-like 21PT cells (Souter et al., 2010). TBX3 is a member of the 
T-box family of transcription factors that play an important role in development of many 
animal species. In mouse embryo development, a model has emerged in which TBX3 
expression is both induced and maintained in early mammary gland initiation by Wnt and 
fibroblast growth factor (FGF) (Eblaghie et al., 2004). In humans, Ulnar-mammary syndrome, 
a congenital autosomal dominant disorder, is caused by mutations that result in 
haploinsufficiency of TBX3 and is characterized by upper-limb anomalies and mammary 
gland hypoplasia (Bamshad et al., 1999). 
TBX3 has been linked to tumorigenesis and is involved in cell cycle control and 
inhibition of cell senescence, through both p53-dependent and independent pathways 
(Brummelkamp et al., 2002, Carlson et al., 2002). The p53-dependent pathway signals 
through p14ARF, a tumor suppressor and cell cycle control protein that is a product of the 
cyclin-dependent kinase inhibitor 2A (CDKN2A) gene, along with p16INK4A. TBX3 directly 
represses transcription of p14ARF (Brummelkamp et al., 2002, Rowley et al., 2004). Down-
regulation or inhibition of p14ARF leads to increased proliferation and immortalization, as well 
as failure of apoptosis (Rowley et al., 2004). Aside from its role in the cell cycle, TBX3 is a 
known repressor of E-cadherin expression in melanoma, leading to enhanced invasiveness 
(Rodriguez et al., 2008, Boyd et al., 2013). TBX3 expression has also been found to be 
associated with cell survival in hepatocellular carcinoma, where it is induced by Wnt/β-
catenin signalling (Renard et al., 2007).  
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Two different isoforms of TBX3 have been identified, TBX3iso1 and TBX3iso2. The 
TBX3iso2 variant has an extra 20 amino acids, encoded by exon 2a, inserted into the T-box 
domain (Bamshad et al., 1999). As the 2a insertion is within the T-box domain, which is 
required for DNA-binding and protein-protein interactions, it was initially proposed that this 
variant may have altered DNA-binding properties, and that it may in fact interfere with the 
senescence-inhibiting properties (Fan et al., 2004). However, it has been found that 
TBX3iso2 can indeed bind to TBEs and act as an anti-senescence factor (Hoogaars et al., 
2008).  
Here we examined whether either or both isoforms of TBX3 can influence breast 
cancer progression, in particular the transition from non-invasive to invasive disease. We 
show that both isoforms of TBX3 have a similar functional effect in promoting breast cancer 
progression to a more malignant phenotype, and identify TBX3-induced changes in 
expression of genes involved in signal transduction, cell cycle control, cell survival and 
epithelial-mesenchymal transition (EMT)/invasiveness that may play a role in this 
progression.  
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2.2 Methods 
 
Cell lines and culture conditions 
The 21T parental cell lines (21PT, 21NT, and 21MT-1) were a kind gift from Dr. Vimla Band 
(Dana Farber Cancer Institute, Boston, MA) (Band et al., 1990) and were cultured in alpha 
modification of Eagle’s medium supplemented with 2.8μM hydrocortisone, 12.5ng/ml 
epidermal growth factor, 2mM L-glutamine, 1μg/ml insulin, 10mM HEPES, 1mM sodium 
pyruvate, 0.1mM non-essential amino acids and 50μg/ml gentamycin reagent (called αHE – 
all supplements from Wisent Bioproducts). For regular culture conditions, the αHE media was 
further supplemented with 10% fetal bovine serum (FBS) (Sigma-Aldrich) and named 
αHE10F. Stably transfected cells were cultured in αHE10F containing either 500μg/ml G418 
(Wisent Bioproducts) or 0.8μg/ml puromycin (Sigma-Aldrich). 
 
Generation of TBX3 expression vectors 
Expression vectors were constructed for each TBX3 isoform (TBX3iso1and TBX3iso2). To 
obtain TBX3iso2, PCR amplification of the whole transcript was performed from a pOTB7 
expression vector containing TBX3iso2 [Genbank:BC025258] (Open Biosystems Thermo 
Scientific) as the cDNA template using Phusion High-Fidelity DNA Taq polymerase (New 
England BioLabs). Primers used to amplify TBX3iso2 were: forward: 5’-GCC ACC ATG AGC 
CTC TCC ATG AGA-3’ and reverse: 5’-TTC GGG ACC GCC TGC GGG ACC TGT CCG GC-
3’. To produce TBX3iso1, two PCR product fragments, representing the transcript before 
(fragment 1) and after (fragment 2) the 60bp TBX3iso2 addition, were PCR amplified. Primers 
used for fragment 1 of TBX3iso1 were: forward: 5’-GCC ACC ATG AGC CTC TCC ATG 
AGA-3’ and reverse: 5’-CAT GGA GTT CAA TAT AGT AAA TCC ATG TTT GAC-3’. Primers 
used for fragment 2 of TBX3iso1 were: forward: 5’-TGG ATT TAC TAT ATT GAA CTC CAT 
GCA CAA AT-3’ and reverse: 5’-TTC GGG ACC GCC TGC GGG ACC TGT CCG GC-3’. All 
primers used for generation of the TBX3 expression vectors were purchased from Sigma-
Aldrich. Products were separated on 1% agarose gel and bands representing TBX3iso2 at 
~2000kb were extracted and pooled. For TBX3iso1, a band at ~660kb for fragment 1 and a 
band at ~1380kb for fragment 2 were gel extracted and pooled. When designing the PCR 
primers for the two fragments of TBX3iso1, the reverse primer of the upstream amplicon 
(fragment 1) and the forward primer for the downstream amplicon (fragment 2) had a 20bp 
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overlap to ensure that the ends of these amplicons would anneal in a subsequent PCR 
reaction to melt the fragments together. This annealed TBX3iso1 PCR product was purified 
and amplified again. After running this PCR product on a 1% agarose gel and extracting at 
~2000bp, both TBX3iso1 and TBX3iso2 PCR products were incubated with T4 
polynucleotide kinase (New England BioLabs), and purified. Both products were inserted 
separately into pZsGreen1-N1 plasmids (Clonetech Laboratories), such that the ZsGreen 
was fused to the C-terminus of TBX3. To prepare the pZsGreen1-N1 plasmid, it was digested 
with Afe1 (New England BioLabs) and incubated with calf intestinal alkaline phosphatase 
(New England BioLabs) to dephosphorylate the cut ends. The digested plasmid was 
electrophoresed and gel extracted. The plasmid and TBX3 PCR products were incubated 
overnight with ATP and T4 DNA Ligase (New England BioLabs) at 16°C to complete ligation. 
Competent bacteria (DH5α) were transformed with the ligated plasmid and kanamycin 
resistant clones were expanded to isolate DNA. Clones were digested with the following 
enzyme pairs to check for proper size and orientation: AgeI/KpnI, MfeI/XhoI, and NheI/HndIII. 
Suitable clones were sequenced (DNA Sequencing Facility at Robarts Research Institute, 
London, ON).  
The use of untagged TBX3 was required so the TBX3 expression vectors underwent 
site directed mutagenesis in order to introduce a stop codon at the end of full length TBX3iso1 
and TBX3iso2 using QuikChange Site-Directed Mutagenesis Kit (Agilent Technologies) 
according to the manufacturer’s protocol. Clones were sent to the DNA Sequencing Facility 
at Robarts Research Institute for sequencing. Clones with the proper sequence were used 
for stable transfections. 
 
Transfections 
Purified TBX3iso1 and TBX3iso2 plasmid DNA was transfected using PolyJet DNA In Vitro 
Transfection Reagent (SignaGen Laboratories) following the manufacturer’s protocol. Empty 
vector (EV) plasmids were transfected as a control. Stable transfectants were selected in 
αHE10F containing 500μg/ml G418 (Wisent Bioproducts). Approximately two weeks post-
transfection, resistant clones were pooled, expanded, and frozen for later use. 
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Generation of lentiviral particles and transduction 
Generation of short hairpin (sh) RNA containing lentivirus particles and knockdown of target 
genes were described previously (Moffat et al., 2006, MacMillan et al., 2014). The shRNA 
target sequence for TBX3 was GCA TAC CAG AAT GAT AAG ATA which targeted the coding 
sequence of both TBX3iso1 and TBX3iso2. The shRNA target sequence for Luciferase (off-
target knockdown control) was ACG CTG AGT ACT TCG AAA TGT. The TBX3 shRNA 
lentivirus particles generated were used to knockdown TBX3 in the 21MT-1 cell line and 
Luciferase shRNA was used a negative control. One week post-transduction, stable clones 
were selected in αHE10F containing 0.8μg/ml puromycin (Sigma-Aldrich) and resistant 
clones were pooled, expanded, and frozen for later use.  
 
Isolation of RNA and quantitative real-time polymerase chain reaction (qRT-PCR) 
Cells were harvested with trypsin and RNA was isolated using the RNeasy Mini Kit (Qiagen). 
Samples were treated with 30U DNase I (Qiagen), and 500ng of RNA was converted into 
cDNA with the Superscript III First-Strand Synthesis System (Invitrogen) using Oligo(dT) 12-
18 primers (Invitrogen). qRT-PCR was performed using RT2 SYBR Green ROX qPCR 
Mastermix (Qiagen) on an Mx3000P QPCR system. Primers used for total TBX3 were: 
forward: 5’-CGC TGT GAC TGC ATA CCA GA-3’ and reverse: 5’-GTG TCC CGG AAA CCT 
TTT GC-3’. Primers used for TBX3iso1 were: forward: 5’-AGT GGA TGT CCA AAG TCG 
TCA C-3’ and reverse: 5’-CAT GGA GTT CAA TAT AGT AAA TCC ATG TTT GTC TG-3’. 
Primers used for TBX3iso2 were: forward: 5’-AGT GGA TGT CCA AAG TCG TCA C-3’ and 
reverse: 5’-CAC TTG GGA AGG CCA AAG TAA ATC CAT G-3’. Primers used for GAPDH 
were: forward: 5’-AGG CTG GGG CTC ATT TGC AG-3’ and reverse: 5-‘CCA TCC ACA GTC 
TTC TGG GTG-3’. All primers were purchased from Sigma-Aldrich. Output values were 
reported relative to GAPDH as fold expression normalized to control cell lines. 
 
Preparation of 21T cell lysates 
Radioimmunoprecipitation (RIPA) buffer (10nM Tris-HCl pH 7.5, 1mM EDTA, 0.5mM EGTA, 
150nM NaCl, 1% Triton-X 100, 0.5% DOC, and 1% SDS) containing one protease inhibitor 
tablet per 10mL (Complete, Mini, EDTA-free Protease Inhibitor Cocktail, Roche) was used to 
lyse cells grown as subconfluent monolayers in 10cm dishes. The cells were removed with a 
cell scraper, collected in a clean microcentrifuge tube, and placed on a rotator for 20 minutes 
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at 4°C. Tubes were spun at 13,000 RPM for 10 minutes at 4°C and the resulting supernatant 
was collected. 
 
Electrophoresis and Western blotting 
Proteins were electrophoresed on 10% polyacrylamide gels and subsequently analyzed after 
transfer by Western blot with anti-TBX3 antibody (Abcam, ab58264; 1:2,000), anti-Vimentin 
(Dako, clone 3B4; 1/1,000), anti-Twist (Abcam, ab50887; 1:1,000), anti-Src (Cell Signaling, 
2108; 1:1,000), and anti-β-actin antibody (Abcam, ab49900; 1:150,000). After incubation with 
the appropriate horseradish peroxidase-conjugated secondary antibody (anti-mouse, 
Amersham GE Healthcare; anti-rabbit, Sigma) diluted 1:10,000, protein bands were detected 
using ECL Plus Western Blotting Detection Reagents (Amersham GE Healthcare) and then 
exposed to film in a dark room. Densitometric quantification was performed using ImageJ 
(Open source software, National Institutes of Health, USA).  
 
Immunohistochemistry of 21T cell pellets 
Trypsinized cells were washed twice in phosphate buffered saline (PBS), and pelleted in 
15mL conical tubes. Pellets were re-suspended in 10% neutral buffered formalin (NBF) and 
stored at 4°C overnight. Formalin was removed, and pellets re-suspended in 1mL of 1% 
agarose cooled to 35°C. The hardened pellets were wrapped in lens paper, cassetted, and 
processed to paraffin. For histology, 4μm sections were deparaffinized, pre-treated with 
10mM citrate buffer pH 6 and blocked for endogenous peroxidises in 3% H2O2/methanol. 
Sections were immunostained with rabbit anti-TBX3 antibody (Abcam, ab99302) diluted 
1:300 at 4°C overnight. Signal detection was accomplished using ThermoScientific 
UltraVision LP Detection System (TL-060-HD). 
 
Three-dimensional Matrigel culture and immunofluorescence 
Three-dimensional Matrigel culture was described previously (Debnath et al., 2003, Lee et 
al., 2007a, MacMillan et al., 2014). Following a 9 day growth period, images were taken at 
both 4X and 10X objective using an inverted microscope. ImageJ (Open source software) 
was used to determine colony formation rates by quantifying the percentage of the population 
that formed colonies greater than 50μm in diameter. ImageJ was also used to determine the 
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proportion of circular colonies; a binary quantification method was utilized, with a circular 
colony having a circularity index above 0.75. 
For immunofluorescence of Matrigel cultures, after 9 days of growth, the Matrigel 
plugs were fixed (10% NBF) and permeabilized (0.5% Triton X-100 in PBS). After blocking 
with normal goat serum (Invitrogen), rabbit anti-Ki67 (Abcam, ab833) and anti-cleaved 
caspase 3 (Cell Signaling, 9661) antibodies were incubated at 1:150 dilution in 10% normal 
goat serum overnight at 4ºC. Cells were incubated with Alexa Fluor 488 Goat Anti-Rabbit 
secondary antibody (Invitrogen, A11034) and counterstained with Hoechst 33342 (Invitrogen, 
H1399) and Alexa Fluor 546 Phalloidin (Invitrogen, A22238). Coverslips were mounted over 
the stained Matrigel plugs with ProLong Gold Antifade Reagent (Invitrogen). Imaging was 
done using an Olympus Confocal Imaging System (FluoView FV1000 coupled to the IX81 
Motorized Inverted System Microscope). Nuclei per colony were manually counted after 
acquiring 3D colony images. 
 
Transwell migration and invasion assays 
To assess the migratory potential of 21NT cells overexpressing TBX3 isoforms, transwell 
inserts with 8.0μm pores (Corning, 3422; 24-well plate) were coated with a thin layer of gelatin 
(6μg) to serve as a substrate for migration without obstructing movement through the pores. 
A 100μL cell suspension (5x105 cells/mL in αHE with 0.1% bovine serum albumin (BSA)) 
was added to the upper chambers and 0.75mL αHE10F media was added to the bottom 
wells. After incubation at 37°C and 5% CO2 for 22 hours, migrated cells were fixed with 1% 
glutaraldehyde for 20 minutes and stained with full-strength Hematoxylin for 15 minutes. 
Cells that remained on top of the membrane were removed using a cotton swab. Images of 
5 non-overlapping fields of view were acquired using Image-Pro Analysis Software (Media 
Cybernetics) coupled to an inverted microscope at 10X objective. Cells were counted from 
the acquired images using ImageJ (Open source software). Similarly, to assess the invasive 
potential, transwell inserts with 8.0μm pores precoated with Matrigel (Corning, 354480) were 
used and incubation lasted 22 hours. Means derived from 4 replicates were used during 
analysis.  
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RT2 PCR arrays 
RNA was isolated from TBX3iso1 and TBX3iso2 transfectants, as well as vector controls, 
using the RNeasy Mini Kit (Qiagen). 1μg RNA was converted into cDNA using the RT2 First 
Strand Kit (Qiagen). RT2 SYBR Green Mastermix was combined with the cDNA and dH2O 
as per the manufacturer’s protocol. Expression of 84 key genes commonly dysregulated in 
breast cancer were assessed using Human Breast Cancer RT2 PCR arrays (Qiagen, PAHS-
131ZA-2). Data analysis was conducted by SA Biosciences PCR Array Data Analysis Web 
portal using the ΔΔCt method normalized to acidic ribosomal phosphoprotein P0 (RPLP0) 
expression. Heat map showing absolute expression of mRNA was generated using the SA 
Biosciences RT2 profiler PCR Array Data Analysis Web Portal. 
 
Statistical analysis 
Statistical analyses were done using GraphPad Prism 5.0 software (La Jolla, CA). Colony 
morphology experiments, stain quantification, migration and invasion assays, and mRNA and 
protein levels were analyzed using one-way ANOVAs followed by Tukey’s post hoc test (for 
comparison between more than two groups) or Student’s t-test (for comparison between two 
groups). Proportions were analyzed via Fisher’s exact test. For all analyses, p<0.05 was 
considered statistically significant. 
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2.3 Results 
 TBX3iso1 and TBX3iso2 are differentially expressed in the 21T cell 
lines. 
We have previously reported that TBX3 is expressed in the 21T cell lines, with low levels in 
the ADH-like 21PT and DCIS-like 21NT cells, and increased expression in the IMC-like 
21MT-1 cells (Souter et al., 2010). This finding is consistent with previous reports that TBX3 
is up-regulated in invasive stages of cancer. Expression of TBX3 was examined in the 
parental 21T cell lines at the mRNA and protein level. Total TBX3 expression was higher in 
invasive 21MT-1 cells relative to the non-invasive (21PT and 21NT) cell lines (Figure 2.3.1 
A,D,E). Similarly, both TBX3iso1 and TBX3iso2 were up-regulated in 21MT-1 relative to 
21PT and 21NT cells (Figure 2.3.1 B,C). In contrast, no difference in either total TBX3 
expression, or expression of either isoform, was observed between the ADH-like 21PT cells 
and DCIS-like 21NT cells (Figure 2.3.1 A-E). 
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Figure 2.3.1 – TBX3iso1 and TBX3iso2 are differentially expressed in the 21T cell lines. 
(A-C) Primers specific for either total TBX3, TBX3iso1, or TBX3iso2 were used to assess 
relative abundance of each transcript in 21T parental cell lines by qRT-PCR. (D-E) Total 
TBX3 protein is differentially expressed in the parental 21T cell lines. An antibody recognizing 
both isoforms of TBX3 was used to assess the relative abundance of TBX3 within the 21T 
cell lines. Means were analyzed using one-way ANOVA followed by Tukey’s post hoc test 
and p<0.05 was considered statistically significant; ** p<0.01. Error bars indicate standard 
deviation. Results are representative of at least 3 independent experiments.  
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 TBX3 expression is increased in DCIS-like 21NT cells after stable 
transfection. 
In order to assess the effect of TBX3 on breast cancer progression, TBX3iso1 or TBX3iso2 
were overexpressed in the DCIS-like 21NT cell line and results were compared to an empty 
vector (EV) control containing the same antibiotic resistant gene (neomycin). The relative 
mRNA expression level of total TBX3, TBX3iso1 and TBX3iso2 was assessed by qRT-PCR 
in the stably transfected cells. Total TBX3 mRNA was significantly up-regulated in both 
TBX3iso1 and TBX3iso2 transfectants (Figure 2.3.2 A), and the overexpression of TBX3 was 
isoform specific (Figure 2.3.2 B,C). Likewise, western blot analysis shows an increase in total 
TBX3 protein levels in the TBX3 transfectant cells compared to the empty vector control 
(Figure 2.3.2 D,E). Cell pellets of TBX3 transfectants were assessed by 
immunohistochemistry (Figure 2.3.2 F,G). TBX3 protein was localized to the nucleus, and 
nuclear expression was significantly higher in TBX3 transfectants. Nuclear localization, as 
observed by immunohistochemistry, is consistent with the known function of TBX3 as a 
transcriptional regulator. 
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Figure 2.3.2 – TBX3 expression is increased in 21NT cell transfectants. 
21NT cell lines were stably transfected with either a TBX3iso1 or TBX3iso2 containing 
plasmid, or an empty vector control. (A-C) Assessment of relative transcript levels of total 
TBX3, TBX3iso1, and TBX3iso2 by qRT-PCR in stably transfected 21NT cells. (D-E) 
Assessment of total TBX3 protein levels by western blot in stably transfected 21NT cells. (F-
G) Assessment of percentage of nuclei staining positive for TBX3 by IHC in stably transfected 
21NT cell pellets. Cell pellets were stained using an anti-human TBX3 antibody and counter 
stained with Harris’s Hematoxylin (Hx). Means were analyzed using one-way ANOVA 
followed by Tukey’s post hoc test and p<0.05 was considered statistically significant; * 
p<0.05, ** p<0.01, ***p<0.001. Error bars indicate standard deviation. Results are 
representative of at least 3 independent experiments. 
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 TBX3 overexpression promotes progression of 21NT (DCIS) cells. 
To assess the role of TBX3 in the progression of DCIS to a more malignant phenotype, the 
3D morphology of the 21NT transfectants was assessed using a 3D Matrigel assay (Figure 
2.3.3 A-B). TBX3 isoform overexpression resulted in an increase in colony formation rates 
(Figure 2.3.3 C). As an index of the infiltrative vs. non-infiltrative nature of the colonies 
forming, we used a circularity index to determine the proportion of colonies that were circular 
(non-infiltrative) vs. non-circular (infiltrative). TBX3 isoform overexpression resulted in 
significantly less rounded, more infiltrative colonies (Figure 2.3.3 D). Immunofluorescence 
staining of colonies after 9 days of growth in Matrigel revealed significantly more nuclei per 
colony with TBX3 isoform overexpression (Figure 2.3.3 E). Additionally, immunofluorescence 
assessment of Ki67 and cleaved caspase 3 showed a significant increase in Ki67 (Figure 
2.3.3 F) and decrease in cleaved caspase 3 (Figure 2.3.3 G) expression in TBX3 isoform 
transfectants. This resulted in an increase in the proliferation to apoptosis (Ki67 / cleaved 
caspase 3) ratio for both TBX3 isoform transfectants (Figure 2.3.3 H). 
To further assess the migratory and invasive ability of TBX3-transfected 21NT cells, 
transwell assays were used. Cells were placed in the upper chamber of transwells (8.0μm 
pores coated with either a thin layer of gelatin for migration assays, or Matrigel for invasion 
assays) and allowed to migrate/invade through the pores towards a chemoattractant in the 
lower chamber. TBX3 isoform overexpression increased the ability of the cells to both migrate 
over gelatin (Figure 2.3.4 A-B) and invade through Matrigel (Figure 2.3.4 4C-D).  
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Figure 2.3.3 – TBX3 overexpression in DCIS-like 21NT cells results in a more 
aggressive phenotype in 3D Matrigel. 
TBX3 transfectants were seeded in 3D Matrigel at 3,000 cells per well and incubated at 37ºC 
and 5% CO2 for 9 days. (A) Immunofluorescence images depicting colony size of 21NT 
transfectants. Cells were grown in Matrigel for 9 days, then stained with Hoechst and 
Phalloidin and imaged using 60X objective. Scale bars represent 20μm. (B) Brightfield and 
phase contrast images showing growth of colonies after 9 days in 3D Matrigel. Brightfield 
images were taken using 4X objective, with the scale bar representing 100μm. Phase 
contrast images (inset) were taken using 40X objective, with the scale bar representing 
20μm. (C) TBX3 overexpression increases colony formation rates. A colony was considered 
to be successfully formed when larger than 50μm in diameter. Analysis was conducted using 
ImageJ. (D) TBX3 overexpression decreased the proportion of round colonies. Analysis was 
conducted using ImageJ. A binary quantification method was utilized; a circularity index 
above 0.75 was considered circular. (E) TBX3 overexpression increases the number of nuclei 
per cell colony. (F) TBX3 overexpression resulted in an increase in the percentage of Ki-67 
positive cells within colonies. (G) TBX3 overexpression resulted in a decrease in the 
percentage of cleaved caspase 3 positive cells within colonies. (H) The 
proliferation/apoptosis ratio, defined as the percentage of positive Ki67 cells divided by the 
percentage of positive cleaved caspase 3 cells, increased with overexpression of both TBX3 
isoforms. Means were analyzed using one-way ANOVA followed by Tukey’s post hoc test. 
The proportion of circular colonies was analyzed using Fisher’s exact test. A value of p<0.05 
was considered statistically significant; *p<0.05, **p<0.01, ***p<0.001. Error bars indicate 
Standard Deviation. Results are representative of at least 3 independent experiments.  
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Figure 2.3.4 – TBX3 overexpression increases migration and invasion of 21NT cells. 
(A-B) TBX3 overexpression increases migration using a transwell migration assay. 21NT cell 
transfectants were placed in the upper chamber of a transwell migration system with media 
containing 1% BSA and allowed to migrate towards αHE10F chemoattractant in the bottom 
chamber for 22 hours at 37ºC. Stable transfectants of both TBX3 isoforms showed an 
increase in migration using the transwell system. Scale bars represent 100μm. Results are 
quantified in panel b. (C-D) TBX3 overexpression increases invasion using a transwell 
invasion system. 21NT cell transfectants were placed in the upper chamber of a transwell 
invasion system with media containing 1% BSA and allowed to invade towards αHE10F 
chemoattractant in the bottom chamber for 22 hours at 37ºC. Stable transfectants of both 
TBX3 isoforms showed an increase in invasion using the transwell system. Scale bars 
represent 100μm. Results are quantified in panel D. Means were analyzed using one-way 
ANOVA followed by Tukey’s post hoc test. A value of p<0.05 was considered statistically 
significant; *p<0.05, **p<0.01, ***p<0.001. Error bars indicate Standard Deviation. Results 
are representative of 4 independent experiments. 
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 TBX3 knockdown reduces some characteristics of an aggressive 
phenotype in 21MT-1 (IMC) cells. 
To examine whether reduction of TBX3 expression has an effect at a later stage of 
progression, TBX3 was knocked down in the invasive 21MT-1 cell line, using shRNA 
targeting both isoforms. TBX3 expression in the knockdown with the greatest reduction in 
both TBX3iso1 and TBX3iso2 mRNA expression is shown, with shLUC representing the off-
target luciferase control (Figure 2.3.5 A-C). Quantitative RT-PCR analysis showed a five-fold 
reduction in total TBX3, TBX3iso1, and TBX3iso2 mRNA expression (Figure 2.3.5 A-C). 
There was also a corresponding reduction in total TBX3 at the protein level (Figure 2.3.5 
D,E). While the TBX3 knockdown cells were still able to form colonies at a rate comparable 
with the shLUC control cells in the 9-day Matrigel assay (Figure 2.3.5 F,G), TBX3 knockdown 
resulted in an increased proportion of round/circular colonies (i.e. less dispersed/infiltrative; 
Figure 2.3.5 H) and fewer nuclei per colony (Figure 2.3.5 I), suggesting a reduction in 
invasiveness and impaired growth in 3D.  
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Figure 2.3.5 – TBX3 knockdown results in a less aggressive phenotype of IMC-like 
21MT-1 cells in 3D Matrigel. 
(A) Total TBX3 mRNA is decreased in 21MT-1 shTBX3 cells after TBX3 knockdown. (B) 
TBX3iso1 mRNA is decreased in 21MT-1 shTBX3 after TBX3 knockdown. (C) TBX3iso2 
mRNA is decreased in 21MT-1 after TBX3 knockdown. (D) Western blot showing total TBX3 
protein is decreased in 21MT-1 shTBX3 cells after TBX3 knockdown. (E) Densitometry 
quantification of western blot shows a significant decrease in total TBX3 protein expression 
in the 21MT-1 shTBX3 cells. (F) Brightfield images showing colonies after 9 days in 3D 
Matrigel. Images were taken at 4X objective. Scale bars represent 100μm. (G-I) Cells were 
seeded in Matrigel and grown for 9 days. All of the cell lines were able to form colonies (G), 
but shTBX3 colonies were rounder (i.e. less dispersed, less invasive) (H) and smaller (I). 
Means were analyzed using one-way ANOVA followed by Tukey’s post hoc test. The 
proportion of circular colonies was analyzed using Fisher’s exact test. A value of p<0.05 was 
considered statistically significant; *p<0.05, **p<0.01, ***p<0.001. Error bars indicate 
Standard Deviation. Results are representative of at least 3 independent experiments. 
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 Up-regulation of TBX3 in 21NT (DCIS) cells results in alterations in 
expression of key regulatory and EMT/invasion associated genes. 
We assessed the mRNA expression patterns of TBX3iso1 and TBX3iso2 transfected 21NT 
cells by RT2 PCR arrays, and found a number of alterations in expression of key regulatory 
and EMT/invasion-associated genes. As 21NT cells transfected with either TBX3iso1 or 
TBX3iso2 had shown a similar more aggressive phenotype, we focused our interest on genes 
whose expression changed in common in both TBX3iso1 and TBX3iso2 transfected cells. 
We identified altered expression of a number of genes involved in signal transduction, cell 
cycle control, cell survival and EMT/invasiveness (Figure 2.3.6). In reference to pathways 
potentially involved in control of cell cycle, proliferation, apoptosis and cell survival, we 
observed significant down-regulation of CDKN2A (previously shown to be a key gene directly 
regulated by TBX3 in blocking cell senescence (Rowley et al., 2004, Yarosh et al., 2008)) 
with up-regulation of marker of proliferation Ki67 (MKI67); Jun proto-oncogene (JUN); 
nuclear receptor subfamily 3, group C, member 1 glucocorticoid receptor (NR3C1); epidermal 
growth factor receptor (EGFR); androgen receptor (AR); interleukin-6 (IL6); SRC proto-
oncogene (SRC); and V-Akt murine thymoma viral oncogene homolog 1 (AKT1). Although 
the observed increase in retinoblastoma 1 (RB1), stratifin (SFN), breast cancer 1, early onset 
(BRCA1) and breast cancer 2, early onset (BRCA2) may seem counter-intuitive when the 
TBX3 up-regulated cells are found to be actively cycling and faster-growing, it is likely that 
these are attempted adaptation responses to the more direct effect of CDKN2A down-
regulation by TBX3, the expected result of which would be release of cell-cycle checkpoint 
control, inhibition of senescence and apoptosis and promotion of progression through the cell 
cycle and cell proliferation. 
 Several genes potentially associated with EMT and cellular invasiveness were also 
altered in TBX3 isoform transfectants. Transcriptional regulators twist family BHLH 
transcription factor 1 (TWIST1) and snail family zinc finger 2 (SNAI2) were both up-regulated, 
as was SRC, and there was also altered expression of several proteases and protease 
inhibitors (including up-regulation of plasminogen activator, urokinase (PLAU), serpin 
peptidase inhibitor, clade E, member 1 (SERPINE1), and matrix metallopeptidase 9 (MMP9); 
and down-regulation of cystatin E/M (CST6)). Up-regulation of mesenchymal marker 
vimentin, as well as EMT-markers Twist and Src were confirmed at the protein level as well 
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(Figure 2.3.6 E). Whether directly or indirectly, up-regulation of either isoform of TBX3 in 
21NT cells thus induced alterations in gene expression in pathways potentially involving cell 
cycle, cell survival, cell growth control and EMT/invasiveness, with the resulting in vitro 
phenotypes of more efficient and larger colony formation, increased proliferation/apoptosis 
ratio and increased motility and invasiveness through Matrigel. 
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Figure 2.3.6 – TBX3 overexpression in DCIS-like 21NT cells alters expression of key 
regulatory and EMT/invasion-associated genes. 
(A) Heat map (84 genes commonly dysregulated in breast cancer) showing absolute mRNA 
expression of 84 breast-cancer related genes within the 21NT transfectant cells. (B) Fold 
changes (mRNA) of genes significantly altered in expression in a similar fashion with 
overexpression of both TBX3iso1 and TBX3iso2 in 21NT cells. Data analysis was conducted 
by SA Biosciences PCR Array Data Analysis Web portal using the ΔΔCt method normalized 
to acidic ribosomal phosphoprotein P0 (RPLP0) expression. Fold changes are compared to 
21NT+EV control and are organized based on increasing fold change of TBX3iso1. The 24 
genes shown had similar alterations in gene expression with statistically significant fold 
changes for both isoforms (* p<0.05, ** p<0.01, ***p<0.001). Genes in green had reduced 
expression, and genes in red had increased expression at the mRNA level with TBX3 isoform 
overexpression. Results are representative of 3 RT2 PCR arrays per cell line. (C) Graphical 
representation of fold changes in panel (A). Dotted line represents normalized expression of 
transcript levels of empty vector control cells (fold change = 1). (D) Gene expression changes 
with TBX3 isoform overexpression organized based on gene function groupings. Genes in 
green had reduced expression, and genes in red had increased expression at the mRNA 
level with TBX3 isoform overexpression. (e) Western blot showing increased expression of 
Vimentin, Twist and Src protein levels with TBX3 overexpression. 
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2.4 Discussion 
By using the 21T cell line series to model the effects of putative drivers of the transition from 
pre-invasive to invasive breast cancer progression, we are able to demonstrate that 
overexpression of TBX3 can promote the transition of DCIS to IMC as assessed by in vitro 
3D Matrigel growth assays. In particular, 21NT (DCIS-like) cells overexpressing TBX3iso1 or 
TBX3iso2 showed increased colony-forming ability, with increased numbers of cells per 
colony and a more dispersed (less “rounded”) colony morphology. Increased cell 
invasiveness was also observed, both in terms of more dispersed colonies in 3D Matrigel 
and increased invasion through Matrigel. In parallel, down-regulation of TBX3 in 21MT-1 cells 
resulted in a less aggressive phenotype in 3D Matrigel, with smaller and less dispersed (less 
invasive) colony morphology. 
 No significant difference in functional activity in any of these in vitro measures of 
malignancy was observed between the TBX3 isoforms. Interestingly, RT2 PCR array analysis 
did show several differences in gene expression profiles induced by TBX3iso1 and 
TBX3iso2, as well as a number of commonalities (Figure 2.3.6 A). As we saw no difference 
in functional effect, our analysis was focused on gene expression alterations occurring in 
common between the two isoforms, which could potentially explain characteristics of the 
more aggressive phenotype observed in both TBX3iso1 and TBX3iso2 transfectants. 
 Firstly, the increased colony-forming ability in 3D Matrigel, with larger colony size and 
increased proliferation vs. apoptosis ratio observed with both TBX3iso1 and TBX3iso2 21NT 
transfectants indicated an increased cell survival and predisposition for proliferation vs. 
apoptosis (or senescence), effects that have been previously ascribed to TBX3 in other 
systems (Brummelkamp et al., 2002, Carlson et al., 2002, Rowley et al., 2004, Yarosh et al., 
2008). Gene expression profiling of the TBX3 transfectants in our study showed altered 
expression of several genes potentially involved in these processes in both TBX3iso1 and 
TBX3iso2 transfected cells (i.e. down-regulation of CDKN2A (p14ARF, p16INK4A), with up-
regulation of MKI67, JUN, NR3C1, EGFR, AR, IL6, SRC and AKT1). Perhaps most 
interesting of these is the down regulation of CDKN2A (p14ARF, p16INK4A) by both TBX3 
isoforms, as previous studies have indicated p14ARF in particular to be a direct transcriptional 
target of TBX3 in other systems (Yarosh et al., 2008), and that isolated down-regulation of 
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p14ARF can accomplish the same effect of increasing cell proliferation, decreasing cell 
senescence and apoptosis (Rowley et al., 2004). Further work is required to determine 
whether p14ARF or others of the candidate genes identified are responsible for the cell 
survival/proliferation vs. apoptosis/senescence aspects of the TBX3 phenotype in these cells.  
Another prominent aspect of the altered phenotype observed with both TBX3iso1 and 
TBX3iso2 21NT transfectants was a more irregular/dispersed colony morphology in 3D 
Matrigel, with increased cellular invasiveness in transwell assays, suggestive of an EMT 
effect. In keeping with this, both TBX3iso1 and TBX3iso2 transfectants showed alteration in 
expression of a number of EMT and invasion-related genes that are consistent with an EMT 
phenomenon, including up-regulation of TWIST1, SRC, SNAI2, PLAU, SERPINE1, and 
MMP9, with down-regulation of CST6. Western blot analysis showed up-regulation of Twist 
and Src, along with mesenchymal marker Vimentin at the protein level as well.  
Our work is in agreement with that of previous studies with other mammary epithelial 
cells (MCF7, MDA-MB-435, HC11) (Platonova et al., 2007, Peres et al., 2010) in which TBX3 
was shown to have functional effects including inhibition of senescence and promotion of cell 
survival, proliferation and migration. We present the added novel finding, using a progression 
series of mammary epithelial cells, that overexpression of TBX3 can trigger non-invasive 
(DCIS-like, 21NT) cells to become invasive, possibly through an EMT-like process. In 
addition, knockdown of TBX3 in invasive (21MT-1) cells can revert them to a less aggressive 
phenotype, with less potential for 3D growth and a less infiltrative phenotype. Furthermore, 
we have shown that these effects are not isoform specific, as both TBX3iso1 and TBX3iso2 
were able to induce the same phenotypes in transfected 21NT cells. Finally, examination of 
TBX3-induced changes in gene expression of 21NT cells has revealed specific cell 
survival/anti-senescence/proliferation and EMT/invasiveness category alterations, which 
may be involved in the functional changes observed. Future work will be necessary to 
establish which of these changes may be key players in the TBX3-induced phenotypes.  
We have demonstrated a role for both TBX3iso1 and TBX3iso2 in promoting the 
transition from non-invasive to invasive breast cancer. We have shown that overexpression 
of TBX3 can alter cell properties involved in cell survival/colony formation and invasiveness, 
as well as regulate EMT/invasiveness-related genes. The identification of TBX3 as a potential 
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regulator of early breast cancer progression from DCIS to IMC is of potential clinical utility 
not only in identifying which DCIS lesions may be more likely to progress to invasion, but 
along with a better understanding of the role of specific TBX3-induced gene expression 
changes, in providing other potential molecular targets to block breast cancer progression at 
this early, pre-invasive stage. The recent finding that TBX3 alterations may be key driver 
mutations in breast cancer, and the suggestion that altered (probably increased) TBX3 
function may be associated with at least some cases of familial breast cancer (Stephens et 
al., 2012a), adds particular significance to the potential of TBX3 as an important regulator of 
breast cancer progression, and added urgency to a better understanding of its role in the 
malignancy of breast cancer. 
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 TBX3 promotes progression of pre-invasive breast cancer cells 
by inducing EMT and directly up-regulating SLUG 
 
 
SUMMARY OF FINDINGS 
 
The acquisition of cellular invasiveness by breast epithelial cells and subsequent transition 
from ductal carcinoma in situ (DCIS) to invasive breast cancer is a critical step in breast 
cancer progression. Little is known about the molecular dynamics governing this transition. 
We have previously shown that overexpression of the transcriptional regulator TBX3 in DCIS-
like cells increases survival, growth, and invasiveness. To explore this mechanism further 
and assess direct transcriptional targets of TBX3 in a high-resolution, isoform-specific 
context, we conducted genome-wide ChIP-arrays coupled with transcriptomic analysis. We 
show that TBX3 regulates expression of several epithelial-mesenchymal transition (EMT) 
related genes, including SLUG and TWIST1. Importantly, we demonstrate that TBX3 is a 
direct regulator of SLUG, and SLUG expression is required for TBX3-induced migration and 
invasion. Assessing TBX3 expression by immunohistochemistry in early stage (Stage 0 and 
Stage I) breast cancers revealed high expression in low-grade lesions. Within a second 
independent, early stage (Stage 0 and Stage I), non-high-grade cohort, we observed an 
association between TBX3 expression in the DCIS and size of the invasive focus. 
Additionally, there was a positive correlation between TBX3 and SLUG expression, and 
TBX3 and TWIST1 expression in the invasive carcinoma. Pathway analysis revealed altered 
expression of several proteases and their inhibitors, consistent with the ability to degrade 
basement membrane in vivo. These findings strongly suggest the involvement of TBX3 in the 
promotion of invasiveness and progression of early stage pre-invasive breast cancer to 
invasive carcinoma through the low-grade molecular pathway. 
 
 
 
Chapter 3 in this dissertation has been submitted, and is currently under peer-review.  
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3.1 Introduction 
Tumorigenesis within the breast is thought to involve advancement through distinct stages, 
from benign ductal epithelial hyperplasia, to atypical ductal hyperplasia (ADH), ductal 
carcinoma in situ (DCIS), and ultimately invasive and metastatic carcinoma (Burstein et al., 
2004). A very critical stage of this progression pathway is the acquisition of cellular 
invasiveness. It is estimated that approximately 25-50% of DCIS will progress to invasive 
carcinoma during the lifetime of the patient, a process generating potentially life-threatening 
disease (Sagara et al., 2015). Clinical management of patients with DCIS usually consists of 
surgical resection with additional radiation therapy for most patients (Fisher et al., 1999, 
Mokbel and Cutuli, 2006). Several recent studies, however, have suggested that a subset of 
patients with early-stage (non-high-grade) DCIS do not benefit from either surgery alone or 
combined surgery and radiation, raising concern regarding over-treatment of this 
subpopulation (Thorat et al., 2007, Formenti et al., 2011, Sagara et al., 2015). Paradoxically, 
we are currently limited in our ability to identify patients with DCIS that have an intrinsically 
higher risk of local and invasive recurrence, such that there is also a risk of under-treatment 
if excision is incomplete or radiation therapy is omitted.  
The 21T series cell lines have been proposed as a unique experimental model of 
breast cancer progression (Band et al., 1990). Three cell lines were isolated from a single 
patient and stably represent distinct stages of progression: 21PT cells mimic ADH (non-
tumorigenic), 21NT cells mimic DCIS (tumorigenic and non-metastatic), and 21MT-1 cells 
depict characteristics of invasive mammary carcinoma (tumorigenic and metastatic) when 
injected orthotopically into nude mice (Band et al., 1990, Souter et al., 2010). We have 
previously conducted extensive characterization of these cell lines, including examination of 
global gene-expression levels coupled with assessment of clinical literature on progression 
(Souter et al., 2010). Importantly, we found that during the transition from the clonally-related 
DCIS-like 21NT cells to invasive 21MT-1 cells, TBX3 was within the list of clinically-relevant 
up-regulated transcripts (Souter et al., 2010). 
TBX3 is a member of T-box family of transcription factors implicated in skeletal, 
cardiac and mammary gland development (Willmer et al., 2017). TBX3 levels are up-
regulated in several cancers, with most of the literature focusing on breast cancer (Fan et al., 
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2004, Lomnytska et al., 2006, Yarosh et al., 2008, Souter et al., 2010) and melanoma 
(Rodriguez et al., 2008, Peres and Prince, 2013). Due to alternative splicing, two TBX3 
isoforms exist: TBX3iso1 and TBX3iso2. TBX3iso2 contains an additional 20-amino acid 
sequence in the DNA binding domain attributed to the 2a exon, which TBX3iso1 lacks. 
Differing expression levels of these isoforms has been reported in several breast cancer cell 
lines (Fan et al., 2004). While the role of TBX3 in tumorigenesis is currently unclear, 
accumulating evidence suggests that the TBX3-mediated transcriptional repression of p14ARF 
(Lingbeek et al., 2002, Yarosh et al., 2008) and/or p21CIP1 (Hoogaars et al., 2008) plays a 
role in bypassing cellular senescence and driving cancer progression. Recent work has 
begun to identify a link between TBX3 expression levels and epithelial-mesenchymal 
transition (EMT), with direct down-regulation of E-cadherin (Rodriguez et al., 2008). These 
findings are important, as the switch from an epithelial to a mesenchymal phenotype has 
been implicated in the acquisition of migratory and invasive properties, suppression of 
senescence and apoptosis, as well as therapeutic resistance (De Craene and Berx, 2013). 
SLUG (encoded by the SNAI2 gene) is a member of the SNAIL family of transcription factors 
and a key mediator in the promotion of EMT (De Craene and Berx, 2013, Phillips and 
Kuperwasser, 2014). Specifically, SLUG has been shown to trigger the initial phases of the 
EMT process (Savagner et al., 1997).  
In this study we explore the role of TBX3 in breast cancer progression pathways, 
focusing specifically on its involvement in the induction of EMT and the transition from DCIS 
to invasive mammary carcinoma. Immunohistochemical analysis has revealed that TBX3 
levels are elevated in low-grade, pre-invasive DCIS lesions with an associated invasive 
component, and significantly correlated with the size of the invasive focus. Using genome-
wide bioinformatic approaches in conjunction with more conventional in vitro studies, we 
have identified SLUG and TWIST1 as downstream targets of TBX3 and have assessed their 
expression by immunohistochemistry in two different patient cohorts. Our findings suggest 
that TBX3 facilitates the process of early invasion in DCIS, by promoting the induction of 
EMT and tumor progression through the low-grade pathway, as described by Bombonati and 
Sgroi (Bombonati and Sgroi, 2011). Finally, we propose a progression model in which SLUG 
is an important and necessary effector downstream of TBX3, leading to increased motility, 
invasiveness, and induction of key invasiveness-associated genes. 
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3.2 Methods 
Cell lines and culture conditions 
The 21T series cell lines (21NT and 21MT-1) were obtained as a gift from Dr. Vimla Band 
(Dana Farber Cancer Institute) (Band et al., 1990). 21T series cell lines underwent 
authentication testing by Idexx Radil (Case No. 20250-2013). Cells were maintained in 
αMEM media supplemented with 2mM L-glutamine, 1µg/mL insulin, 12.5ng/mL EGF, 2.8µM 
hydrocortisone, 10mM HEPES, 1mM sodium pyruvate, 0.1mM non-essential amino acids, 
and 50µg/mL gentamycin sulfate and further supplemented with 10% FBS (αHE10F). All 
reagents were obtained from Wisent Inc. Stable 21NT transfectants previously generated 
(Krstic et al., 2016) were maintained in αHE10F medium supplemented with 500µg/mL G418 
as a selection marker. Stable lentiviral transductants were maintained in αHE10F medium 
supplemented with either 0.8µg/mL puromycin (TBX3 knockdown lines) or 500M 
hygromycin (SLUG knockdown lines) as a selection marker.  
Cell lines representing other molecular breast cancer subtypes were purchased from 
ATCC. Cell lines were maintained in their respective media: T47D (RPMI), SKBR3 (McCoy’s 
5A), and MDA-MB-468 (αMEM) supplemented with 10% FBS. All cell lines were regularly 
tested and negative for Mycoplasma contamination using the Mycoplasma PCR Primer Set 
(Agilent Technologies, 302008). 
 
Stable Transfection 
21NT parental cell lines were seeded into 6-well plates at 350,000 cells per well, and 
transfected the following day at 3g of DNA plasmid per well using the Lipofectamine 3000 
Transfection Kit (Invitrogen, L3000). Plasmid DNA constructs were previously described 
(Krstic et al., 2016) and consist of an empty vector (EV), TBX3iso1, and TBX3iso2 construct 
within a pcDNA3.1 (Invitrogen, V79020) vector. Selection was performed using αHE medium 
supplemented with 500g/mL G418. Resistant clones were pooled, expanded, and frozen 
for later use. 
 
Transient Transfection 
For assessment of E-cadherin expression and localization, 21NT parental cell lines were 
seeded into 6-well plates at 350,000 cells per well, and transfected the following day with 
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3g of DNA plasmid per well using the Lipofectamine 3000 Transfection Kit (Invitrogen, 
L3000). Plasmid DNA constructs consisted of an empty vector (EV), TBX3iso1, and 
TBX3iso2 construct within pZsGreen1-N1 vector containing the ZsGreen reporter gene. For 
immunofluorescence studies, transfected cells were grown under normal conditions for 72 
hours and then underwent immunofluorescent staining.  
For invasion assay studies, cells (T-47D, SKBR3, MDA-MB-468) were incubated with 
transfection reagent and the appropriate plasmid for 24 hours, then harvested and assays 
were performed. Plasmid DNA constructs consist of an empty vector (EV), TBX3iso1, and 
TBX3iso2 construct within pZsGreen1-N1 vector containing the ZsGreen reporter gene. 
 
Lentiviral Transduction 
The generation of shRNA-encoding lentivirus particles for TBX3 knockdown was conducted 
as previously described (Krstic et al., 2016). The shRNA target sequence for TBX3 was 
GCATACCAGAATGATAAGATA, which targeted the coding sequence of both TBX3iso1 and 
TBX3iso2. The shRNA target sequence for Luciferase (representing an off-target control) 
was ACGCTGAGTACTTCGAAATGT. The lentivirus particles were used to generate 21MT-
1 shLUC and 21MT-1 shTBX3 cell lines. Selection was performed using αHE medium 
supplemented with 0.8g/mL puromycin. Resistant clones were pooled, expanded, and 
frozen for later use. 
Down-regulation of SLUG (SNAI2) was performed using lentivirus-mediated shRNA 
transduction. 293T packaging cells were seeded at 80% confluence in 6-well plates with low-
antibiotic growth media (DMEM with 10% FBS and 0.1x Penicillin/Streptomycin). The 
following day the packaging cells were transfected with the packaging plasmid (Addgene, 
pCMV-dR8.91, 900ng), envelope plasmid (Addgene, VSV-G/pDM2.G, 100ng), and psi-
LVRU6H vector encoding one of 4 shRNAs specific to SNAI2 (Genecopoeia, HSH017502-
LVRU6H, 1g) or an empty vector control (Genecopoeia, CSHCTR001-LVRU6H, 1g) 
(quantities reported per well). The FuGENE transfection reagent (Promega, E2311) was 
mixed with the 3-plasmid mix as per the manufacturer’s protocol. The transfection mix was 
incubated for 30 minutes at room temperature, and 200L was added to the packaging cells. 
Viral harvesting was done three times, spaced out by 12-24 hours by replacing media with 
6mL of high-BSA growth media (20g BSA per 100mL DMEM). The three viral harvests were 
pooled and the viral supernatant was frozen.  
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21NT transfectants (21NT+EV, 21NT+TBX3iso1, 21NT+TBX3iso2) were seeded at 
200,000 cells per well in 6-well plates. The following day 300L of the shRNA-encoding 
lentiviral particles were added to the cells along with 2g polybrene (Sigma, TR-1003-G) per 
2mL media. The cells were incubated at 37ºC overnight and transduced cells were selected 
for by including 500M hygromycin (Invitrogen, 10687-010) in the media (aHE10F with 
500M hygromycin, 500ug/mL G418). Media was replaced again the following day, and cells 
were trypsinized and expanded into T25 flasks on the third day.  
 
Preparation of 21T protein lysates 
Protein lysates were prepared by adding 1mL of RIPA buffer (150mM NaCl, 1% Triton-X, 
0.5% deoxycholic acid, 0.1% SDS, 50mM Tris-base; pH 8.0) with Halt Protease Inhibitor 
Cocktail (Thermo Scientific, 78429) to confluent 10cm plates. Cells were scraped, collected 
in a microcentrifuge tube, and incubated on ice for 10 minutes. Lysates were then centrifuged 
at 13,000 RPM for 10 minutes at 4ºC. The supernatant was collected and protein 
concentrations were determined using a Bradford Protein Assay kit (BioRad, 5000002) by 
comparing to BSA standards.  
 
Preparation of Conditioned Media and Western Blotting 
For assessment of secreted protein expression (MMP9), conditioned media was prepared by 
seeding 1.0x106 cells into T75 flasks, and cells were maintained in low serum media (αMEM 
with 0.1% FBS) for 48 hours. Media was collected and concentrated 25X using centrifugal 
filters (Amicon Ultra-4, UFC803024). Protein was resolved (40g) on a 10% SDS-PAGE gel. 
Immediately after transferring proteins to a PVDF membrane, total protein was visualized by 
Ponceau Stain using the BioRad ChemiDoc imaging system, and an image of the membrane 
was acquired for subsequent normalization. The membrane was then de-stained and MMP9 
protein levels were assessed by western blot (specifications can be found in ‘Electrophoresis 
and Western Blotting’ section). 
 
Electrophoresis and Western Blotting 
Protein (10-50µg) was resolved on a 10% SDS-PAGE gel. The membrane was blocked with 
5% milk for one hour (or 5% BSA where specified), then incubated with primary antibody 
overnight at 4ºC; anti-TBX3 (Invitrogen, 424800; 1:1,000), anti-SLUG (Abcam, ab27568; 
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1:1,000 in BSA), anti-Vimentin (Abcam, ab92547; 1:1,000), anti-Fibronectin (Abcam, 
ab2413; 1:1,000), anti-uPa (Abcam, ab133563; 1:250), anti-MMP9 (Abcam, ab38898, 
1:1,000), anti-MMP14 (Abcam, ab51074; 1:500), anti-Src (Cell Signaling, 2110; 1:1,000), 
anti-pSrc (Y416) (Cell Signaling, 2101; 1:1,000 in BSA), anti-pSrc (Y527) (Cell Signaling, 
2105; 1:1,000 in BSA), anti-TWIST1 (Abcam, ab50887; 1:100 in BSA), anti-CST6 (Sigma, 
WH0001474M1; 1:1,000), anti-N-Cadherin (Abcam, 18203, 1:1,000), anti-Vinculin (Sigma, 
V9264; 1:20,000). The membrane was incubated with secondary antibody conjugated to 
HRP, either anti-rabbit (Sigma, A0545; 1:1,000) or anti-mouse (GE Healthcare, NXA931; 
1:1,000) as appropriate, for 1 hour at room temperature. The western blots were visualized 
using Luminata Crescendo (EDM Millipore, WBLUR0500) and images were taken using the 
BioRad ChemiDoc imaging system. Densitometric quantification was performed using 
ImageLab (BioRad), and quantities were normalized to vinculin expression. Where 
quantifications of western blots is shown, data was acquired through densitometric 
quantifications across three biological replicates.  
 
Immunofluorescence 
ZsGreen vector transiently transfected cells (described above) were fixed with 10% neutral 
buffered formalin for 10 minutes, and permeabilized with 0.5% Triton X-100 in PBS for 10 
minutes. Blocking was conducted with normal goat serum (Invitrogen, 50-0627) at room 
temperature for 1 hour. Rabbit anti-E-cadherin antibody (BD Biosciences, 610181) was 
added at a dilution of 1:150 in 10% normal goat serum and was incubated overnight at 4ºC. 
The following day, cells were washed three times with PBS, and secondary antibody 
Alexa647 Goat Anti-Rabbit IgG (Invitrogen, A21245) was added at a dilution of 1:1,000 in 
10% normal goat serum and incubated for 1 hour at room temperature. Cells were washed 
5 times with PBS. Hoechst 33342 (Invitrogen, H1399) diluted to 1:5,000 in PBS was 
incubated for 30 minutes at room temperature. Cells were washed once with PBS. Coverslips 
were mounted with ProLong Gold Antifade Reagent (Invitrogen, P36930). Images were 
captured at 40X magnification using an Olympus Confocal Imaging System (FluoView 
FV1000 coupled to the IX81 Motorized Inverted System Microscope). Images were converted 
to 8-bit images by separating channels. Mean grey area was quantified within the red channel 
across ZsGreen positive (transfected) cells. E-cadherin expression across the cell lines was 
normalized to the empty vector control. 
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Scratch Wound (Migration) Assay 
Cells were cultured to near confluence in 6-well plates and starved in low serum media 
(αMEM with 0.1% FBS) for 16 hours. A 2 mm wide scratch was then made in the confluent 
monolayer. The cells were rinsed with PBS and fresh media (αMEM media with 10% FBS) 
was added. Cell migration was visualized and phase contrast images were taken at 10X 
using the Olympus IX70 inverted microscope after 6h, 12h and 24h. Cell migration was 
calculated by comparing the wound area at the specified time points using ImageJ (Open 
source, https://imagej.nih.gov/ij/). Means derived from four biological replicates were used 
during analysis. 
 
Transwell Invasion Assay 
Transwell invasion assays were conducted to examine the invasive potential of the 
transfected cell lines. Stably transfected 21NT cells (representing luminal B subtype) were 
used for initial studies. For stable 21NT transfectant cells, 50,000 cells per 100L of media 
were added to the upper chamber of a 8.0m pore transwell insert (Corning, 3422; 24-well 
plate) coated with 10g of Matrigel (Corning, 354480). After incubation at 37ºC and 5% CO2 
for 18 hours, the membranes were fixed with 1% glutaraldehyde for 20 min and stained with 
full-strength Hematoxylin for 15 minutes. Cells which did not migrate and remained on the 
upper surface of the membrane were removed using a cotton swab. Images of 5 non-
overlapping fields of view were acquired using an Olympus IX70 inverted microscope at 10X 
objective. Cells were counted from the acquired images using ImageJ. Means derived from 
4 replicates were used during analysis.  
Invasiveness of transiently transfected cells was also assessed, including T-47D 
(luminal A), SKBR3 (HER2-enriched), and MDA-MB-468 (basal-like) cells transfected with 
either an empty vector (EV), TBX3iso1, or TBX3iso2 construct within the pZsGreen1-N1 
vector containing a ZsGreen reporter gene. Twenty-four hours post-transfection, cells were 
trypsinized, harvested, and suspended in their respective media in the absence of FBS and 
addition of 0.1% BSA. Cells were then added to the upper layer of a 8.0M transwell insert 
coated with 10g of Matrigel at 50,000 cells per 100L of media. After incubation at 37ºC 
and 5% CO2 for 18 hours, the membranes were fixed with 1% glutaraldehyde for 20 min. 
Cells which did not migrate and remained on the upper surface of the membrane were 
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removed using a cotton swab. Green fluorescent images and brightfield images of 3 non-
overlapping fields of view were acquired and superimposed using an EVOS FL Auto 
microscope at 10X objective. The number of green cells was determined using ImageJ 
software. Means derived from four biological replicates were used during analysis. 
 
Cell-Cell Adhesion Assay 
The cell-cell adhesion assay was done as described (Rodriguez et al., 2008). Briefly, T75 
plates were rinsed twice with PBS and cells were dissociated using 3mM EDTA. Cells were 
resuspended in HE10F media and passed through a cell strainer to dissociate cell clusters. 
Cells (200,000) were added to the appropriate media (HE10F with 3mM EDTA, or HE10F 
with 1mM CaCl2) in a 6 cm petri dish. Plates were incubated at 37ºC on a shaking platform 
for 30 minutes. After this incubation period, 10 non-overlapping fields of view per dish were 
captured using the Olympus IX70 inverted microscope at 10X objective. Clusters containing 
more than 4 cells were counted, and counts from 10 fields of view were added together for 
each plate. Means derived from four biological replicates were used during analysis. 
 
Gelatin Zymography 
Cells (1.5x106) were seeded onto 10cm plates. The following day, media was replaced by 
10mL of serum-free αHE media with 500µg/mL G418, and cells were serum-starved for 24 
hours. Media was collected and concentrated 25X using centrifugal filters (Amicon Ultra-4, 
UFC803024). Equal volumes (normalized to 1.5x106 cells) of the conditioned media was 
loaded into a 10% Criterion Zymogram gel (BioRad, 3450080) without boiling/reducing and 
resolved at 4ºC. To remove SDS from the gel, the gel was washed with renaturation buffer 
(2.5% Triton X-100) twice for 30 minutes each, followed by two 20 minute washes with 
distilled water. The gel was then incubated in development buffer (50mM Tris, 200mM NaCl, 
5mM CaCl2 (anhydrous), 0.02% Brij-35, pH 7.5) at 37ºC for 16 hours. The gel was then 
stained (40% methanol, 10% acetic acid, 0.5% Coomassie Blue R-250) for 1 hour at room 
temperature with gentle agitation, followed by de-staining (40% methanol, 10% acetic acid) 
until clear bands appeared. Images were taken using the BioRad ChemiDoc imaging system. 
Reverse images were used for quantification. Means derived from three biological replicates 
were used during analysis. 
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Chick Chorioallantoic Membrane (CAM) Extravasation Assays 
Cells were pre-labeled with 1µM CellTracker conjugated to Green CMFDA Dye (Thermo 
Fischer Scientific, C7025) and washed once with PBS. Using the chorioallantoic membrane 
(CAM) of the chicken embryo, embryonic day 12 embryos were intravenously (IV) injected 
with 50,000 cells (50µL of 1×106 cells/mL cell suspension). 
For the extravasation assays, rhodamine-labelled lectin (75µL of 0.1mg/mL, Vector 
Laboratories Inc, RLK-2200) was intravenously injected 10 minutes after injection of 
fluorescently-labelled cells in order to visualize the luminal surface of endothelial cells in the 
CAM. Immediately following IV injection of lectin-rhodamine, a 1cm×1cm field of the CAM 
marked by foil markers at the corners was made for each animal and the number of cells that 
were intravascular, in the process of extravasation and extravasated into the CAM stroma 
were counted at T=10 min and T=24 hours. A resonance scanner confocal microscope 
(Olympus FluoView FV1000 coupled to the IX81 Motorized Inverted System Microscope) 
was used to determine each cell's location within the CAM with respect to lectin-rhodamine 
signal in real time. All quantifications were conducted blinded. Values reported represent the 
percentage of cells that successfully extravasated in the 1cm×1cm field across 30 biological 
replicates. All quantifications were conducted blinded. 
For in vivo invadopodia assays, the chick embryos were returned to their incubators 
after injection of labelled cells, and at the 6-hour time-point were intravenously injected with 
rhodamine-labelled lectin (75µL of 0.1 mg/mL, Vector Laboratories Inc.) in order to visualize 
the luminal surface of the endothelial cells in the CAM. A resonance scanner confocal 
microscope was used to determine each cell's location within the CAM with respect to lectin-
rhodamine signal in real time. By scanning across the Z-axis, green fluorescently labeled 
cells were assessed for the presence of functional invadopodia protruding between the 
intravascular/extravascular boundary. Values reported represent the percentage of cells 
displaying functional invadopodia in vivo across 6 biological replicates consisting of 
approximately 30 scanned cells each. All quantifications were conducted blinded. 
 
Invadopodia Formation Assay 
The in vitro invadopodia formation assay was conducted as described (Artym et al., 2009). 
Briefly, cover slips were coated with 1mL of cold poly-L–lysine (Sigma, P7405; 50µg/mL in 
PBS) and aspirated after 20 minutes, followed by a 15 minute incubation with 0.5% 
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glutaraldehyde. Coverslips were then inverted on an 80µl drop of 0.2% gelatin in PBS 
labelled with Alexa594 (Thermo Fischer Scientific, G13187), and incubated for 10 minutes. 
Coverslips were lifted, then incubated with 5mg/mL sodium borohydride for 15 minutes to 
quench reactive groups in the gelatin matrix, followed by extensive washing with PBS. Cells 
were trypsinized and plated on coverslips for 12-24 hours (as optimized) followed by fixation 
with 4% paraformaldehyde and permeabilization with 0.1% Triton X-100 in PBS. Samples 
were blocked with 5% skim milk powder, followed by staining with Alexa488-labelled 
phalloidin (Thermo Fischer Scientific, A12379) to label F-actin. Cells were imaged using the 
Nikon Fast A1R Upright Microscope. Cells with actin cores overlaying spots of degradation 
were counted as invadopodia forming cells. Percentage of cells forming invadopodia was 
quantified from 4 biological replicates, assessing invadopodia formation in 10-20 random, 
non-overlapping fields. 
 
RNA Isolation and Quantitative Real-Time PCR (qRT-PCR) 
RNA was isolated using the RNeasy Mini Kit (Qiagen, 74104). RNA (500ng) was transcribed 
into cDNA using the qScript cDNA SuperMix (Quanta Biosciences, 84034). The RT2 SYBR 
Green ROX qPCR Mastermix (Qiagen, 330521) was utilized for quantitative PCR with the 
primer sequences as listed in Table 3.1. The output Ct values were normalized to GAPDH 
and RPLP0 expression for 21NT transfected and transduced cells, respectively, using the 
∆∆Ct method. Means derived from a minimum of three biological replicates were used during 
analysis. 
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Table 3.1 – Primer sequences utilized for qRT-PCR in mRNA studies. 
 
 
mRNA Probe 
 
(F) Forward and (R) Reverse Primer Sequences, 5’ to 3’ 
Total TBX3 
F: CGCTGTGACTGCATACCAGA 
R: GTGTCCCGGAAACCTTTTGC 
TBX3iso1 
F: AGTGGATGTCCAAAGTCGTCAC 
R: CATGGAGTTCAATATAGTAAATCCATGTTTGTCTG 
TBX3iso2 
F: AGTGGATGTCCAAAGTCGTCAC 
R: CACTTGGGAAGGCCAAAGTAAATCCATG 
CDH2 (N-cadherin) 
F: GACGATCCCAATGCCCTCAA 
R: ACATGTTGGGTGAAGGGGTG 
CST6 
F: TGAGGTCCTTGTGGTTCCCT 
R: CCCTCGGGGACTTATCACATC 
FN1 (Fibronectin) 
F: AGGAGAATGGACCTGCAAGC 
R: GAAGTGCAAGTGATGCGTCC 
GAPDH 
F: AGGCTGGGGCTCATTTGAAG 
R: CCATCCACAGTCTTCTGGGTG 
MMP14 
F: CCAGCAACTTTATGGGGGTG 
R: GGCCCATAGGTGGGGTTTTT 
MMP9 
F: CTTTGAGTCCGGTGGACGAT 
R: TCGCCAGTACTTCCCATCCT 
TWIST1 
F: GCAAGAAGTCGAGCGAAGAT 
R: GCTCTGCAGCTCCTCGAA 
RPLP0 
F: CCTCATATCCGGGGGAATGTG 
R: GCAGCAGCTGGCACCTTATTG 
SLUG 
F: GCCAAACTACAGCGAACTGG 
R: GATGGGGCTGTATGCTCCTG 
SRC 
F: GCACAGGACAGACAGGCTAC 
R: TCTGACTCCCGTCTGGTGAT 
uPa 
F: TCCAAAGGCAGCAATGAACT 
R: GTGCTGCCCTCCGAATTTCT 
VIM (Vimentin) 
F: GGACCAGCTAACCAACGA 
R: AAGGTCAAGACGTGCCAGAG 
 
Chromatin Immunoprecipitation 
Twenty million cells (per replicate) were grown to confluence for each cell line. The cells were 
washed twice with cold PBS, and then cross-linked with 10mL of PBS with 1% formaldehyde 
solution for 15 minutes at room temperature on a rocking platform. The reaction was 
quenched with 1mL of 2.625M glycine. The cells were then scraped into the supernatant and 
washed twice with cold PBS.  
Pellets were resuspended in 1mL nuclei isolation buffer (50mM Tris pH 8.0, 60mM 
KCl, 0.5% NP-40) with protease inhibitors (Thermo Scientific, 78429) and incubated on ice 
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for 10 minutes, then spun at 3,000 RPM for 3 minutes at 4ºC for nuclei isolation. Nuclei were 
resuspended in 1mL of Lysis Buffer (0.5% SDS, 10mM EDTA, 0.5mM EGTA, 50mM Tris 
HCl, pH 8.0) with protease inhibitors. Chromatin was sonicated for 40 minutes at 2ºC (using 
Diagenode Bioruptor Pico; 30 seconds on, 30 seconds off). The sonicated samples were 
centrifuged at 13,000 RPM for 10 minutes at 4ºC to remove cell debris. Sonicated chromatin 
was then pre-cleared with 200L Protein-A Dynabeads (Life Technologies, 10002D) for 1 
hour at 4ºC on a rocking platform. Simultaneously, 50L of Protein-A Dynabeads were 
washed with 0.5% BSA-PBS and incubated with 5g of normal rabbit IgG antibody 
(Invitrogen, 10500C) or 5g of rabbit anti-TBX3 antibody (Invitrogen, 424800) in 100L of 
dilution buffer (PBS with 0.2% Tween20 and 1% BSA) for 2 hours at room temperature on a 
rocking platform (quantities listed per biological replicate). The bead-antibody complex was 
then washed twice with 0.5% BSA-PBS, resuspended in dilution buffer and then added to 
the sample. Immunoprecipitation was conducted overnight (16 hours) at 4ºC on a rocking 
platform. 
Bound chromatin was eluted the following day. Each wash step was performed at 4ºC 
for 5 minutes on a rocking platform. Chromatin was washed with Wash Buffer I (20mM Tris 
HCl, 150mM NaCl, 2mM EDTA, 1% Triton X-100, 0.1% SDS) twice, Wash Buffer II (20mM 
Tris HCl, 500mM NaCl, 2mM EDTA, 1% Triton X-100, 0.1% SDS) once, and TE buffer (10mM 
Tris HCl, 1mM EDTA, pH 8.0) twice. Bound chromatin was eluted using 200L of Elution 
Buffer (100mM NaHCO3, 1% SDS) at 65ºC for 20 minutes. NaCl was added to a final 
concentration of 200mM and incubated with the chromatin overnight at 65ºC for de-
crosslinking. Proteinase K (Thermo Scientific, AM2546) was added and incubated for 2 hours 
at 50ºC, followed by RNase A (Thermo Scientific, 12091039) treatment for 60 minutes at 
37ºC for protein and RNA degradation, respectively. The DNA was purified using the 
QIAquick PCR Purification Kit (Qiagen, 28106) and eluted with 20L elution buffer.  
For ChIP array purposes, the eluted DNA was amplified using the Whole Genome 
Amplification Kit (Sigma, WGA2) as per the manufacturer’s protocol, with the omission of the 
fragmentation step. In order to obtain sufficient DNA for ChIP-array hybridization, the 
amplified DNA was re-amplified using the GenomePlex Complete Whole Genome 
Reamplification kit (Sigma, WGA3) with the incorporation of dUTP (Jena Bioscience, NU-
1021S) at a final concentration of 2mM, and dTTP was reduced to 8mM. The DNA was once 
again purified using the QIAquick PCR Purification Kit. 
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For validation of select ChIP targets, 5uL of the eluate was used for qPCR. The % 
input method was utilized for quantification of enrichment. An input of 5% was saved prior to 
immunoprecipitation and was de-crosslinked and purified as described above. The Ct values 
for the input was subtracted from the Ct values of the immunoprecipitated samples. A fold 
change was then calculated consisting of TBX3 IP over IgG control (signal over noise) to 
allow for easy comparison between primer sets. The primers used for ChIP-qPCR 
experiments are listed in Table 3.2. The CDH1 transcription start site (TSS) and coding 
region served as the positive and negative control, respectively. The CDH1 control primer 
sequences were obtained from a previously published study reporting the TBX3 binding site 
within E-cadherin in melanoma cell lines (Rodriguez et al., 2008).  
Table 3.2 – Primer sequences utilized for ChIP-qPCR validation studies. 
 
DNA Probe 
 
(F) Forward and (R) Reverse Primer Sequences, 5’ to 3’ 
CDH1 TSS 
F: TCACAGGTGCTTTGCAGTTC 
R: GTGAACCCTCAGCCAATCAG 
CDH1 coding region 
F: AACAGCTGCTTGGTGACGTT 
R: CAAGCCTGGGAGTTAGGTG 
SNAI2 
F: AATGGGGCTTTCTGAGCCAC 
R: TCCACGCCCAGCTACCCAA 
 
RNA-Seq 
Cells were grown to 80% confluence and RNA was isolated using the RNeasy Mini Kit 
(Qiagen, 74104) incorporating DNase I digestion (Qiagen, 79254). Samples were sent to the 
Donnelly Sequencing Centre (Toronto, Canada) and assessed for RNA integrity using an 
Agilent bioanalyzer. For each sample, stranded mRNA libraries were prepared and 
sequenced on an Illumina HiSeq 2500 sequencer using V4 chemistry. Paired-end read 
length was 51 base pairs. Raw reads were then uploaded to Basespace 
(https://basespace.illumina.com/) and imported into Galaxy software (https://usegalaxy.org). 
The FastqGroomer tool within Galaxy was used to prepare the files for alignment, and the 
TopHat tool within Galaxy was used to align the FASTQ files to the reference genome (Hg19) 
using the default parameters, except that the maximum number of alignments was capped 
at 10. Aligned sequences were imported as .bam files into Partek Genomics Suite (PGS; 
http://www.partek.com/pgs) software and analyzed using the RNA-Seq analysis 
workflow. Gene reads were normalized for transcript length using the RPKM normalization 
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algorithm, and differentially expressed genes between TBX3iso1 or TBX3iso2 compared to 
empty vector were determined using ANOVA statistical tests. For each comparison, final 
gene lists were created using a minimum fold change cut-off of 1.5-fold, and a maximum 
False Discovery Rate (FDR) of 0.05 (step-up FDR algorithm of Benjamini and Hochberg). 
 
ChIP Promoter Arrays 
Chromatin was immunoprecipitated as described above. The amplified product (7.5g) was 
fragmented, labeled, and hybridized to the GeneChip Human Promoter 1.0R Array 
(Affymetrix, 900776), and the hybridized array was scanned as per manufacturer’s 
instructions. All microarray work was done at the London Regional Genomics Centre 
(Robarts Research Institute, London, Canada). Resultant .cel files were then imported into 
Partek Genomic Suites (PGS) and analyzed using the Chromatin Immunoprecipitation 
workflow. Differential probe intensities between TBX3iso1 or TBX3iso2 vs. empty vector 
were determined by ANOVA and enriched regions of significance were determined using the 
MAT algorithm. To be further considered, an enriched region had to have a minimum MAT 
score of 5 at p<0.05. 
 
Bioinformatics Analysis 
To compare RNA-Seq and ChIP-array datasets, gene lists were constructed using Venny 2.1 
(Spanish National Biotechnology Centre; http://bioinfogp.cnb.csic.es/tools/venny/). Genes of 
interest include those significantly altered with overexpression of both TBX3 isoforms by 
RNA-Seq (fold change >1.5 relative to the empty vector, p<0.05), and genes which both 
TBX3 isoforms directly bound in ChIP-array datasets (MAT score >5, p<0.05). Altered 
biological functions with TBX3 isoform overexpression were examined using Ingenuity 
Pathway Analysis (IPA) (Qiagen) by examining RNA-Seq data. Gene reads and ChIP binding 
locations were visualized using Interactive Gene Viewer (IGV) software (Broad Institute). 
Consensus binding motifs of highly conserved T-box proteins (TBX1, TBX2, TBX4, TBX5, 
TBX15, TBX20, TBX21) within the JASPAR database (University of Copenhagen Centre for 
Molecular Medicine and Therapeutics; http://jaspar.genereg.net) were assessed, and 
coordinates that had overlap for all aforementioned related T-box transcription factors were 
imported into IGV. DNase I hypersensitivity and RNA polymerase II ChIP tracks were also 
imported into IGV. A cutoff threshold of >40 for each coordinate occurring in the RNA pol II 
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(POLR2A) ChIA-PET combined dataset in various cell lines was introduced to assess 
consistent binding sites. The aforementioned ENCODE tracks are listed in Table 3.3. 
The TCGA BRCA, Farmer Breast and Desmedt Breast datasets were interrogated 
and data was exported using XenaBrowser (University of California, Santa Cruz; 
https://xenabrowser.net/datapages/). The aforementioned datasets are listed in Table 3.3. 
The PANTHER database (University of Southern California; http://pantherdb.org) was 
used to conduct over-representation analysis using Fischer’s exact test with FDR multiple 
test correction and focusing on protein class and Gene Ontology (GO) biological pathways. 
Enrichr pathway analysis (Icahn School of Medicine, Mount Sinai; 
http://amp.pharm.mssm.edu/Enrichr/) was conducted with the input list consisting of 194 
genes significantly altered (fold change >1.5, p<0.05) for cells overexpressing either 
TBX3iso1 or TBX3iso2 relative to the empty vector control from the normalized RNA-Seq 
data. Results assessing Jensen TISSUES expression data are reported.  
 
Table 3.3 – Publicly-available datasets utilized for analysis. 
 
 
 
 
 
 
FILE SOURCE REFERENCE (or LINK) 
POLR2A ChIA-
PET 
ENCODE: 
ENCSR000CAA 
http://hgdownload.cse.ucsc.edu/goldenPath/hg19/encode
DCC/wgEncodeGisChiaPet/ 
DNase I 
hypersensitivity 
(master list) 
ENCODE: 
wgEncodeAwgDna
seMasterSites 
http://hgdownload.cse.ucsc.edu/goldenpath/hg19/encode
DCC/wgEncodeAwgDnaseMasterSites/  
TCGA Breast 
Cancer (BRCA) 
GDC Project ID: 
TCGA-BRCA 
https://portal.gdc.cancer.gov/projects/TCGA-BRCA  
Farmer Breast 
GEO: 
GSE1561 
• Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M et 
al. Identification of molecular apocrine breast tumours by 
microarray analysis. Oncogene 2005 Jul 7;24(29):4660-
71. PMID: 15897907 
Desmedt Breast 
GEO: 
GSE7390 
Desmedt C, Piette F, Loi S, Want Y et al. Strong time 
dependence of the 76-gene prognostic signature for node-
negative breast cancer patients in the TRANSBIG 
multicenter independent validation series. Clin Cancer 
Res 2007 Jun 1;13(11)3207-14. PMID: 17545524 
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Patient Characteristics in Immunohistochemistry Study 
Patients with early-stage breast cancer were identified from the London Breast Cancer 
Database on the basis of having either DCIS only (Stage 0), or DCIS with an associated 
invasive component (Stage I; 2cm, and either pN0 or pN0mi). Cohort 1 consisted of 186 
patients with low, intermediate, or high grade DCIS with the aforementioned characteristics 
of no invasion or early invasion (Stage 0 or Stage I). Cohort 2 consisted of 118 patients with 
non-high grade DCIS with the aforementioned characteristics, with either no invasion or early 
invasion (Stage 0 or Stage I). Clinicopathological variables for cohort 1 and cohort 2 patients 
entered into this study are listed in Table 3.4, left and right panel, respectively. There was no 
overlap between patients in cohort 1 and cohort 2. The study was conducted under a protocol 
approved by the Western University Health Sciences Research Ethics Board and the Clinical 
Research Impact Committee of Lawson Health Research Institute.  
 
Immunohistochemistry 
Formalin-fixed, paraffin embedded tissues were sectioned at 4.0µm and added to a charged 
glass slide. Sections were de-paraffinized, rehydrated, and incubated in TBS-Tween or TBS-
Triton (Tris buffered saline (TBS) + 0.5% Tween-20 for TBX3 and SLUG stains, and TBS + 
0.1% Triton-X for TWIST1 stain) for 20 minutes for membrane permeabilization. Heat 
induced antigen retrieval was conducted with citrate buffer (pH 6.0) for 20 minutes. The 
UltraVision LP Detection System (Thermo Fischer Scientific, TL-015-HD) was used with 
optimization of incubation length. Endogenous peroxidase activity was blocked for 10 
minutes for all samples. For the TBX3 stain, slides were blocked for 5 minutes, incubated in 
TBX3 primary antibody (Abcam, ab99302) at 1/200 dilution for 15 minutes at room 
temperature, and 11 minutes in the HRP polymer. For the SLUG stain, slides were blocked 
for 6 minutes using the UltraVision protein block and an additional 30 minutes using the Dako 
protein block (Dako, CD310081) in order to reduce non-specific background staining. Slides 
were incubated in SLUG primary antibody (Abcam, ab27568) at 1/750 dilution for 70 minutes 
at room temperature, and 15 minutes in the HRP polymer. For the TWIST1 stain, slides were 
blocked for 6 minutes, incubated in TWIST1 primary antibody (Abcam, ab50887) at 1/200 
dilution for 1 hour at room temperature, 10 minutes in primary antibody enhancer, and 15 
minutes in the HRP polymer. Signal for all markers was developed using DAB and slides 
were counter-stained in Harris’s Hematoxylin.  
 125 
125 
Quantification of Immunohistochemistry 
Slides were stained and scanned using an Aperio AT2 slide scanner (Leica Biosystems). Full 
scanned digital slides were analyzed by an anatomical pathologist (blinded as to the 
diagnosis) and representative images were captured at 20x magnification using the Aperio 
ImageScope slide viewing software. Each image represented one of four tissue 
compartments including benign non-columnar cells, benign columnar cell lesions (CCLs; 
includes columnar cell change, columnar cell hyperplasia or flat epithelial atypia), ductal 
carcinoma in situ (DCIS), and invasive cancer. The expression of each molecular marker 
was assessed using the ImmunoRatio plugin (University of Tampere, Finland) for ImageJ to 
assess percentage of positive cells. For each image, the cell type of interest was solely 
analyzed and the remaining cells (i.e. stromal cells) were cropped out. A control slide 
representing serial sections was run for each batch of slides (with quantification and 
statistical analysis) to ensure identical and reproducible staining for each run.  
 
Statistical Analysis 
Statistical analyses were conducted using GraphPad Prism 5. One-way ANOVAs were used 
for experiments containing three or more groups, with either a Tukey or Dunnett’s post-hoc 
test. T-tests were used for experiments containing two groups. Error bars represent standard 
deviation. P-values less than 0.05 were considered statistically significant. 
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3.3 Results 
 TBX3 overexpression is associated with an invasive and EMT 
phenotype. 
To examine the role of TBX3 in breast cancer, non-invasive 21NT cells (which endogenously 
express low levels of TBX3) were stably transfected with either an empty vector, TBX3iso1 
or TBX3iso2. Isoform specific up-regulation was confirmed at the mRNA level using isoform 
specific primers, in addition to up-regulation of total TBX3 protein levels (Figures 3.3.1 A-B 
and Appendix 1A). Functionally, up-regulation of either TBX3 isoform in DCIS-like 21NT cells 
led to an increase in migration using the wound scratch assay (Appendix 2A). TBX3 
overexpressing 21NT cells also exhibited reduced cell-to-cell adhesion in vitro (Appendix 
2B). In the presence of calcium ions (+CaCl2), or after adding increasing doses of EDTA to 
chelate free calcium, there were reduced levels of cell-to-cell adhesion, implying that several 
cell-adhesion molecules may be involved (not solely Ca2+ dependent cadherins). As TBX3 
has previously been shown to directly down-regulate E-cadherin (CDH1) in melanoma lines 
(Rodriguez et al., 2008), and as loss of E-cadherin has been associated with the switch to 
an EMT phenotype, we assessed E-cadherin expression by immunofluorescence. We 
confirmed a down-regulation of E-cadherin protein levels as well as decreased membrane 
localization with TBX3 overexpression (Appendix 2C).  
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Figure 3.3.1 – TBX3 overexpression is associated with an invasive and EMT 
phenotype. 
(A) Total TBX3 protein levels were assessed by western blot in 21NT transfectant cells. (B) 
Total TBX3, TBX3iso1, and TBX3iso2 transcript levels were assessed by qRT-PCR in 21NT 
transfectant cells, normalized to GAPDH expression levels, and depicted as fold change 
relative to the empty vector control. Means derived from three biological replicates were used 
during analysis. (C-D) Assessment of cell extravasation and functional invadopodia formation 
in vivo in the chick chorioallantoic membrane (CAM) model. Green (CMFDA) fluorescently 
labeled cells were injected into the vasculature of the CAM (50,000 cells each), and the 
vasculature was labeled red with lectin-rhodamine at T=0. For cell extravasation, cells were 
counted 24 hours post injection in a 1cm2 area across 30 biological replicates. For functional 
invadopodia formation, a binary quantification of in vivo invadopodia formation was 
conducted 6 hours post cell injection. Cells were deemed positive for invadopodia formation 
when they possessed protrusions from the vasculature into the stroma. Values reported 
represent the percentage of cells displaying functional invadopodia in vivo across 6 biological 
replicates consisting of approximately 30 scanned cells each. (E) In vitro invadopodia 
formation assay for assessment of local cell invasion. Cells were added to red fluorescently 
labeled gelatin and incubated for 12-24 hours (as optimized) to allow for substrate 
degradation. Cells were visualized using labelled phalloidin for identification of cellular F-
actin cores at sites of local matrix degradation, signifying the presence of invadopodia. 
Percentage of cells forming invadopodia was quantified from 4 biological replicates, 
assessing invadopodia formation in 10-20 random, non-overlapping fields. (F-G) Protein 
expression of EMT markers was assessed by western blot. Protein samples were separated 
by 10% SDS-PAGE and quantified by densitometry. Protein levels were normalized to 
Vinculin, which served as the loading control for all proteins aside from MMP9 (* secreted 
protein); in the latter case, MMP9 levels in the conditioned media samples were normalized 
to total protein per lane based on Ponceau staining of the membrane. Where quantification 
of western blots are shown, data was acquired through densitometric quantifications across 
three biological replicates. 
*p<0.05, **p<0.01, ***p<0.001 by one-way ANOVA with Tukey post-hoc for comparison 
between three groups, and Student’s t-test for comparison between two groups. Error bars 
represent standard deviation. 
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In order to assess the aggressiveness of the cell lines in an in vivo system, we made 
use of the chick embryo chorioallantoic membrane (CAM) model. Fluorescently labeled cells 
were injected into the vasculature of chicks at embryonic day 12 and cell extravasation was 
assessed as previously described (Kim et al., 2016) (Figure 3.3.1 C). Stable overexpression 
of either isoform in 21NT cells resulted in an increase in extravasation within the CAM model. 
Extravasation levels were reduced drastically with shRNA-mediated knockdown of TBX3 in 
invasive 21MT-1 cells, which natively express TBX3 at high levels (protein levels shown in 
Appendix 1B-C). In order to confirm that the cells are indeed better able to exit the 
vasculature (and are not simply better able to survive at T=24h), we performed live functional 
invadopodia assays within the CAM using confocal microscopy. Six hours after the injection 
of fluorescently labeled cells into the vasculature of chick embryos, rhodamine-labelled lectin 
was injected to visualize the vessel lumen and a binary quantification of invadopodia 
formation was conducted (Figure 3.3.1 D). An increase in functional invadopodia was 
observed with overexpression of either TBX3 isoform in 21NT cells. Furthermore, the 
presence of functional invadopodia was reduced with TBX3 knockdown in 21MT-1 cells. 
Changes to rates of invadopodia formation were also verified using a standard in vitro 
invadopodia formation assay (Figure 1E), which mirrored the in vivo CAM data obtained. 
More invasive phenotypes were also observed using transient transfections of 
TBX3iso1 or TBX3iso2 into T47D (luminal A; ER+/PR+/HER2-), SKBR3 (HER2-enriched; 
ER-/PR-/HER2+), and MDA-MB-468 (basal-like; ER-/PR-/HER2-) breast cancer cell lines, 
representing different molecular subtypes (Appendix 3A-C). Collectively, this suggests that 
these findings have broad applicability and are not cell-type specific. 
The functional alterations associated with TBX3 isoform overexpression here suggest 
a more invasive, epithelial-mesenchymal transition (EMT) phenotype. We examined the 
expression of several EMT markers and observed alterations in multiple proteolytic enzymes 
and their inhibitors (MMP9, MMP14, uPA up-regulated; CST6, down-regulated), as well as 
EMT-associated transcription factors (TWIST1, SLUG up-regulated) with stable 
overexpression of either TBX3 isoform. These were confirmed at both the mRNA and protein 
levels (Figure 3.3.1 F-G and Appendix 4A). We observed an increase in levels of active 
MMP2, as assayed by gelatin zymography (Appendix 4B), indicating functional activation of 
pathways involved in substrate degradation and invasiveness 
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 TBX3 overexpression leads to an alteration of mesenchymal transcript 
levels and direct up-regulation of SLUG. 
To examine transcriptional changes associated with TBX3 isoform overexpression and 
elucidate mechanisms involved, RNA-Seq was conducted for TBX3iso1 and TBX3iso2 
overexpressing cell lines. Ingenuity Pathway Analysis (IPA) indicated that the top predicted 
functional changes associated with the unique transcriptional profiles obtained for the TBX3 
transfectants include alterations in cellular movement, cellular growth and proliferation, cell 
death, cell survival and cancer-associated processes (Figure 3.3.2 A). Enrichment analysis 
(Enrichr) was conducted, with the input list consisting of genes significantly altered (>1.5 fold 
up or down, FDR<0.05) for cells overexpressing either TBX3iso1 or TBX3iso2 relative to the 
empty vector control. Comparison to the Jensen TISSUES expression database of large-
scale tissue expression profiles revealed mesenchymal genes as most enriched (Figure 3.3.2 
B). The dbEMT database (Zhao et al., 2015) was used to compile a list of 377 EMT-related 
genes for analysis of RNA-Seq data. Relative to the empty vector, alterations in abundance 
of a large proportion of EMT-related genes were detected with TBX3 isoform overexpression 
(Figure 3.3.2 C).  
To determine whether the TBX3-dependent changes in gene expression are direct, 
chromatin immunoprecipitation (ChIP) experiments were conducted using either an anti-
TBX3 antibody or rabbit IgG antibody as a non-specific control for background, and 
immunoprecipitated DNA was hybridized to Affymetrix Promoter 1.0R arrays. Using this 
approach we identified 5652 and 5512 specific binding sites for TBX3iso1 and TBX3iso2, 
respectively. Further comparison of TBX3 binding sites with our expression analysis 
identified 194 genes that were directly regulated by both TBX3 isoforms (>1.5 fold up or 
down, FDR<0.05) (Figure 3.3.2 D). These 194 genes were analyzed using the PANTHER 
database by conducting over-representation analysis and focusing on protein class 
(Appendix 5). The lowest p-value and corrected FDR statistic corresponded to the protease 
inhibitor protein class. Several other protein classes related to EMT were also altered, 
including extracellular matrix proteins, metalloproteases, and serine protease inhibitors. 
Importantly, within this list of 194 genes directly induced by TBX3 was SLUG (encoded by 
the SNAI2 gene), a transcriptional regulator and potent inducer of EMT, that may provide a 
 131 
131 
mechanism for the previously described EMT and invasion-associated functional changes in 
the TBX3-transfected cells.  
Both TBX3 isoforms were shown to bind near an intron/exon junction of the SNAI2 
(SLUG) gene based on the ChIP-array data (Figure 3.3.2 E). TBX3 has previously been 
shown to bind to the consensus T-box binding element (TBE) in several different contexts 
(Coll et al., 2002b). Consensus TBEs were investigated using the JASPAR database of 
transcription factor binding sites by assessing predicted binding coordinates of highly 
conserved T-box proteins (Figure 3.3.2 E). A highly conserved TBE was found within the 
SNAI2 (SLUG) gene region that coincides with binding of both TBX3 isoforms in the ChIP-
array dataset. We conducted ChIP qRT-PCR validation, using ChIP primers spanning this 
identified TBE. Published primer sequences were used for the transcription start site (CDH1 
TSS) and coding region (CDH1 coding) of E-cadherin (Rodriguez et al., 2008), representing 
positive and negative controls, respectively (Figure 3.3.2 F). With TBX3 overexpression, 
there was a 3-4-fold enrichment of TBX3 protein bound to the conserved TBE of the SNAI2 
(SLUG) gene. Interestingly, this binding region overlaps with a DNase I hypersensitive region 
and RNA polymerase II binding region, which is suggestive of open and transcriptionally 
active chromatin (Figure 3.3.2 E).  
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Figure 3.3.2 – TBX3 overexpression leads to an alteration of mesenchymal transcript 
levels and direct up-regulation of SLUG. 
Total mRNA was isolated from 21NT+EV, 21NT+TBX3iso1 and 21NT+TBX3iso2 cells in 
duplicate and examined by RNA-Seq. (A) Pathway Analysis was conducted using all output 
RNA-Seq data for TBX3iso1 and TBX3iso2 overexpressing cells and compared to the empty 
vector control. (B) Enrichment analysis was conducted with the input list consisting of genes 
significantly altered (fold change >1.5, FDR<0.05) for cells overexpressing either TBX3iso1 
or TBX3iso2 relative to the empty vector control. Results comparing resultant RNA-Seq 
profiles with the Jensen tissue dataset and lowest p-value tissue sites are shown. (C) Heat 
map of EMT genes. The dbEMT database was used to compile a list of 377 EMT genes and 
hierarchial clustering was conducted of RNA-Seq data. Duplicate samples are shown for 
each cell line. (D) Chromatin Immunoprecipitation (ChIP) experiments were conducted with 
either specific anti-TBX3 antibody or a nonspecific rabbit IgG control antibody. 
Immunoprecipitated DNA was hybridized to an Affymetrix Promoter Array. Datasets from 
RNA-Seq and ChIP-array experiments were integrated in order to examine the effects of 
TBX3 isoform binding on gene transcript levels (all fold change >1.5, FDR<0.05). (E) RNA-
Seq reads across the SNAI2 (SLUG) gene for 21NT+EV, 21NT+TBX3iso1 and 
21NT+TBX3iso2 cell lines are shown in the top three lines, followed by the identified TBX3 
ChIP array binding site. Binding sites for highly conserved T-box proteins within the SNAI2 
(SLUG) gene were assessed using the Jaspar database of transcription factor binding sites. 
Highly conserved T-box binding elements (TBEs) are shown. DNAse I hypersensitivity and 
RNA polymerase II binding sites are shown in the bottom two lines. (F) TBX3 binds directly 
to the SNAI2 (SLUG) gene. ChIP experiments were conducted with either a specific anti-
TBX3 antibody or a nonspecific rabbit IgG control antibody. Relative amounts of 
immunoprecipitated DNA were assessed by qRT-PCR, using published sequences of the E-
cadherin (CDH1) coding region and transcription start site (TSS) as negative and positive 
controls, respectively. The SLUG primers used spanned both the predicted overlapping TBE 
site identified in silico and the identified binding site from ChIP-array experiments. Values 
shown represent input-adjusted, IgG control subtracted values for the specific TBX3 IP 
normalized to the empty vector control. Means derived from four biological replicates were 
used during analysis. *p<0.05, **p<0.01, ***p<0.001 by one-way ANOVA with Tukey post-
hoc for comparison between three groups. Error bars represent standard deviation. 
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 SLUG up-regulation by TBX3 is essential for increased migration and 
invasion. 
We have shown that TBX3iso1 and TBX3iso2 directly bind to a consensus TBE within the 
SNAI2 (SLUG) gene and leads to its transcriptional up-regulation. Given the strong evidence 
within existing literature of SLUG involvement in the induction of EMT (De Craene and Berx, 
2013, Phillips and Kuperwasser, 2014), we proceeded to investigate whether SLUG was 
essential for the phenotypes observed with TBX3 overexpression. SLUG levels were 
efficiently knocked down in 21NT control and TBX3 transfectant cell lines using stable 
shRNA-mediated lentiviral transduction (Figure 3.3.3 A-B). In the scramble control (SCR), 
cells overexpressing either TBX3iso1 or TBX3iso2 had higher rates of migration and invasion 
relative to the empty vector control, similar to levels we previously reported in these cell lines 
(Krstic et al., 2016). With SLUG knockdown, the rates of migration and invasion of TBX3 
isoform transfectants were reduced to baseline levels, despite expressing high levels of 
TBX3 (Figure 3.3.3 C-D). 
A large proportion (7/10) of our previous list of EMT and invasion-associated genes 
were still significantly altered with high TBX3 isoform expression in cells with SLUG 
knockdown (Figure 3.3.3 E-F). However, the induction of several key invasiveness-
associated genes up-regulated by TBX3 was significantly impaired in the absence of SLUG, 
including MMP14, vimentin and fibronectin (Figure 3.3.3 E-F). Importantly, these findings 
suggest that there are TBX3-induced changes in expression of EMT-related genes that are 
both SLUG-dependent and SLUG-independent, and that the SLUG-dependent changes are 
required (although not necessarily sufficient) for TBX3-induced migration and invasion. 
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Figure 3.3.3 – SLUG up-regulation by TBX3 is essential for increased migration and 
invasion. 
(A) Western blot analysis showing knockdown of SLUG protein expression in shRNA 
transductants. Protein levels were normalized to Vinculin, which served as the loading 
control. (B) SLUG transcript levels were assessed by qRT-PCR, normalized to RPLP0 
expression levels, and depicted as fold change relative to the empty vector control. (C-D) 
Migration and invasion assays were conducted using 8.0µm pore transwells coated with 
either gelatin (migration) or Matrigel (invasion). Cells were allowed to migrate or invade for 
22 hours. The number of cells that migrated or invaded per high power field are shown. 
Means derived from four biological replicates were used during analysis. (E) Protein 
expression levels of EMT and invasion-associated genes were assessed by western blot. 
Protein samples were separated by 10% SDS-PAGE and normalized to Vinculin, which 
served as the loading control for all proteins. (F) The mRNA expression of several EMT and 
invasion-associated genes was evaluated by qRT-PCR. Expression was normalized to 
RPLP0 transcript levels and is depicted as fold change relative to the empty vector 
shScramble control (+EV+SCR). Means derived from three biological replicates were used 
during analysis. *p<0.05, **p<0.01, ***p<0.001 by either one-way ANOVA with Tukey post-
hoc or two-way ANOVA with Tukey post-hoc for comparison within and between sub-groups, 
respectively. Error bars represent standard deviation. 
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 TBX3 expression is elevated in low-grade, hormone-receptor positive 
invasive breast cancers and associated precursor lesions. 
Based on the association between TBX3 and an invasive and EMT phenotype in vitro and in 
vivo in chick embryo assays, along with a direct link to SLUG signaling, we extended our 
studies to human patient samples. To first assess the expression levels of TBX3, we focused 
on nuclear TBX3 expression by immunohistochemistry in 186 pre-invasive (Stage 0, DCIS 
only) and early invasive breast cancer (Stage I, invasion ≤2.0 cm) patient samples from the 
London Breast Cancer Database. Clinicopathologic variables for cohort 1 patients entered 
into this study are listed in Table 3.4 (left panel). We examined 4 sub-populations of cells 
including 1) benign non-columnar, 2) benign columnar, 3) DCIS, and 4) invasive cancer, after 
observing high expression of TBX3 in benign columnar cells (Figure 3.3.4 A). Earlier studies, 
based on genome sequencing data and mutational association, suggest that columnar cell 
lesions (CCL; includes columnar cell change, columnar cell hyperplasia, flat epithelial atypia 
(FEA)) may be an early morphologic indicator of propensity for, or non-obligate precursor to 
the development of breast cancer (Dabbs et al., 2006, Turashvili et al., 2008). We did not 
see a significant association between level of TBX3 in the DCIS and the presence vs. 
absence of invasion in cohort 1. We confirmed an association between TBX3 and estrogen 
receptor (ER) and progesterone receptor (PR) expression in invasive breast cancers (Figure 
3.3.4 B-C), which has been suggested by previous studies (Fillmore et al., 2010). TBX3 
positivity was highest in low and intermediate grade DCIS and significantly lower in high-
grade DCIS (Figure 3.3.4 D). We then examined a second independent patient cohort of 118 
patients with non-high-grade (low and intermediate grade) DCIS, with or without associated 
early invasive cancer (Stage 0 and Stage I) for increased power in evaluation of TBX3 
association with invasiveness of low-grade breast cancers. Clinicopathologic variables for 
cohort 2 patients entered into this study are listed in Table 3.4 (right panel). Based on results 
from our second cohort assessing patient samples with early invasion, we found that nuclear 
TBX3 expression by immunohistochemistry in the DCIS was associated with the size of the 
invasive focus (p<0.001) (Figure 3.3.4 E).  
Possible downstream effectors of TBX3 were identified in our ChIP-array and RNA-
Seq studies. We conducted immunohistochemical staining for EMT transcription factors 
SLUG and TWIST1 (which were shown to be directly and indirectly up-regulated by TBX3, 
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respectively) in our second patient cohort (staining patterns shown in Figure 3.3.4 A). 
Expression of each marker was assessed in all four cell populations in the same manner as 
for TBX3. We identified a positive correlation between TBX3 expression and both SLUG 
(p<0.05) and TWIST1 (p<0.001) expression in the invasive component (Figure 3.3.4 F-G). 
Additionally, both SLUG and TWIST1 protein levels were up-regulated in CCLs, and SLUG 
levels were significantly higher in low grade (Grade 1) DCIS lesions relative to both Grade 
1+2 (mixed) and Grade 2 DCIS lesions (Figure 3.3.4 H), exhibiting staining patterns similar 
to TBX3. Collectively, these results suggest that TBX3 may be facilitating the process of early 
invasion even at the earliest stages of progression (i.e. CCLs, DCIS), and offer potential roles 
for downstream EMT-related proteins such as SLUG and TWIST1 in invasiveness of early 
stage breast cancer.  
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Table 3.4 – Clinicopathologic variables for patients entered into this study. 
 COHORT 1 COHORT 2 
Characteristic No. of patients (%) No. of patients (%) 
Total 186 (100) 118 (100) 
Age (yr) 
     ≤50 
     >50 
 
17 (9.1) 
169 (90.9) 
 
14 (11.9) 
104 (88.1) 
Associated invasion 
     No invasion  
     Micro-invasion 
     Invasion 
 
100 (53.8) 
12 (6.5) 
74 (39.8) 
 
84 (71.2) 
2 (1.7) 
32 (27.1) 
Histological type of invasive cancer 
     Total cases with invasion 
     NST 
     NST with lobular features 
     NST with tubular features 
     NST with mucinous features 
     NST with micropapillary features 
     Invasive lobular carcinoma 
     Invasive tubular carcinoma 
     Invasive mucinous carcinoma 
 
74 (100) 
55 (74.3) 
9 (12.2) 
3 (4.1) 
3 (4.1) 
1 (1.4) 
1 (1.4) 
1 (1.4) 
1 (1.4) 
      
34 (100) 
26 (76.5) 
3 (8.8) 
3 (8.8) 
0 (0.0) 
0 (0.0) 
0 (0.0) 
1 (2.9) 
1 (2.9) 
 
IMC histologic grade 
     Total cases with invasion 
     Low 
     Intermediate 
     High 
  
74 (100) 
26 (35.1) 
36 (48.6) 
12 (16.2) 
 
34 (100) 
16 (47.1) 
18 (52.9) 
0 (0.0) 
DCIS nuclear grade 
     Total cases with DCIS 
     Low 
     Low + Intermediate 
     Intermediate 
     High 
 
100 (100) 
10 (10.0) 
0 (0.0) 
41 (41.0) 
49 (49.0) 
 
118 (100) 
16 (13.6) 
44 (37.3) 
58 (49.2) 
0 (0.0) 
Hormone receptor status * 
     ER positive 
     PR positive 
     HER2 positive 
 
66/82 (80.5) 
52/71 (73.2) 
16/57 (28.1) 
 
33/34 (97.1) 
29/34 (85.3) 
3/34 (8.8) 
Recurrence 
     No recurrence 
     Yes recurrence 
            Invasive recurrence 
            Non-invasive recurrence 
     Unknown 
 
162 (87.1) 
13 (7.0) 
10 (76.9) 
3 (23.1) 
11 (5.9) 
 
0 (0.0) 
Micro-metastasis 8 (4.3) 0 (0.0) 
 
Table 3.4. Clinicopathologic variables for patients entered into Cohort 1 and 2. 
NST, no special type; IMC, invasive mammary carcinoma; DCIS, ductal carcinoma in situ;  
ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 
2; *only available for patients with IMC 
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Figure 3.3.4 – TBX3 expression is elevated in low-grade, hormone-receptor positive 
invasive breast cancers and associated precursor lesions. 
Patient samples representing Cohort 1 were immunohistochemically stained and assessed 
for nuclear TBX3 expression, and Cohort 2 samples were stained and assessed for nuclear 
TBX3, SLUG and TWIST1 expression. (A) Representative expression and staining patterns 
of Cohort 2 samples (TBX3 expression and staining patterns were similar in Cohort 1; not 
shown). (B-D) Nuclear TBX3 expression was assessed by immunohistochemistry in Cohort 
1, consisting of 186 patients with early-stage breast cancer (all nuclear grades) identified 
from the London Breast Cancer Database on the basis of having either DCIS only (Stage 0), 
or DCIS with an associated early invasive component (Stage I; 2cm, and either pN0 or 
pN0mi). Nuclear TBX3 expression was compared across ductal epithelial cell types (benign 
non-columnar, benign columnar, DCIS and invasive mammary carcinoma). The association 
between TBX3 expression and (B) estrogen receptor (ER), (C) progesterone receptor (PR), 
and (D) DCIS nuclear grade is shown. (E-H) Nuclear TBX3, SLUG and TWIST1 expression 
was assessed by immunohistochemistry in Cohort 2, consisting of 118 patients with non-
high-grade (nuclear grade 1 or 2) DCIS lesions, with or without associated early invasive 
cancer (Stage 0 or Stage I). Expression levels were compared across ductal epithelial cell 
types and clinical data. (E) Correlation analysis for nuclear TBX3 expression and size of the 
invasive focus in patients with Stage I breast cancer. (F-G) Correlation analysis of 
TBX3/SLUG expression and TBX3/TWIST1 expression in the invasive carcinoma. (H) 
Association between nuclear SLUG expression and DCIS nuclear grade.  
*p<0.05, **p<0.01, ***p<0.001 by one-way ANOVA with Tukey post-hoc for comparison 
between three groups, and Student’s t-test for comparison between two groups. Correlation 
and p-values were calculated using the Pearson correlation statistic. Error bars represent 
standard deviation. 
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 Elevated TBX3 levels are associated with poor prognosis of breast 
cancer and are highly correlated with SLUG expression. 
To assess the applicability of our findings in a broader breast cancer and pan-cancer context 
we compared our findings with that of available transcriptomic datasets. Using the ICGC US 
donor cohort, we found that TBX3 mRNA levels are elevated in tumor cells of several cancer 
subtypes, including breast cancer (data not shown). By further profiling transcriptomic data 
from the TCGA BRCA and the Farmer Breast study (Farmer et al., 2005), we identified an 
association of higher TBX3 levels in luminal subtypes of breast cancer, and estrogen receptor 
(ER) and progesterone receptor (PR) positive cancers (Figure 3.3.5 A-B). Survival analysis 
of luminal A patients in the TCGA BRCA dataset showed a statistically significant difference 
in survival (p<0.001) between patients with high and low TBX3 expression relative to the 
median (Figure 3.3.5 C).  
Our immunohistochemical biomarker analysis revealed a significant positive 
correlation between TBX3, SLUG and TWIST1 expression within invasive breast cancer 
lesions. To further examine the association between TBX3 and our identified downstream 
targets SLUG and TWIST1 and relate it to histopathological grade, we interrogated 
transcriptomics datasets with relevant grade information: TCGA BRCA (n=680 with grade 
information) and Desmedt (n=196, node-negative breast cancers, all with grade information 
(Desmedt et al., 2007)). TBX3 and SLUG mRNA levels were significantly lower in high-grade 
breast cancers relative to low and intermediate-grade breast cancers (Figure 3.3.5 D) 
(p<0.001), consistent with our immunohistochemical data. The Desmedt dataset also 
showed reduced TWIST1 levels in high-grade breast cancers. There was a high degree of 
overlap between TBX3 and SLUG in terms of patient characteristics and lesion types 
identified in our immunohistochemical staining and within the transcriptomics datasets. 
Additionally, upon examination of the TCGA TARGET GTEx dataset, we observed high co-
expression of SLUG and TBX3 in 19,120 normal and tumor samples represented, and tight 
association with MMP14 with high expression of both transcription factors (Figure 3.3.5 E). 
Collectively, analysis of publicly available data further supports the association and likely 
involvement of TBX3, along with downstream EMT transcription factors SLUG and TWIST1 
in aggressiveness of low-grade breast cancers.  
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Figure 3.3.5 – Elevated TBX3 levels are associated with poor prognosis of breast 
cancer, and are highly correlated with SLUG expression. 
(A-B) TBX3 expression was assessed across tumor characteristics in deposited 
transcriptomics data consisting of the Farmer Breast and TCGA BRCA cohorts. TBX3 mRNA 
expression by molecular subtype was further investigated in the TCGA BRCA dataset. (C) 
Kaplan Meier survival curves for luminal A patients (ER+ PR+ HER2-) from the TCGA BRCA 
dataset, separated into high (above median) vs. low (below median) TBX3 expression. 
Number of events (breast cancer related deaths) are shown in the associated table. (D) 
Expression of TBX3, SLUG and TWIST1 was assessed in the TCGA BRCA and Desmedt 
datasets to compare expression levels across grades. Data shown represent median-
centered, z-score normalized values. (E) Correlation of SLUG, TBX3 and MMP14 expression 
was assessed in the TCGA Target GTEx dataset, consisting of 19,120 normal and tumor 
patient samples.  
*p<0.05, **p<0.01, ***p<0.001 by one-way ANOVA with Tukey post-hoc for comparison 
between three groups. Survival analysis for Kaplan-Meier curve was calculated using the log-
rank test statistic. Correlation and p-values were calculated using the Pearson correlation 
statistic. Error bars represent standard deviation. 
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Figure 3.3.6 – TBX3 promotes progression of pre-invasive breast cancer cells by 
inducing EMT and directly up-regulating SLUG.  
Proposed model through which TBX3 promotes progression of pre-invasive ductal carcinoma 
in situ (DCIS) lesions. TBX3 levels are low in benign non-columnar ductal breast epithelial 
cells. In columnar cell lesions (CCLs), expression of TBX3 levels are up-regulated, with a 
concomitant increase in SLUG and TWIST1 expression levels. This is predicted to promote 
proliferation and plasticity of early, pre-invasive lesions. In a subset of low-grade DCIS, TBX3 
expression is particularly high. Overexpression of TBX3 induces altered expression of 
several proteases and protease inhibitors, leading to degradation of the basement membrane 
and priming for early invasion of DCIS into adjacent stroma. These events are facilitated by 
TBX3-induced and SLUG-dependent expression of pro-migratory molecules such as MMP14 
(membrane-bound), fibronectin (extracellular matrix), and vimentin (intracellular). 
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3.4 Discussion 
The use of screening mammography over the past four decades has drastically increased 
our ability to detect DCIS (Kerlikowske, 2010), but has been criticized as causing an over-
diagnosis of breast cancer (Miller et al., 2014). Gene expression profiling has allowed for the 
successful stratification of node-negative invasive breast cancer patients into low-risk and 
high-risk groups, providing information useful in clinical decision-making for this population 
(van 't Veer et al., 2002). These techniques have been extended to DCIS with some success 
(Solin et al., 2013, Bartlett et al., 2014, Rakovitch et al., 2015). Additionally, panels of selected 
markers, including p16, COX2 and Ki67 have shown some utility in their ability to predict 
behaviour of DCIS in specific subsets of patients (Kerlikowske et al., 2010). Despite these 
efforts, there are few validated diagnostic tests or biomarkers to aid in optimization of 
treatment strategies for women with DCIS, and none that reliably predict risk for invasion, 
leading to the possibility of both over-treatment and under-treatment of this subpopulation.  
We have previously established a role for the transcriptional regulatory protein TBX3 
in invasiveness of breast cancer (Krstic et al., 2016). In this current study we further explored 
the mechanism of this activity, particularly as associated with the phenomenon of EMT. We 
sought to take a high-resolution approach to identifying downstream targets of TBX3, 
beginning with identification of transcriptomic changes with TBX3 overexpression and 
assessment of direct TBX3 binding sites. From these initial genomic studies, we identified 
SLUG and TWIST1 as potential downstream effectors up-regulated with TBX3 
overexpression, and SLUG as a direct downstream mediator of TBX3-induced migration and 
invasion. Importantly, we have discerned expression differences in these proteins between 
benign non-columnar ductal epithelial cells, columnar cell lesions (CCLs), DCIS, and within 
the invasive carcinoma. Our examination of TBX3 expression by immunohistochemistry in 
two independent patient cohorts revealed that expression is highest in hormone receptor 
positive, low-grade DCIS (and co-existing columnar cell lesions) and is associated with the 
extent of invasion in early-stage breast cancers. These findings, coupled with our in vitro data 
of an EMT-link, are consistent with a role for the TBX3 transcription factor in early invasion 
events, likely working in conjunction with other EMT-related factors such as SLUG and 
TWIST1, to facilitate a phenotype conducive to invasion. 
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The prevailing breast cancer progression model supported by numerous genomic and 
transcriptomic studies includes two divergent molecular pathways of progression – the low-
grade (ER+/PR+) and high-grade (ER-/PR-) pathway (Bombonati and Sgroi, 2011). Only a 
subset of DCIS within each pathway will progress to invasive cancer. Interestingly, 
sequencing and hierarchical clustering of DCIS and invasive samples has shown that 
samples do not cluster by diagnosis, but rather by intrinsic molecular subtype (Muggerud et 
al., 2010). This suggests that factors associated with invasiveness are distinct from histologic 
grade and stage, and may indeed be present within the pre-invasive DCIS (Muggerud et al., 
2010). 
Our proposed model of the stage-specific role of TBX3 in early breast cancer 
progression is depicted in Figure 3.3.6. As observed in our immunohistochemical studies, 
expression of EMT-related transcription factors (including TBX3) is low in benign non-
columnar breast epithelium. We have identified that TBX3 levels are significantly elevated in 
CCLs. This is in accordance with existing studies examining patterns of gene expression 
changes through breast cancer progression showing up-regulation of several malignancy-
associated genes at the pre-invasive stage (Ma et al., 2003). This pro-EMT phenotype in 
CCLs, with concomitant up-regulation of SLUG and TWIST1, is predicted to promote 
proliferation and plasticity of the breast epithelial cells (De Craene and Berx, 2013). There is 
accumulating evidence that CCLs, and in particular the CCL variant termed ‘flat epithelial 
atypia’ (FEA), may be non-obligate precursors to the development of breast cancer (Dabbs 
et al., 2006, Turashvili et al., 2008). Only some columnar cell lesions progress, even though 
TBX3 and EMT transcription factors SLUG and TWIST1 are expressed in most (at least when 
observed in association with DCIS). This suggests that there are likely other changes that 
act in concert to allow for progression to occur.  
In our present study, the significant level of enrichment of proteases, protease 
inhibitors and enzyme modulators in RNA-Seq and ChIP-array datasets of DCIS-like 21NT 
cells overexpressing TBX3 is consistent with the propensity to break down basement 
membrane and invade. Previous studies have suggested that the gradual loss of basement 
membrane, leading to changes in cell organization and polarity (rather than the acquisition 
of additional mutations) is the main driver in the transition from an in situ to invasive 
phenotype (Hu et al., 2008). We have confirmed up-regulation of MMP14 and urokinase-type 
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plasminogen activator (uPA), and down-regulation of CST6 by qRT-PCR and western blot 
analysis. Consistent with this, uPA and MMP14 overexpression have been shown to be 
strong and independent predictors of breast cancer survival (Look et al., 2002, Têtu et al., 
2006). Furthermore, CST6 has been shown to be down-regulated in breast cancer 
progression, with promoter hypermethylation documented at the DCIS stage (Ai et al., 2006). 
We have shown that induction of MMP14 with TBX3 overexpression is a SLUG-dependent 
process, and this signaling cascade may be important for TBX3-induced migration and 
invasion. In keeping with this, it has been previously reported that MMP14 is among the main 
regulators of the basement membrane transmigration process in vivo (Hotary et al., 2006), 
likely due to MMP14 dependent activation of the main type IV collagenase MMP2 (Duffy et 
al., 2000). Importantly, we have shown increased activity of MMP2 with TBX3 
overexpression. Additionally, increased expression of several proteases has been shown to 
indirectly enhance the activity of EMT transcription factors, leading to a positive feedback 
loop (De Craene and Berx, 2013), potentially resulting in high expression levels of EMT 
transcription factors and proteases as we have observed both in vitro and in our two patient 
cohorts. 
In conclusion, we propose a unique pathway in which TBX3 promotes progression 
through advancement of low-grade DCIS to invasive carcinoma (Figure 3.3.6). Our proposed 
model is particularly relevant in the non-high grade, ER-positive pathway of progression. 
Overexpression of TBX3 at early pre-invasive stages (CCL, DCIS) of breast cancer 
progression, inducing other molecular regulators of EMT (including SLUG and TWIST1), acts 
as an enabler to set the stage for basement membrane breakdown and invasion into adjacent 
stroma. Further validation of our findings in an independent cohort of Stage 0 and Stage I 
breast cancer patients and comparison with follow-up data should be conducted in order to 
assess whether TBX3 expression may provide reliable risk stratification for patients 
diagnosed with DCIS, possibly in concert with multiple biomarkers such as Ki67, p16, COX2, 
and/or multi-parameter gene expression assays (Kerlikowske et al., 2010, Bartlett et al., 
2014). As T-box proteins such as TBX3 have been shown to have detrimental effects with 
respect to cancer progression and survival, a thorough understanding of the underlying 
mechanisms involved is crucial. 
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 Isoform-specific promotion of breast cancer tumorigenicity by 
TBX3 involves induction of angiogenesis 
 
SUMMARY OF FINDINGS 
 
TBX3 is a member of the highly conserved family of T-box transcription factors involved in 
embryogenesis, organogenesis and tumor progression. While the functional role of TBX3 in 
tumorigenesis has been widely studied, less is known about the specific functions of the 
different TBX3 isoforms. Through alternative splicing and exon skipping events, TBX3 
encodes two isoforms – TBX3iso1 and TBX3iso2. TBX3iso2 contains an additional 20 amino 
acid sequence inserted into the DNA binding domain which TBX3iso1 lacks. We report, for 
the first time, that TBX3 isoforms have differential tumorigenic potential in nude mouse 
xenograft experiments when transfected into non-tumorigenic DCIS-like 21NT cells, with 
overexpression of TBX3iso1 more commonly associated with invasive carcinoma. Histologic 
examination showed high vascularity of tumors that arise from TBX3iso1 overexpressing 
cells. Through transcriptomic analysis of signaling pathways altered with TBX3iso1 and 
TBX3iso2 overexpression, we reveal that there are significant differences in angiogenesis-
related genes. Importantly, osteopontin (OPN), a cancer-associated secreted 
phosphoprotein, was shown to be significantly up-regulated with TBX3iso1 overexpression. 
This pattern was observed across three non/weakly-tumorigenic breast cancer cell lines 
(21PT, 21NT, MCF7). Up-regulation of OPN in TBX3iso1 overexpressing cells resulted in 
induction of hyaluronan synthase 2 (HAS2) expression and increased retention of hyaluronan 
in pericellular matrices. The described changes involving TBX3iso1-dependent promotion of 
angiogenesis may explain the differences in tumor formation rates between TBX3 isoforms 
in vivo. Within the TCGA breast cancer cohort, there was an 8.1-fold higher 
TBX3iso1/TBX3iso2 ratio in tumors relative to control, and this ratio was positively associated 
with tumor grade. This shift of an increased TBX3iso1/TBX3iso2 ratio in tumors relative to 
control tissue is observed across several TCGA tumor subtypes that overexpress TBX3. 
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4.1 Introduction 
TBX3 is a member of the highly conserved family of T-box transcription factors involved in 
embryogenesis and organogenesis. Germline mutations or haploinsufficiency of TBX3 
results in ulnar-mammary syndrome (UMS, OMIM 181450), characterized by mammary 
gland hypoplasia, apocrine gland, dental, and genital defects, emphasizing its broad 
expression profile (Bamshad et al., 1999, Bamshad et al., 1997). TBX3 levels are up-
regulated in several cancer types, including breast (Fan et al., 2004, Lomnytska et al., 2006, 
Yarosh et al., 2008, Souter et al., 2010), melanoma (Rodriguez et al., 2008), colorectal (Shan 
et al., 2015), pancreatic (Cavard et al., 2009), cervical (Lyng et al., 2006), ovarian (Lomnytska 
et al., 2006), gastric (Miao et al., 2016), and prostate cancers (Gudmundsson et al., 2010), 
suggesting its potential role as an oncogenic driver in multiple cancer types. 
TBX3 is alternatively spliced, leading to two predominant isoforms: TBX3iso1 and 
TBX3iso2. TBX3iso2 contains a unique 20 amino acid sequence inserted into the DNA 
binding domain attributed to the 2a exon. Addition of the 2a exon within TBX3iso2 shifts 
residues critical for TBX3 interaction with DNA (particularly Ser224 and Met225) (Coll et al., 
2002), however, the effect on transcriptional regulation and its functional relevance remains 
unclear.  
TBX3 isoform ratios have been found to be tissue and species specific (Fan et al., 
2004), with differing relative levels of TBX3iso1/TBX3iso2 reported in several breast cancer 
cell lines (Bamshad et al., 1999, Fan et al., 2004). Additionally, the T-box binding domain 
which differs between the two TBX3 isoforms has been shown to be important for protein-
protein interactions, facilitating interactions with core histones and chromatin-interacting 
proteins such as methyltransferases (Demay et al., 2007, DeBenedittis and Jiao, 2011, Miller 
et al., 2008).  
Conflicting results have been published regarding functionality of the TBX3 isoforms. 
Fan et al. reported that the 20-amino acid addition in TBX3iso2 hinders its binding to a 
previously identified T-box element (TBE) through in vitro oligonucleotide binding assays, 
suggesting that the protein’s DNA binding is altered (Fan et al., 2004). In a study by Hoogaars 
et al., both TBX3 isoforms were able to bind to the TBE in the Nppa and p21CIP1 promoters, 
suggesting that they have similar functions in vitro (Hoogaars et al., 2008). Due to the growing 
amount of literature implicating TBX3 in the promotion of tumorigenesis in several cancer 
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types (Fan et al., 2004, Lomnytska et al., 2006, Yarosh et al., 2008, Souter et al., 2010, 
Rodriguez et al., 2008, Cavard et al., 2009, Lyng et al., 2006, Gudmundsson et al., 2010, 
Krstic et al., 2016), it is essential to address the functional relevance of TBX3 isoforms and 
their altered expression in cancer.  
In this study, we provide evidence for differential tumorigenicity of TBX3 isoforms 
through in vivo nude mouse xenograft experiments. Importantly, by conducting high 
throughput RNA sequencing, we have shown that TBX3iso1-induced tumorigenicity is 
associated with selective up-regulation of angiogenesis-promoting genes, including 
osteopontin (OPN), and subsequent induction of hyaluronan synthase 2 (HAS2) expression. 
This is accompanied by induction of endothelial cell tubule formation by conditioned media 
from TBX3iso1 overexpressing cells in vitro. Increased expression of OPN has been 
associated with advanced tumor stage and poor prognosis of breast cancer (Rudland et al., 
2002, Tuck et al., 1998), and both OPN and hyaluronan promote the process of angiogenesis 
(Chakraborty et al., 2008, Chakraborty et al., 2006, Takahashi et al., 2002, Cook et al., 2005, 
Hirama et al., 2003, Takano et al., 2000, Shijubo et al., 1999, Asou et al., 2001, Pröls et al., 
1998, Koyama et al., 2007, Rooney et al., 1995). Lastly, we utilized the TCGA breast cancer 
dataset to determine differential expression of TBX3 isoforms. We found an 8.1-fold higher 
TBX3iso1/TBX3iso2 ratio in tumor tissues relative to control. This pattern of an increased 
TBX3iso1/TBX3iso2 ratio for tumor tissues relative to control was observed across several 
different tumor types which overexpress TBX3. This study is the first of its kind to report 
significant functional differences between the two TBX3 isoforms, both in vivo and in vitro. 
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4.2 Methods 
Cell lines and culture conditions 
The 21T series cell lines (21PT, 21NT) were obtained as a gift from Dr. Vimla Band (Dana 
Farber Cancer Institute) (Band et al., 1990). The 21PT and 21NT cell lines and transfectants 
underwent cell line authentication by Idexx Radil (Case No. 20250-2013). The 21PT and 
21NT cell lines were maintained in αMEM media supplemented with 2mM L-glutamine, 
1µg/mL insulin, 12.5ng/mL EGF, 2.8µM hydrocortisone, 10mM HEPES, 1mM sodium 
pyruvate, 0.1mM non-essential amino acids, 50µg/mL gentamycin sulfate, and 10% FBS. 
MCF7 cells were maintained in DMEM media supplemented with 10% FBS. Stable 21PT, 
21NT and MCF7 transfectants were maintained in their respective media supplemented with 
500µg/mL G418 as a selection marker. All reagents for culture of breast cancer cell lines 
were obtained from Wisent Inc. Human neonatal dermal microvascular endothelial cells 
(HDMECs) were obtained from Lonza (CC2516; Walkersville, MD). Cells were expanded in 
Endothelial Basal Media-2 (EBM-2; Lonza, 00190860) supplemented with 20% FBS and 
SingleQuots (Lonza, CC-4176) growth factors. The minimum density for sub-culturing was 
maintained at 2500 cells/cm2. Only HDMECs under passage 10 were used for experiments. 
 
Generation of stable transfectant cell lines 
Stable transfectants were generated using plasmid constructs previously described (Krstic et 
al., 2016), consisting of either an empty vector (EV), TBX3iso1, or TBX3iso2 construct within 
a pcDNA3.1 vector (Invitrogen, V79020). Briefly, cells (21PT, 21NT, MCF7) were seeded into 
6-well plates at 350,000 cells per well. The following day, cells were transfected using the 
Lipofectamine 3000 Transfection Kit (Invitrogen, L3000; 3g of plasmid DNA per well) as per 
the manufacturer’s protocol. Selection was performed using the aforementioned media for 
each cell line, further supplemented with 500µg/mL G418. Resistant clones were pooled, 
expanded, and frozen for later use. 
 
RNA isolation and qRT-PCR 
RNA was isolated using the RNeasy Mini Kit (Qiagen, 74104) and converted into cDNA using 
the qScript cDNA SuperMix (Quanta Biosciences, 84034). The RT2 SYBR Green ROX qPCR 
Mastermix (Qiagen, 330521) was utilized for quantitative PCR with the primer sequences 
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listed in Table 4.1. The output values were normalized to GAPDH expression and are shown 
as fold changes relative to the empty vector control. 
 
Table 4.1 – Primer sequences utilized for qRT-PCR in mRNA studies. 
mRNA Probe Primer Sequences (Forward and Reverse, 5’ to 3’) 
Total TBX3 
F: CGCTGTGACTGCATACCAGA 
R: GTGTCCCGGAAACCTTTTGC 
TBX3iso1 
F: AGTGGATGTCCAAAGTCGTCAC 
R: CATGGAGTTCAATATAGTAAATCCATGTTTGTCTG 
TBX3iso2 
F: AGTGGATGTCCAAAGTCGTCAC 
R: CACTTGGGAAGGCCAAAGTAAATCCATG 
GAPDH 
F: AGGCTGGGGCTCATTTGAAG 
R: CCATCCACAGTCTTCTGGGTG 
COX1 
F: CGCCAGTGAATCCCTGTTGT 
R: GTCACACTGGTAGCGGTCAA 
HAS2 
F: GTTGGGGGAGATGTCCAGATTT 
R: CGGTTCGTGAGATGCCTGT 
IL1RN 
F: AGCAAGATGCAAGCCTTCAG 
R: CCTTGCAAGTATCCAGCAACTA 
OPN 
F: TTGCAGTGATTTGCTTTTGC 
R: TCAATGGAGTCCTGGCTGTC 
VEGFR2 
F: CCCAGATGACAACCAGACGG 
R: GCCTTCAGATGCCACAGACT 
 
Nude mouse xenografts 
Cells were grown to confluence on 150mm tissue culture dishes. Cells were harvested, 
washed twice with ice cold PBS, and resuspended in serum-free αHE media. The cell 
suspension (100µL containing 1.0x107 cells) was injected into the second thoracic mammary 
fat pad of 8 to 9 week old female nude mice at 10 mice per group. Mice were monitored 
regularly for tumor growth up to 1 year post-injection and euthanized either when tumors 
reached a volume of 2,500mm3 or one year post-injection, whichever occurred first. The 
primary tumor and/or mammary fat pad, brain, liver, spleen, kidneys, lungs, along with left 
and right axillary, brachial, and inguinal lymph nodes were collected. All tissues were 
formalin-fixed, paraffin-embedded, sectioned and H&E stained. Tissues were examined by 
an anatomic pathologist, and where indicated, sections were stained using anti-human 
mitochondrial antibody to confirm metastasis of xenograft cells. Animal care and surgical 
 158 
158 
procedures were conducted in accordance with the recommendations of the Canadian 
Council on Animal Care, under a protocol approved by Western University’s Council on 
Animal Care. 
 
Immunohistochemistry of mouse xenograft tissues 
Formalin-fixed, paraffin embedded tissues were sectioned at 4.0µm thickness onto charged 
glass slides. Sections were de-paraffinized and rehydrated. Antigen retrieval was conducted 
with 10mM citrate buffer (pH 6.0) for 20 minutes, maintaining sub-boiling conditions. The 
UltraVision LP Detection System (Thermo Fischer Scientific, TL-015-HD) was used as per 
the manufacturer’s protocol. Suspect tissues and lymph nodes were stained using an anti-
human mitochondrial antibody (Thermo Fischer Scientific, MS-1372-P0; 1/100 for 20 minutes 
at room temperature) to confirm metastases. The degree of angiogenesis was assessed 
across primary tumors using an anti-mouse CD31 antibody (BD Pharmingen, 550274; 1/50 
at 4ºC overnight). OPN expression was assessed across primary tumors using an anti-
human OPN antibody (AssayDesigns mAb53, 905-629; 1/750 for 90 minutes at room 
temperature). Signal for all stains was developed using DAB, and slides were counter-stained 
in Harris’s Hematoxylin. Expression of human mitochondria was classified as either positive 
or negative. For quantification of CD31 expression by immunohistochemistry, images of 10 
non-overlapping areas exhibiting high vessel density were acquired using the Olympus IX70 
inverted microscope at 10X objective, and the number of vessels per high power field was 
assessed using ImageJ. For quantification of OPN expression by immunohistochemistry, 
images of 10 random, non-overlapping areas were acquired using the Olympus IX70 inverted 
microscope at 10X objective across. Images were imported to ImageJ, and colour 
deconvolution using the H DAB setting was conducted. DAB images representing positive 
OPN signal were kept, thresholded, and the percentage of positive signal within the image 
area was quantified. 
 
In vitro endothelial tubule formation assay 
In vitro endothelial tubule formation assays were conducted as previously described 
(Arnaoutova and Kleinman, 2010). Briefly, human neonatal dermal microvascular endothelial 
cells (HDMECs) were grown to 80% confluency. Growth factor reduced Matrigel (Thermo 
Fischer Scientific, CB356239) was added to 96 well plates (50µL/well). HDMECs were 
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trypsinized, washed twice with PBS, and re-suspended at 200,000 cells/mL in media (1:1 
mixture of conditioned media and basal EBM-2 media with 20% FBS and no SingleQuots 
growth factors). Conditioned media was prepared by seeding 1.0x106 cells into T75 flasks, 
and cells were maintained in low serum media (αMEM with 0.1% FBS) for 48 hours. The 
endothelial cells suspended in conditioned media were added to the 96 well plate on top of 
the Matrigel (100µL, 20,000 cells per well) and incubated at 37ºC for 16 hours. For all studies, 
tubule formation was observed after 16 hours and phase contrast images were taken of 3 
non-overlapping fields of view per well using the Olympus IX70 inverted microscope at 10X 
objective. The number of endothelial cell tubules formed per well were counted using ImageJ 
(represented as branch points per 3 high power fields). All experiments were done with 
HDMECs under 10 passages.  
 
Analysis of secreted OPN by ELISA 
Cells were seeded at a density of 1.0x106 into T75 flasks (with 10mL media) and grown in 
serum-free αMEM media (with the aforementioned supplements) for 48 hours. Conditioned 
media (100µL) were subject to ELISA using a Dual Mono ELISA kit (Enzo Life Sciences, ADI-
900-142) following the manufacturer’s instructions. Human recombinant OPN provided within 
the kit was used to create a standard curve. OPN levels were normalized to equal amounts 
of cells. 
 
Particle exclusion assay 
Particle exclusion assays were conducted to visualize pericellular matrices, as previously 
described (Cook et al., 2006). Briefly, 1.5x104 cells were plated in 6-well plates in triplicate 
and allowed to adhere overnight. The following day, cells were pre-treated in the presence 
or absence of hyaluronidase (Sigma, H1136) (16 units/mL in αHE media with 0.1% BSA) for 
20 minutes at 37ºC. The media was then removed, and fixed sheep erythrocytes (Innovative 
Research, IC100-0210) were added in PBS with 0.1% BSA and allowed to settle for 10 
minutes. Plates were imaged using the phase contrast setting on an Olympus IX70 inverted 
microscope at 10X objective. Pericellular matrices appeared as halos surrounding cell 
surfaces from which fixed red blood cells were excluded. In order to quantify matrix 
production, a ratio of the pericellular matrix area over the cell area was calculated by tracing 
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around the cell coats (matrices) and cell areas of 30 randomly selected cells using ImageJ. 
A ratio of 1.0 indicated the absence of a pericellular matrix for a particular cell. 
 
Bioinformatics analyses 
RNA-Seq data from 21NT+EV, 21NT+TBX3iso1 and 21NT+TBX3iso2 cell lines was 
analyzed in order to examine differences in resultant transcriptional profiles with 
overexpression of TBX3iso1 and TBX3iso2. Enrichment analysis (Enrichr; Icahn School of 
Medicine, Mount Sinai) was conducted for cells overexpressing either TBX3iso1 or TBX3iso2 
relative to the empty vector control, focusing on genes altered >1.5 fold up or down for only 
one isoform, or >1.5 fold in opposite directions for both isoforms, and all with corrected 
FDR<0.05 (http://amp.pharm.mssm.edu/Enrichr/). Results from WikiPathways analysis are 
reported. 
An angiogenesis gene signature consisting of 222 genes was compiled by integration 
of genes with the Ingenuity Pathway Analysis (IPA; Qiagen) gene ontology term 
‘angiogenesis of tumor’, along with the angiogenesis gene lists from the databases in Table 
2 (top datasets, white). 
The ICGC (US donors) data was exported using XenaBrowser (University of 
California, Santa Cruz; https://xenabrowser.net/datapages/), and TBX3 mRNA expression 
was assessed across all cancer subtypes. Transcript levels of TBX3 isoforms were acquired 
from the TCGA portal, and examined in the breast cancer (BRCA) dataset. A ratio of total 
transcript reads for TBX3iso1 (uc001tvu) over total transcript reads for TBX3iso2 (uc001tvt) 
was compared against clinical data and tumor characteristics. Grade information for patients 
within the TCGA BRCA was obtained from Budczies et al. (Budczies et al., 2015). The TCGA 
and GTEx datasets were compared simultaneously through the use of the ‘transcripts’ 
function in XenaBrowser. The aforementioned datasets are listed in Table 4.2 (bottom 
datasets, black).  
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Table 4.2 – Publicly-available datasets utilized for analysis. 
 
Statistical Analysis 
Statistical analyses were conducted using GraphPad Prism 5. One-way ANOVA with Tukey 
post-hoc tests were conducted for the majority of analyses unless otherwise specified. Error 
bars are representative of standard deviation measurements. P-values less than 0.05 were 
considered statistically significant.  
 
  
Project Dataset REFERENCE (or LINK) 
 
MsigDB (Broad Institute) http://software.broadinstitute.org/gsea/index.jsp 
PubAngioGen 
(East China Normal University) 
http://www.megabionet.org/aspd 
Li et al, 2015 (Li et al., 2015) 
AngioDB 
(Pusan National University) 
Sohn et al, 2002 (Sohn et al., 2002) 
dbANGIO 
(Memorial University of 
Newfoundland) 
http://www.med.mun.ca/angio/ 
Savas et al, 2012 (Savas, 2012) 
 
ICGC (US Donors) https://xenabrowser.net/datapages/ 
TCGA breast cancer (BRCA) https://portal.gdc.cancer.gov/projects/TCGA-BRCA 
TCGA BRCA grade information Budczies et al, 2015 (Budczies et al., 2015) 
GTEx (Genotype Tissue 
Expression) 
https://xenabrowser.net/transcripts/ 
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4.3 Results 
 TBX3iso1 possesses enhanced tumorigenic potential in nude mice. 
In order to examine tumorigenicity of TBX3 isoforms, we overexpressed either TBX3iso1 or 
TBX3iso2 in non-tumorigenic, DCIS-like 21NT breast cancer cell lines (Figure 4.3.1 A). Cells 
were injected into the mammary fat pad of nude mice. Mice were monitored for up to a year, 
or until primary tumors reached a volume of 2,500 mm3, whichever occurred first. A majority 
(6/10) of mice injected with cells overexpressing TBX3iso1 developed invasive carcinoma 
and reached the end-point tumor volume, a significantly higher rate than mice injected with 
cells overexpressing TBX3iso2 (1/9; p<0.05 relative to TBX3iso1) or the empty vector control 
(0/10; p<0.01 relative to TBX3iso1) (Figure 4.3.1 B-D). Additionally, the TBX3iso1 tumors 
exhibited a shorter lag period of in vivo growth, all forming before the TBX3iso2 tumor (Figure 
4.3.1 C). All primary tumors (or mammary fat pad injection site) were assessed histologically 
by an anatomical pathologist, and the presence of precursor lesions (atypical ductal 
hyperplasia, ADH; ductal carcinoma in situ, DCIS) was documented (Figure 4.3.1 D). 
Representative images of histological lesions observed are shown in Figure 1E, representing 
DCIS, invasive mammary carcinoma (IMC) invading into skeletal muscle, and a metastatic 
lesion within the brachial lymph node (Figure 4.3.1 E). All collected organs were assessed 
for metastases, and suspect tissues were stained using anti-human mitochondrial antibody 
for confirmation (Figure 4.3.1 E, bottom right panel). One of the mice in the TBX3iso2 group 
developed lymphoma and was removed from the study. 
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Figure 4.3.1 – TBX3iso1 possess enhanced tumorigenic potential in nude mice. 
(A) Total TBX3, TBX3iso1 and TBX3iso2 expression was assessed by qRT-PCR, normalized 
to GAPDH expression levels, and depicted as fold change relative to the empty vector 
control. (B) Cells (1x107) were injected into the mammary fat pad of nude mice. Mice were 
sacrificed when the tumor volume reached 2,500mm3, or one-year post injection, whichever 
occurred first. The Kaplan-Meier plot shows disease-free survival over 365 days post-
injection. An event was defined as tumor volume reaching the 2,500mm3 end-point. (C) 
Tumor volume showing growth kinetics over time. TBX3iso1 tumors are shown in different 
colours, while the TBX3iso2 tumor is shown in black. (D) Histological analysis of H&E stained 
slides was conducted by an anatomical pathologist for all mammary fat pads and primary 
tumors. Cases with atypical ductal hyperplasia (ADH), ductal carcinoma in situ (DCIS), 
invasive mammary carcinoma (IMC) and metastasis were documented. All tissues and lymph 
nodes collected were examined for metastases in mice with IMC. Metastases were confirmed 
through positive immunohistochemical staining for anti-human mitochondria. (E) 
Representative images of cases of DCIS, IMC showing invasion into skeletal muscle, and 
metastasis into right brachial lymph node. Suspect metastases from H&E slides were 
confirmed through immunohistochemistry with anti-human mitochondrial antibody.  
*p<0.05, **p<0.01, ***p<0.001 by one way ANOVA with Tukey post-hoc for comparison 
between three groups. Survival analysis for Kaplan-Meier curve was calculated using the log-
rank test statistic. Error bars represent standard deviation. 
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 TBX3iso1 promotes angiogenesis in vivo and in vitro. 
Differential tumorigenicity between TBX3 isoform transfectants was a striking and novel 
finding. We re-examined our previous RNA-Seq dataset of 21NT transfectant cell lines 
(21NT+EV, 21NT+TBX3iso1, 21NT+TBX3iso2) to specifically assess for differences in 
expression profiles between the two TBX3 isoform transfectants. Interestingly, all of the cell 
lines had distinct expression signatures and clustering patterns (Figure 4.3.2 A), suggesting 
differential transcriptional function of the TBX3 isoforms. We observed 470 differentially 
expressed genes between TBX3iso1 and TBX3iso2. Pathway analysis of up-regulated genes 
with TBX3iso1 overexpression identified its potential role in osteopontin signaling, 
glycolysis/gluconeogenesis, and angiogenesis (Figure 4.3.2 B). Alternatively, pathway 
analysis of the up-regulated genes with TBX3iso2 overexpression identified alterations in the 
cytokines and inflammatory responses (Figure 4.3.2 C). Notably, TBX3iso2 overexpression 
resulted in down-regulation of genes involved in glycolysis/gluconeogenesis, showing 
inverse patterns from TBX3iso1 overexpressing cells. 
Gross examinations of xenograft tumors revealed high vascularity of tumors formed 
by TBX3iso1 overexpressing cells. Given this observation, and our finding of an enrichment 
of angiogenesis-related genes upon TBX3iso1 overexpression, we examined tumor 
vascularity through CD31 immunohistochemistry and quantification of microvascular density 
(Figure 4.3.2 D). Microvascular density within the TBX3iso1 tumors was significantly higher 
than the TBX3iso2 tumor for the majority (4/6) of tumors tested. In order to functionally 
examine for angiogenic properties, we isolated conditioned media from 21NT transfectant 
cells and incubated them with human dermal microvascular endothelial cells (HDMECs) on 
Matrigel for 16 hours to allow for endothelial cell migration and formation of tubule structures, 
mimicking angiogenesis in vitro (Figure 4.3.2 E). We observed marked differences in the 
promotion of angiogenesis in vitro between conditioned media from cells overexpressing 
TBX3iso1, which resulted in significantly higher rates of tubule formation by endothelial cells, 
relative to conditioned media from TBX3iso2 overexpressing cells or the empty vector 
control. 
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Figure 4.3.2 – TBX3iso1 promotes angiogenesis in vitro and in vivo.  
(A) Heat map showing large-scale transcriptional changes by RNA-Seq across 21NT+EV, 
21NT+TBX3iso1, and 21NT+TBX3iso2 cell lines. Principle component analysis (PCA) was 
conducted to assess the similarity in global transcriptional profiles between transfectant cell 
lines. (B) Enrichment analysis highlights pathways associated with transcripts up-regulated 
(red) and down-regulated (green) with TBX3iso1 overexpression relative to the empty vector 
control. (C) Enrichment analysis highlights pathways associated with transcripts up-regulated 
(red) and down-regulated (green) with TBX3iso2 overexpression relative to the empty vector 
control. (D) Assessment of blood vessel density within primary tumors by CD31 
immunohistochemistry. Primary tumors were stained for CD31 by immunohistochemistry and 
the number of vessels per non-overlapping high power field were quantified across 10 tumor 
hotspots. Averages across 10 hotspots for each mouse is shown. (E) Tubule formation assay 
to asses in vitro angiogenesis. Conditioned media was collected after 48h incubation with 
1x106 cells of each cell type. Conditioned media was incubated with human dermal 
microvascular endothelial cells (HDMEC) on growth factor reduced Matrigel for 16 hours at 
37ºC. Tubule branch points per 3 high power fields (one well) was quantified at the 16h mark.  
*p<0.05, **p<0.01, ***p<0.001 by one way ANOVA with Tukey post-hoc for comparison 
between three groups. Error bars represent standard deviation. 
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 Osteopontin is specifically up-regulated by TBX3iso1. 
In order to explore differences in transcriptional profiles between the two TBX3 isoforms on 
angiogenesis-related gene expression, we generated an angiogenesis gene signature 
consisting of 222 genes using publicly-available databases (as described in Bioinformatics 
Methods, Table 4.2) and conducted hierarchical clustering of RNA-Seq expression data for 
all cell lines (Figure 4.3.3 A). Investigation of the depicted cluster at a higher resolution 
revealed up-regulation of a subset of pro-angiogenic transcripts in TBX3iso1 overexpressing 
cells and down-regulation in TBX3iso2 overexpressing cells relative to the empty vector 
(Figure 4.3.3 B). Genes showing the most pronounced differences between TBX3iso1 and 
TBX3iso2 transfectants (OPN, COX1, IL1RN) were validated by qRT-PCR (Figure 4.3.3 C). 
The VEGF family is commonly referred to as the main pro-angiogenic factors across cancer 
subtypes (Oltean and Bates, 2014, Ladomery et al., 2007), with VEGFR2 acting as the key 
receptor responsible for mediating VEGF-induced angiogenic activity (Takahashi et al., 
2002). For this reason, expression of VEGFR2 was also validated by qRT-PCR and found to 
be down-regulated in TBX3iso2 overexpressing cells (as observed in RNA-Seq data) 
(Appendix 10).  
We focused our further studies on OPN since its mRNA levels displayed the greatest 
difference between TBX3iso1 and TBX3iso2 overexpressing cells, and OPN is known to be 
pro-angiogenic (Takahashi et al., 2002, Asou et al., 2001, Pröls et al., 1998, Takano et al., 
2000, Cook et al., 2005). OPN expression was then assessed in additional stable TBX3 
transfectant cell lines (TBX3 expression levels for 21PT and MCF7 transfectant cell lines are 
shown in Appendix 11 A-B). Overexpression of TBX3iso1 resulted in significant up-regulation 
of OPN mRNA levels in all three transfectant cell lines (Figure 4.3.3 C-D). Additionally, OPN 
mRNA levels were significantly down-regulated in all three cell lines overexpressing 
TBX3iso2. We then proceeded to evaluate the levels of OPN protein released into the 
conditioned media previously used for in vitro tubule formation assays. OPN protein levels 
were quantified by ELISA by comparing to recombinant human osteopontin standards 
(Figure 4.3.3 E). Relative to the empty vector control, there was a 49.0-fold and 3.9-fold 
increase in secreted OPN levels for TBX3iso1 and TBX3iso2 overexpressing cells, 
respectively. As another mode of confirmation, we conducted immunohistochemical staining 
for OPN in the xenograft primary tumors and observed a significantly higher proportion of 
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OPN positive tumor cells in TBX3iso1 tumors relative to the TBX3iso2 tumor (Figure 4.3.3 
F).  
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Figure 4.3.3 – Osteopontin is specifically up-regulated by TBX3iso1.  
(A) Heat map showing expression of 222 angiogenesis-related genes by RNA-Seq across 
21NT+EV, 21NT+TBX3iso1, and 21NT+TBX3iso2 cell lines. (B) Cluster showing up-
regulation of pro-angiogenic transcript with TBX3iso1 overexpression and down-regulation 
with TBX3iso2 overexpression. Osteopontin (OPN) mRNA expression is shown in red. (C) 
Expression of OPN mRNA levels in 21PT, 21NT and MCF7 transfectant cell lines was 
assessed by qRT-PCR, normalized to GAPDH expression levels, and depicted as fold 
change relative to the empty vector control. (D) OPN protein levels from conditioned media 
was assessed by ELISA and normalized to cell numbers. Human recombinant OPN (hrOPN) 
was used to generate a standard curve for determination of OPN protein concentration. (E) 
Primary tumors were stained for OPN by immunohistochemistry. Color deconvolution was 
conducted using ImageJ, followed by thresholding of brown signal to assess percentage of 
high power field positive for OPN expression across ten non-overlapping areas. Percentage 
of the high power field (HPF) positive for OPN is shown across 10 fields of view per tumor. 
*p<0.05, **p<0.01, ***p<0.001 by one way ANOVA with Tukey post-hoc for comparison 
between three groups, and Student’s t-test for comparison between two groups. Error bars 
represent standard deviation. 
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 TBX3iso1 overexpression leads to increased HAS2 levels and 
pericellular hyaluronan retention. 
We have previously shown that OPN induction of hyaluronan synthase 2 (HAS2) and hence 
hyaluronan (HA) production is associated with aggressiveness of 21NT cells (Cook et al., 
2006). Given that all three of the cell lines we tested (21PT, 21NT, MCF7) showed up-
regulation of OPN only with TBX3iso1 overexpression, we examined HAS2 mRNA levels. 
For all three cell line transfectants, overexpression of TBX3iso1 was associated with a 
significant up-regulation of HAS2 expression (Figure 4.3.4 A). Alternatively, overexpression 
of TBX3iso2 resulted in down-regulation of HAS2 mRNA expression in 21PT and MCF7 
transfectant cell lines, with no change in HAS2 expression in the 21NT transfectant cell line. 
Hyaluronan (HA) is produced by hyaluronan synthase enzymes (HAS1-3) at the intracellular 
face of the plasma membrane, and then extruded from the cell and either released into the 
microenvironment, or retained in pericellular coats (Weigel and DeAngelis, 2007, Tammi et 
al., 1998, Evanko et al., 2007). High levels of synthesis and retention of HA in pericellular 
coats has been shown to have an important role in malignant progression (Cook et al., 2006) 
and is an indicator of poor prognosis in epithelial cancers (Auvinen et al., 2014, Tammi et al., 
2008, Auvinen et al., 2000). In order to examine the phenomenon of HA retention, particle 
exclusion experiments were conducted using fixed sheep erythrocytes in order to visualize 
matrix production and retention (Figure 4.3.4 B-C). Due to the unique biochemical properties 
of HA, including its highly polar structure and large size, addition of partially negatively 
charged erythrocytes allows for visualization of matrices due to erythrocyte exclusion. Cells 
overexpressing TBX3iso1 had significantly larger pericellular coats relative to TBX3iso2 
overexpressing cells and the empty vector control, suggesting higher levels of hyaluronan 
production. Administration of hyaluronidase (HAse) completely abolished matrix assembly in 
TBX3iso1 overexpressing cells, confirming the presence of HA in the pericellular coats.  
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Figure 4.3.4 – TBX3iso1 overexpression leads to increased HAS2 levels and 
pericellular hyaluronan retention.  
(A) Expression of HAS2 mRNA levels in 21PT, 21NT and MCF7 transfectant cell lines was 
assessed by qRT-PCR, normalized to GAPDH expression levels, and depicted as fold 
change relative to the empty vector control. (B-C) Particle exclusion experiment for 
visualization of pericellular matrices. Cells were pre-treated in the presence or absence of 
hyaluronidase for 20 minutes, followed by removal of media and addition of fixed sheep 
erythrocytes. Pericellular matrix area was calculated by tracing around cell coats (matrices) 
and cell areas across 30 randomly selected cells. A ratio of 1.0 indicated the absence of a 
pericellular matrix for a particular cell. 
*p<0.05, **p<0.01, ***p<0.001 by one way ANOVA with Tukey post-hoc for comparison 
between three or more groups. Error bars represent standard deviation. 
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 Cancer progression involves transcriptional changes resulting in an 
increase in the TBX3iso1/TBX3iso2 ratio. 
TBX3 is overexpressed in several different cancer types (Fan et al., 2004, Lomnytska et al., 
2006, Yarosh et al., 2008, Souter et al., 2010, Rodriguez et al., 2008, Cavard et al., 2009, 
Lyng et al., 2006b, Gudmundsson et al., 2010, Miao et al., 2016). Examination of ICGC data 
(US Donor-centric) revealed breast cancer as amongst the cancers with the highest 
expression of all tumor tissue sites (Figure 4.3.5 A). We then interrogated TBX3 isoform 
expression in the TCGA breast cancer cohort, assessing the ratio of transcript reads for 
TBX3iso1 over TBX3iso2 for each breast cancer patient and comparing to clinical 
characteristics (Summarized in Figure 4.3.5 B). The TBX3iso1/TBX3iso2 expression ratio 
was 8.1-fold higher in tumor samples relative to normal controls (Figure 4.3.5 C). Additionally, 
this ratio was positively associated with higher tumor grade (Figure 4.3.5 D) along with more 
aggressive breast cancer subtypes (Figure 4.3.5 E). Upon examination of isoform-specific 
expression in tumor types where TBX3 overexpression has been documented (breast 
cancer, melanoma, colon, and pancreatic cancer), we observed an upwards shift in 
TBX3iso1 expression and downwards shift in TBX3iso2 expression within tumor tissues 
(TCGA cohorts) relative to an expanded cohort of normal tissue controls (GTEx normal tissue 
dataset) (Appendix 12). 
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Figure 4.3.5 – Cancer progression involves transcriptional changes resulting in an 
increase in TBX3iso1 to TBX3iso2 ratio. 
(A) Assessment of ICGC data (US Donor-centric) data shows total TBX3 levels across tumor 
subtypes. Total TBX3 transcript expression in breast cancer is shown in orange. (B) TBX3 
isoform ratios were interrogated in the TCGA breast cancer cohort by calculating the total 
transcript reads for TBX3iso1 over the total transcript reads for TBX3iso2 for each patient. 
Ratios were compared between normal and tumor tissues. (C) The TBX3iso1/TBX3iso2 
across breast cancer grades.  
*p<0.05, **p<0.01, ***p<0.001 by the non-parametric Kruskal-Wallis statistic with Dunn’s 
multiple comparison post-hoc test due to non-Gaussian distribution of ratios. Error bars 
represent standard deviation. 
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4.4 Discussion 
Alternative splicing is a post-transcriptional mechanism that adds an enhanced layer of 
complexity and diversification to genes encoded in the genome. Cancer cells are able to 
exploit the process of alternative splicing to produce isoform switches, resulting in enhanced 
survival, proliferation and invasiveness (Oltean and Bates, 2014, Shen et al., 2016). 
Interestingly, transcriptional analysis of alternative-splicing and assessment of exon inclusion 
events have been shown to outperform gene expression-based survival predictors across 6 
different cancer types, including breast cancer (Shen et al., 2016).  
 Existing literature examining TBX3-induced tumorigenicity through the use of 
xenograft models (Rodriguez et al., 2008, Peres and Prince, 2013, Willmer et al., 2016), 
along with the single published transgenic TBX3-inducible mouse model (Liu et al., 2011), 
have focused on only one isoform of TBX3 in different parental cell lines which makes 
comparison of results difficult. Liu et al. showed that inducible overexpression of TBX3iso2 
in murine mammary glands results in mild focal hyperplasia and importantly no tumor 
formation (Liu et al., 2011). For several other studies, which isoform was cloned and 
overexpressed is not stated (Peres and Prince, 2013, Perkhofer et al., 2016). Additionally, 
studies which employed knockdown of total TBX3 expression followed by 
xenotransplantation of cells into mice has revealed that TBX3 is associated with tumor 
formation, but not whether differences exist between isoforms (Peres et al., 2010). 
 We therefore sought to investigate the functional consequence of this highly 
conserved splice event as it relates to TBX3-induced tumorigenesis. We have conducted 
nude mouse xenograft experiments utilizing non-tumorigenic, DCIS-like 21NT cell lines, and 
have reported significant differences between TBX3 isoforms in the promotion of 
tumorigenesis, with TBX3iso1 overexpression more commonly associated with invasive 
carcinoma in vivo. This difference is likely associated with differing ability to induce 
angiogenesis, and is related to differential expression of a number of angiogenesis-
associated genes.  
 While angiogenesis has a limited role in normal physiology, it is a fundamental 
requirement in malignant progression (Hanahan and Weinberg, 2000). This requirement of 
angiogenesis is due to the inability of avascular tumors to access oxygen and nutrients 
through diffusion alone (Rooney et al., 1995, Hanahan and Weinberg, 2000, Ladomery et al., 
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2007). After cytokines are released from cells, they are able to diffuse into the extracellular 
milieu and act on nearby quiescent endothelial cells to induce proliferation and migration 
towards the tumor (Ladomery et al., 2007). As observed by in vitro tubule formation assays, 
pro-angiogenic factors are released from cells overexpressing TBX3iso1 that are functional 
in activating endothelial cells. We report that one key pro-angiogenic factor up-regulated by 
TBX3iso1 is OPN. OPN has previously been described to act as a cytokine in various 
contexts (Ashkar et al., 2000, Denhardt et al., 2001, Takahashi et al., 2002), with several 
studies ascribing it a pro-angiogenic function (Pröls et al., 1998, Takano et al., 2000, Asou 
et al., 2001, Takahashi et al., 2002). Importantly, elevated OPN expression is associated with 
several breast cancer-related prognostic factors, including early metastasis and poor 
outcome (Bellahcène and Castronovo, 1995, Rudland et al., 2002, El-Tanani et al., 2004, 
Bramwell et al., 2006, El-Tanani et al., 2006). A great deal of overlap has been reported on 
the cellular functions affected by OPN and HA (Kim et al., 2005). The two markers have both 
been correlated with cancer survival (Bellahcène and Castronovo, 1995, Auvinen et al., 2000, 
Rudland et al., 2002, El-Tanani et al., 2004, Bramwell et al., 2006, El-Tanani et al., 2006, 
Tammi et al., 2008, Veiseh et al., 2014) and are frequently co-expressed (Kim et al., 2005, 
Lee et al., 2007). We have previously reported OPN-induced up-regulation of HAS2 in 21NT 
breast cancer cell lines is necessary for both anchorage-independent growth and adhesion 
of tumor cells to bone marrow endothelial cells (Cook et al., 2006). Moreover, both HA and 
OPN are ligands for CD44 (in this case on endothelial cells) (Weber et al., 1996), and their 
binding promotes angiogenesis through stimulation of endothelial cell migration, survival and 
lumen formation (Brooks et al., 1994, Senger et al., 1996, Trochon et al., 1996, Griffioen et 
al., 1997, Arap et al., 1998, Scatena et al., 1998, Bayless et al., 2000, Cao et al., 2006). 
Our novel in vivo findings relating to differential tumorigenicity of TBX3 isoforms and 
downstream confirmation of associated pathways suggest that the assessment of relative 
levels of splice variants may be more important than the assessment of total transcript levels 
per gene (Blencowe, 2006, Li et al., 2006, Zhang et al., 2006). This focus on isoform ratios 
has been suggested by several studies (Venables, 2004, Blencowe, 2006, Ladomery et al., 
2007, Pajares et al., 2007). There are additional examples of alternatively spliced transcripts 
having diverse and even antagonistic functions (Pajares et al., 2007). A prominent example 
includes alternative splicing of VEGF; most splice variants are actively pro-angiogenic, while 
the VEGFb splice variant is only six amino acids different relative to its most similar isoform 
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but is actively anti-angiogenic (Ladomery et al., 2007). A splicing switch from the anti-
angiogenic to pro-angiogenic variant is observed both in cancer progression (Venables, 
2004, Pajares et al., 2007, Oltean and Bates, 2014), along with diseases such as proliferative 
diabetic retinopathy (Blencowe, 2006, Ladomery et al., 2007).  
It is unknown whether this increase of TBX3iso1 over TBX3iso2 expression is a cause 
or effect of the tumorigenic process; a splice shift phenomenon may be due to several factors, 
including potential epigenetic changes within the TBX3 gene, or due to changes in upstream 
splicing machinery (Cui et al., 2004, Ladomery et al., 2007). It is becoming quite clear that 
splice changes and isoform shifts in cancer are non-random and play a key role in cancer 
progression (Venables, 2004, Ladomery et al., 2007, Pajares et al., 2007). Various strategies 
are being employed in an attempt to exploit alternative splicing in diagnosis, prognosis and 
treatment of cancer (Yamaguchi et al., 1998, Venables, 2004, Ladomery et al., 2007). On 
this note, Venables et al. examined expression of breast cancer-associated genes and their 
alternatively spliced transcripts through assessment of isoform ratios (Venables et al., 2008). 
They reported cancer-specific exon loss for several transcripts as well as a significant overlap 
with previously identified ovarian cancer-specific splice changes (Klinck et al., 2008, 
Venables et al., 2008). This suggests that a subset of the alternative splicing events identified 
by high throughput transcriptomic analysis may be common across cancer subtypes. 
It is well established that TBX3 is aberrantly overexpressed in several cancer types 
(Fan et al., 2004, Lomnytska et al., 2006, Lyng et al., 2006, Rodriguez et al., 2008, Yarosh 
et al., 2008, Cavard et al., 2009, Souter et al., 2010, Shan et al., 2015, Miao et al., 2016, 
Gudmundsson et al., 2010). We have added to the existing literature and reported that in 
particular, an increased TBX3iso1/TBX3iso2 ratio is associated with several 
clinicopathological parameters in the TCGA breast cancer cohort. Additionally, TBX3iso1 
promotes a pro-angiogenic gene signature associated with elevated OPN and HAS2 
expression, as well as increased pericellular HA retention. These pro-angiogenic changes 
associated with elevated TBX3iso1 expression promote vascular channel formation by 
endothelial cells in vitro, and likely explain the high tumor formation rates and high vascularity 
of primary tumors formed in mouse xenograft assays. A thorough understanding of 
transcriptional control by TBX3, in an isoform-specific context, is therefore vital in order to 
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understand the effect of TBX3 in promotion of tumorigenicity in breast cancer as well as other 
cancer types. 
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 General Discussion 
Through the use of the 21T series breast cancer cell lines representing distinct stages of 
progression (ADH, DCIS, IDC) in the 3D Matrigel system, our lab employed array-based 
transcriptional profiling to identify clinically-relevant genes which may be implicated in the 
DCIS to IDC transition (Souter et al., 2010). TBX3 was identified as 2.8-fold up-regulated in 
this transition (Souter et al., 2010). Based on these preliminary findings, as well as 
accumulating literature implicating TBX3 in the promotion of malignancy, I focused on 
elucidating the role of TBX3 isoforms in breast cancer progression.  
I hypothesized that the transcriptional regulatory proteins TBX3iso1 and TBX3iso2 
have distinct roles in breast cancer progression, which is likely mediated by their 
downstream transcriptional targets. The follow-up work to address my hypothesis was 
organized into three main chapters, dealing with (1) functionality of TBX3 isoforms in vitro, 
(2) mechanism by which TBX3 isoforms promote EMT, and (3) in vivo differences between 
TBX3iso1 and TBX3iso2.  
(1) CHAPTER 2 – Examination of functional and phenotypic changes associated with 
modulation of TBX3 levels at various stages of breast cancer progression 
I have shown that overexpression of TBX3iso1 and TBX3iso2 promotes progression in an 
in vitro model of early stage breast cancer. This occurs through alteration of several 
cellular properties including growth, survival, invasiveness, and the acquisition of an EMT 
phenotype. Prominent functional and phenotypic changes initially identified with 
overexpression of TBX3iso1 and TBX3iso2 were identical. I therefore focused on the 
molecular mechanism by which TBX3 isoforms promote invasiveness and induction of 
EMT in the next chapter, since the acquisition of an EMT phenotype is associated with 
several clinical parameters including reduced survival and chemo-resistance (Polyak and 
Weinberg, 2009, De Craene and Berx, 2013, Nieto et al., 2016). 
 
 
 186 
186 
(2) CHAPTER 3 – TBX3 promotes progression of pre-invasive breast cancer cells by 
inducing EMT and directly up-regulating SLUG 
In order to assess the downstream mechanisms responsible for TBX3-induced EMT, I 
conducted ChIP-arrays and RNA-Seq to assess the direct transcriptional targets of 
TBX3iso1 and TBX3iso2, focusing on genes/pathways similarly regulated by both 
isoforms. I found that both TBX3 isoforms regulate expression of several EMT-related 
genes, including SLUG (directly) and TWIST1 (indirectly). Translating these in vitro 
molecular findings to clinical samples of early-stage breast cancers, I showed that TBX3 
levels are up-regulated in CCLs, with a concomitant increase in SLUG and TWIST1 
expression. This is predicted to promote proliferation and plasticity of early, pre-invasive 
lesions. TBX3 expression is maintained in a subset of low-grade DCIS, and was 
associated with the degree of invasiveness of Stage I breast cancers. Pathway analysis 
revealed that overexpression of both TBX3 isoforms induces altered expression of several 
proteases and protease inhibitors, which is consistent with the ability to degrade basement 
membrane and prime for early invasion. These events are facilitated by TBX3-induced 
and SLUG-dependent expression of pro-migratory molecules such as MMP14, fibronectin, 
and vimentin. My proposed model of TBX3-dependent advancement of low-grade DCIS 
to IDC is particularly relevant in the non-high grade, ER-positive pathway of progression. 
(3) CHAPTER 4 – Isoform-specific promotion of breast cancer tumorigenicity by TBX3 
involves induction of angiogenesis 
My last chapter deals with elucidation of relevant mechanisms responsible for increased 
tumorigenicity of TBX3iso1 in vivo in nude mouse xenograft assays. Tumors generated 
from non-tumorigenic cells overexpressing TBX3iso1 were invasive and highly vascular. 
Mining of transcriptional differences in RNA-Seq data revealed up-regulation of pro-
angiogenic transcripts with overexpression of TBX3iso1; this was not observed with 
overexpression of TBX3iso2. Importantly, overexpression of TBX3iso1 consistently 
resulted in up-regulation of OPN and HAS2 across three non-tumorigenic breast cancer 
cell lines, and increased hyaluronan retention in 21NT transfectants. Lastly, examination 
of the TCGA breast cancer cohort revealed a transcriptional shift during cancer 
progression, with an 8.1-fold higher TBX3iso1/TBX3iso2 ratio in tumors relative to control. 
This ratio was also associated with tumor grade and aggressive breast cancer subtypes.  
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5.1 Promotion of invasiveness by TBX3 
Transcriptional profiling of isogenic DCIS-like and IDC-like cells grown in 3D Matrigel was 
previously conducted by our laboratory, in which TBX3 was identified as significantly up-
regulated in the DCIS to IDC transition (Souter et al., 2010). At that time, the focus of TBX3-
related studies within the literature was characterization of functional and phenotypic 
changes associated with TBX3 (irrespective of isoform), along with identification of 
transcriptional targets and validation across cancer subtypes. Additionally, much of the 
existing literature focused on TBX3 in embryogenesis and development of organ systems. 
TBX3 transcriptional targets are likely context dependent, as studies have shown that 
conclusions regarding effects mediated by TBX3 are often not consistent across cancer 
subtypes, let alone in the process of embryogenesis vs. tumorigenesis (Willmer et al., 2016a, 
Zhu et al., 2016). 
My initial studies required characterization of TBX3-mediated effects in breast cancer, 
with validation across cell lines representing different molecular subtypes. I characterized the 
phenotypic and functional changes associated with overexpression of TBX3iso1 and 
TBX3iso2 in breast cancer cell lines. Changes associated with overexpression of TBX3 
isoforms included increased cell survival, proliferation and colony-forming ability, decreased 
apoptosis, and increased invasiveness. In contrast, shRNA-mediated knockdown of total 
TBX3 levels in invasive 21MT-1 cells resulted in decreased colony formation rates, along 
with decreased invasiveness. Throughout my studies, overexpression of either TBX3iso1 or 
TBX3iso2 resulted in increased invasiveness, as shown by transwell invasion assays, along 
with in vitro invadopodia formation, and in vivo extravasation and invadopodia formation 
assays within the CAM model. Use of the CAM model further aided in demonstrating changes 
in invasiveness between 21MT-1 transductant cells (shTBX3 21MT-1 and shLUC 21MT-1), 
as we were unable to use them in traditional in vitro migration and invasion assays due to 
the larger size of the cells. The inclusion of several layers of validation regarding in vivo 
invasiveness as well as several methods of detecting invadopodia formation are novel 
findings, further supporting the existing literature regarding TBX3-induced invasiveness 
across several cancer types (Rodriguez et al., 2008, Peres et al., 2010, Willmer et al., 2016a).  
Initiation of invadopodia formation commences through the binding of growth factor 
ligands to their cognate receptor, leading to activation of Src kinase required for induction of 
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invadopodia-specific proteins (Murphy and Courtneidge, 2011, Burger et al., 2014). Several 
growth factors (i.e. TGF-ß, FGF, Wnts) are able to induce expression of TBX3 (Renard et al., 
2007, Fillmore et al., 2010, Li et al., 2013). I have shown that overexpression of either 
TBX3iso1 or TBX3iso2 leads to up-regulation of Src at the mRNA and protein level. The 
activity of Src is modulated through phosphorylation at residues Y527 (inhibitory) and Y416 
(activating) (Irtegun et al., 2013). Overexpression of TBX3iso1 and TBX3iso2 resulted in 
reduced phosphorylation at the inhibitory Y527 site suggesting increased functionality 
(Irtegun et al., 2013), with no change in phosphorylation at Y416. Several proteases are also 
enriched within invadopodia structures, including MMP2, MMP9 and MMP14 (Weaver, 
2006). Importantly, both TBX3iso1 and TBX3iso2 up-regulate MMP9 and MMP14 
expression, and an increase in the active MMP2 was observed by gelatin zymography, 
further aiding in focal ECM degradation. I have also shown that the induction of the 
membrane-bound protease MMP14 by TBX3 is dependent on SLUG expression. My work 
has therefore added to the literature in terms of characterization of functionality of TBX3 
isoforms, including promotion of invadopodia formation and focal substrate degradation. 
TBX3 may be an important regulator of invasiveness through enhancing invadopodia 
formation, as TBX3 is induced by several upstream growth factors, and modulates 
expression of downstream effectors important for the proper functionality of invadopodia.  
5.2 Transcriptional targets of TBX3 – Cell Cycle Control 
While transcriptional regulation by TBX3 is not well understood and continues to focus on its 
repressive effects on transcription (with much of the literature focusing on direct repression 
of p14ARF by TBX3), there are a few studies in which TBX3 was shown to directly up-regulate 
gene transcription. This includes direct up-regulation and binding to the TBE in the promoter 
of jun dimerization protein 2 (JDP2), a histone chaperone with an important role in 
differentiation and senescence, along with Connexin 43 (GJA1) and GATA6, which are 
important regulators of heart development (Jin et al., 2002, Nakade et al., 2009, Boogerd et 
al., 2011, Lu et al., 2011, Yao et al., 2014).  
Through integrated analysis of coupled ChIP-array and RNA-Seq data for TBX3iso1 
and TBX3iso2 overexpressing cells, I observed that approximately 2/3 of TBX3iso1 and 
TBX3iso2-bound genes were down-regulated, and 1/3 of TBX3iso1 and TBX3iso2-bound 
genes were up-regulated at the mRNA level. Noteworthy genes which were bound in ChIP-
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arrays and transcriptionally up-regulated by both TBX3 isoforms include cyclin D (CCND1), 
cyclin E (CCNE1) and cell division cycle 25 homolog A (CDC25A), all of which are important 
cell cycle regulators, as well as SLUG (SNAI2), an EMT-inducing transcription factor. 
Importantly, the aforementioned cell cycle regulators are all involved in mediating the 
transition from G1 to S phase. The CDC25A phosphatase removes the inhibitory phosphate 
groups on the cyclin D-CDK4/6 and cyclin E-CDK2 complexes (Robert, 2015). Once 
activated, the major role of the cyclin D-CDK4/6 and cyclin E-CDK2 complexes is 
phosphorylation of the Rb protein (Robert, 2015). Rb is first phosphorylated by the cyclin D-
CDK4/6 complex, resulting in reduced affinity of Rb for E2F (Robert, 2015). The cyclin E-
CDK2 complex further phosphorylates Rb, ensuring maximal release of E2F (Robert, 2015). 
Upon release from Rb, E2F activates transcription of genes involved in DNA replication 
(Robert, 2015).  
The processes associated with G1/S phase transition are negatively regulated by 
inhibitors of CDKs previously described: p16INK4A (inhibitor of kinases; inhibits cyclin D-
CDK4/6 complex) and p21CIP1 (cyclin inhibitory protein; inhibits cyclin D-CDK4/6, cyclin E-
CDK2, cyclin A-CDK2 complexes). The well-described anti-senescence effect mediated by 
TBX3 through direct down-regulation of p14ARF (Brummelkamp et al., 2002, Lingbeek et al., 
2002, Yarosh et al., 2008), p16INK4A (Kumar P et al., 2014), and p21CIP1 (Hoogaars et al., 
2008, Willmer et al., 2016b) are therefore amplified through direct up-regulation of cyclin D1, 
cyclin E1, and CDC25A, all of which are required for progression from G1 to S phase. 
Interestingly, cyclin D is often up-regulated in breast cancer and is strongly expressed 
in ER+ breast cancers resistant to hormone therapy (Kenny et al., 1999, Hui et al., 2002, 
Hodges et al., 2003), displaying similar expression patterns with TBX3 (Fillmore et al., 2010). 
Additionally, up-regulation of cyclin E and CDC25A is associated with reduced survival in 
breast cancer (Cangi et al., 2000, Keyomarsi et al., 2002). 
The various direct mechanisms whereby TBX3 controls expression of important 
mediators of cell cycle progression is summarized in Figure 5.2.1. As highlighted above, up-
regulation of CDC25A is suggestive of increased activation of G1-phase cyclin-CDK 
complexes which are required for G1/S phase transition (Sandhu et al., 2000). Down-
regulation of p14ARF, p16INK4A, and p21CIP1 results in reduced inhibitory effects on G1-phase 
cyclin-CDK complexes. This increased expression and potentially increased activity of cyclin 
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D-CDK4/6 and cyclin E-CDK2 is expected to result in accelerated cell cycle progression and 
increased rates of proliferation (Masamha and Benbrook, 2009). TBX3 is also required for 
S/G2 phase transition, as depletion of TBX3 results in accumulation in S phase; the authors 
suggested that this may be mediated through TBX3-dependent down-regulation of p21CIP1 
(Willmer et al., 2015). TBX3 is therefore able to promote progression through both G1/S and 
S/G2 phase transitions, which is associated with increased proliferation rates. Indeed, these 
findings are in accordance with the widely-documented pro-proliferative effect associated 
with up-regulation of TBX3, as well as my findings of increased proliferation and growth rates 
in 3D Matrigel with overexpression of TBX3iso1 and TBX3iso2 reported in Chapter 1 (Lee et 
al., 2007a, Platonova et al., 2007, Miao et al., 2016, Willmer et al., 2016b, Wu et al., 2017).  
While binding events for CCND1, CCNE1 and CDC25A contain significant FDR-
corrected statistical values, and are transcriptionally up-regulated with overexpression of 
both TBX3 isoforms, further validation studies are needed to assess whether these binding 
events are direct and occur in breast cancer cell lines and various other cancer cell lines. 
Further elucidation of direct transcriptional targets of TBX3 is important in order to understand 
the functionality of TBX3 with regards to transcriptional regulation. This should be assessed 
in an isoform-specific context. 
 
Figure 5.2.1 – Proposed model of control of cell cycle progression by TBX3. 
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5.3 Transcriptional targets of TBX3 – EMT Regulation 
Through assessment of gene expression changes associated with overexpression of 
TBX3iso1 or TBX3iso2 relative to the control, there were prominent alterations in expression 
of EMT and invasion-associated genes. This was observed in the high-throughput RNA-Seq 
data, and recapitulated in the qRT-PCR arrays and through various functional assays. While 
the association between TBX3 and an EMT phenotype has been previously suggested 
through profiling of epithelial and mesenchymal markers (Humtsoe et al., 2012, Shan et al., 
2015, Miao et al., 2016) along with direct down-regulation of E-cadherin (Rodriguez et al., 
2008, Dong et al., 2018), direct modulation of transcription factors and inducers of EMT by 
TBX3 has not been reported and is therefore a novel finding. 
Although several genes involved in the cell cycle were both bound by and up-regulated 
by both TBX3 isoforms (according to ChIP-array and RNA-Seq data, respectively), I focused 
on TBX3-induced up-regulation of SLUG transcript levels due to its well-documented role in 
EMT (Barrallo-Gimeno and Nieto, 2005, Humtsoe et al., 2012, Phillips and Kuperwasser, 
2014). ChIP-array analysis showed that TBX3iso1 and TBX3iso2 bind near an intron-exon 
junction of the SLUG (SNAI2) gene. Through merging of ChIP-array data with Encyclopedia 
of DNA Elements (ENCODE) files, this binding site was revealed to possess a highly 
conserved TBE, located within the 5’ end of exon 2. This identified TBE overlaps with an 
RNA polymerase II (Pol II) binding site and a DNase I hypersensitivity (DHS) region. This 
binding has been validated by ChIP qRT-PCR, showing that overexpression of TBX3iso1 or 
TBX3iso2 leads to their enrichment at this genomic location. Since this binding is not located 
in an upstream promoter region and rather is located near an intron/exon boundary, my 
interpretation is that TBX3 promotes transcriptional elongation of the SLUG transcript and 
prevents stalling of Pol II transcriptional machinery. The effect of these proposed molecular 
events would lead to elevated SLUG transcript levels, as shown by RNA-Seq, and validated 
by qRT-PCR and western blot. 
High throughput experiments utilizing Pol II ChIP-Seq (Guenther et al., 2007, Muse et 
al., 2007, Zeitlinger et al., 2007) and global run-on sequencing (GRO)-Seq to assess sites of 
active transcription (Core et al., 2008, Larschan et al., 2011, Min et al., 2011) have revealed 
that Pol II pausing is a widespread and critical rate-limiting step governing gene transcription 
(Kwak and Lis, 2013). The prolonged binding of transcription factors, along with Pol II stalling 
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contributes to maintenance of an open chromatin structure, and is therefore a feature of 
active, highly-regulated genes (Fuda et al., 2009, Gilchrist et al., 2010, Jonkers and Lis, 
2015). Assessment of TBX3 binding sites across the genome has identified a significant 
overlap with Pol II binding sites from the ENCODE database; this may be inherent due to 
close associations with transcription factors and Pol II, and/or a byproduct of promoter array 
usage and enrichment of promoter binding sites which are also occupied by Pol II. 
This identified TBX3 binding site in the SNAI2 gene contains a DHS region, which is 
associated with open and transcriptionally active chromatin. DHS is often used as markers 
of cis-regulatory elements including promotors, enhancers, and silencers (Lewin et al., 2011). 
The ENCODE DNase-Seq datasets revealed a high degree of overlap of DHS regions for 
the TBX3 binding site across a panel of 125 diverse cell and tissue types (identified in 41/125 
cell lines) (Thurman et al., 2012). This region may therefore act as an enhancer and regulate 
transcription of the SNAI2 gene through binding of various co-activators and/or transcription 
factors such as TBX3. Enhancers are cis-regulatory elements that promote transcription of 
nearby gene(s) through binding of trans-activating transcription factors, and by interacting 
with proximal regulatory factors through chromatin looping mechanisms (Lewin et al., 2011). 
While enhancers play a modest role on transcriptional initiation, they are able to increase 
elongation efficiency (Krumm et al., 1993, Yankulov et al., 1994, Krumm et al., 1995). The 
process of enhanced transcriptional elongation may be mediated through 3D chromatin 
looping, which brings promoters and enhancers into close proximity, attracting transcription 
factors and promoting continuation of transcriptional elongation (Ghavi-Helm et al., 2014, 
Heinz et al., 2015, Jonkers and Lis, 2015). Some transcription factors (such as MYC and 
NFKB) are also able to increase Pol II efficiency through recruiting elongation factors 
(Yankulov et al., 1994, Rahl et al., 2010, Danko et al., 2013, Diamant and Dikstein, 2013, 
Kwak and Lis, 2013). TBX3 may therefore regulate expression of SLUG through the 
promotion of transcriptional elongation of SLUG transcripts, and prevention of Pol II stalling. 
Further studies are needed in order to substantiate this hypothesis, as association with 
enhancers and non-promoter binding of TBX3 have not been reported. 
TBX3 may also promote SLUG expression through indirect mechanisms as well. As 
degradation of SLUG is induced through binding of p53 and p21CIP1 (Kim et al., 2014), direct 
down-regulation of p21CIP1 by TBX3 may also result in reduced degradation of SLUG. 
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5.4 TBX3 in precursor lesions – CCLs and DCIS 
My findings from Chapter 3 represent the first study to assess TBX3 expression by 
immunohistochemistry separately in various cell compartments, and the first in-depth TBX3 
IHC study in breast cancer. Elevated expression of EMT-transcription factors, including 
TBX3, SLUG and TWIST1 in CCLs was an interesting and unexpected finding. CCLs, and 
particularly the FEA variant, are on a histological continuum with ADH, DCIS and IDC, 
representing the earliest morphological precursor in the LG breast cancer progression 
pathway (Wellings and Jensen, 1973, Wellings et al., 1975, Lee et al., 2006, Abdel-Fatah et 
al., 2008, Feeley and Quinn, 2008, Turashvili et al., 2008). As such, CCLs possess increased 
levels of genomic aberrations including low rates of allelic imbalances relative to 
morphologically normal breast epithelial cells (Simpson et al., 2005, Dabbs et al., 2006, 
Turashvili et al., 2008, Bürger et al., 2013, Bombonati and Sgroi, 2011), often coexist with 
both precursor lesions (ADH, DCIS) and IDC (Go et al., 2012), and are frequently detected 
as abnormalities on mammographically screening (Lerwill, 2008). It has been demonstrated 
that loss of 16q, an early mutational event associated with progression along the LG breast 
cancer pathway, occurs in similar rates across FEA, ADH and DCIS; the degree of genomic 
instability, however, increases with further progression (O'Connell et al., 1998, Moinfar et al., 
2000, Simpson et al., 2005, Larson et al., 2006, Gao et al., 2009).  
CCLs are typically ER+, PR+, HER2-, and prominently express increased levels of 
Ki67, Bcl2 and cyclin D, thereby promoting a proliferative and anti-apoptotic profile 
(Polosukhin, 1999, Vincent-Salomon, 2003, Tremblay et al., 2005, Simpson et al., 2005, 
Dabbs et al., 2006, Lee et al., 2006, Noel et al., 2006, Bombonati and Sgroi, 2011). 
Interestingly, previous studies have reported increased ER expression in CCLs relative to 
adjacent morphologically normal breast epithelial cells (Tremblay et al., 2005, Lee et al., 
2006, Lee et al., 2007b, Abdel-Fatah et al., 2008). Downstream targets of ER include several 
genes involved in proliferation and apoptosis (Gompel et al., 2000, Anderson and Clarke, 
2004), and it has therefore been suggested that the pro-proliferative and anti-apoptotic profile 
in CCLs may be stimulated by estrogen and mediated through ER (Wellings et al., 1975, Lee 
et al., 2007b). Overexpression of ER-α in breast epithelial cells of transgenic mice results in 
rapid development of hyperplasia and DCIS, with occasional progression to invasive 
carcinoma (Frech et al., 2005). These studies suggest that the effects mediated by estrogen 
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through ER may be partially responsible for the development of CCLs, as well as subsequent 
progression to more advanced lesions (Frech et al., 2005). 
Our group, and others, have shown that TBX3 expression is tightly correlated with ER 
expression (Fan et al., 2004, Fillmore et al., 2010). It is intriguing to speculate whether ER 
and TBX3 are coordinately expressed to similar degrees in precursor lesions of the breast. 
Indeed, the TBX3 promoter possesses multiple half-estrogen response elements (Fan et al., 
2004), and administration of endogenous estradiol induces expression of TBX3 (Fillmore et 
al., 2010). Additionally, TBX3 is required for the formation of ER+ mammary epithelial cells 
(Kunasegaran et al., 2014), showing reciprocal induction of gene expression between TBX3 
and ER. The reported benefits of anti-estrogen therapies such as tamoxifen for patients with 
precursor lesions (Fisher et al., 1999, Esteva and Hortobagyi, 2004, Allred et al., 2012, 
Coopey et al., 2012) may work, in part, through inhibition of TBX3 expression at this early, 
critical stage of tumorigenesis. While this is only speculative, more work is needed in order 
to fully establish this link, including examination of TBX3 expression in epithelial cell 
compartments (FEA, ADH and DCIS) in patients who have undergone treatment with 
tamoxifen.  
Aside from up-regulation of ER expression, there is currently limited knowledge 
regarding transcriptional profiles of CCLs. Through micro-dissection of histologically normal 
epithelial cells and CCLs, Lee et al. conducted microarray analysis in order to examine 
changes in gene expression profiles and associated molecular pathways altered in CCLs 
(Lee et al., 2007b). They reported that CCLs frequently reactivate pathways involved in 
embryonic development and suppress pathways involved in terminal differentiation (Lee et 
al., 2007b). My finding of elevated expression of EMT transcription factors, particularly the 
estrogen responsive transcription factor TBX3 with critical roles in development, is in 
agreement with the aforementioned studies. In addition to the high throughput transcriptional 
studies, my IHC studies have shed light on the elevated expression of EMT transcription 
factors in CCLs, including TBX3, SLUG and TWIST1. It is possible that TBX3 is inducing 
expression of SLUG and TWIST1 at this early stage of progression, as expressions of all 
aforementioned markers is coordinately elevated. Although associations in expression has 
been shown in vitro, this may not necessarily hold true in vivo. Sophisticated experiments 
involving temporal induction of TBX3 in mouse mammary glands, and assessment of induced 
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genes at various stages may be the best way to answer this experimental question. While 
one may obtain correlational data through assessment of expression of particular markers 
through IHC, one cannot conclude that direct transcriptional up-regulation of particular genes 
is occurring in a particular lesion in vivo. 
The prevailing view is that activation of a single oncogene is insufficient to drive cancer 
progression; cooperation with other oncogenes and/or mutational events is frequently 
employed by EMT transcription factors in the process of malignant transformation (Ansieau 
et al., 2008, Smit and Peeper, 2010, Morel et al., 2012, Tran et al., 2012, Puisieux et al., 
2014). For example, while TBX3 expression on its own is usually not enough to impart 
malignant properties to genomically stable cells, overexpression of MYC or oncogenic H-
RasVal17 with TBX3 (but not by themselves), protects cells from apoptosis through inhibition 
of p14ARF (Carlson et al., 2002). Additionally, up-regulation of EMT transcription factor 
reduces the number of genetic events required for malignant transformation of breast 
epithelial cells, allowing cells to overcome onco-suppressive mechanisms (Morel et al., 2012, 
De Craene and Berx, 2013, Puisieux et al., 2014). Increased ER expression and downstream 
signaling is also permissive for the accumulation of genetic alterations (Lee et al., 2007b). 
The aforementioned processes, acting together and regulated by TBX3, may lead to 
promotion of an EMT phenotype at early stages, and allow for full progression to IDC.  
Expression of TBX3, SLUG and TWIST1 is up-regulated in CCLs and maintained in 
some DCIS lesions, and may impart additional properties associated with induction of 
invasiveness. In my evaluation of DCIS lesions with and without associated invasion, there 
was no difference in TBX3 expression between Stage 0 and Stage I samples. I did, however, 
observe a strong positive correlation between TBX3 expression in the DCIS lesion and size 
of the invasive focus. Importantly, I showed that elevated TBX3 expression within LG DCIS 
was associated with larger invasive carcinomas across Stage I cancers. While TBX3 itself 
was not useful in predicting invasion, it may have an association with the degree of 
invasiveness, as observed in my IHC, functional and molecular studies. These findings 
suggests that there are potentially other co-factors that may be acting in concert with TBX3 
in the promotion of invasiveness.  
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Interestingly, pathway analysis of transcripts altered by both TBX3iso1 and TBX3iso2 
revealed significant enrichment of proteases and protease inhibitors. This transcriptional 
event is particularly important at the pre-invasive stage, as focal disruption of the basement 
membrane has been shown to coincide with the dissolution of the myoepithelial cell layer and 
progression of DCIS to IDC (Man et al., 2003, Hu et al., 2008). Proteases secreted by tumor 
cells are able to progressively destroy the basement membrane, which leads to dissolution 
of the myoepithelial cell layer (Hu et al., 2008). This is important, as additional mutations 
within tumor cells of DCIS are not required for progression; the loss of basement membrane, 
myoepithelial cell dissolution, and loss of epithelial cell organization and polarity is sufficient 
to promote this transition (Hu et al., 2008). Previous studies have reported that MMP14 is 
amongst the main regulators of the basement membrane transmigration process in vivo 
(Hotary et al., 2006), likely through activation of MMP2 (Duffy et al., 2000). Through my 
studies I have shown that overexpression of TBX3 isoforms results in increased MMP14 
expression, and induction of MMP14 is dependent on SLUG. Additionally, I have shown that 
overexpression of both TBX3 isoforms is associated with increased activity of MMP2.  
In conclusion, I have proposed a unique pathway in which TBX3 promotes progression 
through advancement of low-grade DCIS to invasive carcinoma, as depicted in Figure 3.3.6 
of Chapter 3. This model is particularly relevant in patients with ER+, non-high grade 
precursor lesions (CCL, DCIS), in which overexpression of TBX3 induces other molecular 
regulators of EMT (including SLUG and TWIST1). Additionally, TBX3 up-regulates 
expression of several proteases (i.e. MMP9, MMP14, uPa), and down-regulates expression 
of several protease inhibitors (i.e. CST6). These transcriptional changes mediated by TBX3 
set the stage for basement membrane breakdown and invasion into adjacent stroma. Further 
studies are needed in order to assess whether TBX3 expression may provide reliable risk 
stratification for patients diagnosed with DCIS. This may potentially be conducted in concert 
with multiple biomarkers and/or multi-parameter gene expression assays in order to increase 
predictive and/or prognostic value. 
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5.5 TBX3 in IDC 
I have demonstrated significant differences in tumorigenicity between the TBX3 
isoforms through nude mouse xenograft experiments, which was a surprising and novel 
finding. Although existing literature has focused solely only one isoform of TBX3 (often the 
clone used is not specified), a few existing studies have suggested that the two TBX3 
isoforms have differential functionality (Stennard et al., 1999, Fan et al., 2004, Lee et al., 
2007a, DeBenedittis and Jiao, 2011, Zhao et al., 2014). Through mining of differences in 
transcriptional profiles between TBX3iso1 and TBX3iso2 overexpressing cells and 
conducting pathway analysis, I have reported that overexpression of TBX3iso1 is associated 
with a pro-angiogenic gene signature.  
The effects mediated by TBX3 isoforms with regard to EMT and promotion of 
invasiveness were identical throughout my findings in Chapter 2 and Chapter 3. Due to these 
similarities, along with an absence of commercially available isoform-specific antibodies for 
TBX3, I focused on total TBX3 protein expression in my IHC study. While I have shown that 
expression of total TBX3 levels are up-regulated in early stages of breast cancer progression, 
the relative abundance of each isoform is unknown. As TBX3iso1 is associated with the 
promotion of angiogenesis, it may therefore be helpful at later stages of tumor development. 
The process of angiogenesis is vital for tumor growth, since solid cancers must form 
a blood supply if they are to grow beyond 1-2 mm in size; tumor vascularization thus allows 
for acquisition of nutrients, oxygen perfusion, and systemic spread (Hanahan and Weinberg, 
2000, Knowles and Selby, 2005). Indeed, the xenograft tumors formed by TBX3iso1 
overexpressing cells were highly vascular, as gauged by microvascular density counts. As 
observed by in vitro tubule formation assays, pro-angiogenic soluble factors are released 
from cells overexpressing TBX3iso1 that are functional in activating endothelial cells. On the 
contrary, conditioned media from cells overexpressing TBX3iso2 had similar effects on 
endothelial cells as the empty vector control. Importantly, TBX3iso1 (but not TBX3iso2) is 
able to up-regulate expression of OPN and HAS2, and lead to increased pericellular HA 
retention. The aforementioned transcriptional changes were robust and observed across 
three cell lines, with expression of OPN and HAS2 often down-regulated with overexpression 
of TBX3iso2. It is well documented that elevated levels of OPN and HA within the 
microenvironment are able to promote angiogenesis in vivo through binding of OPN (via 
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integrins, CD44) and HA (via CD44) on endothelial cells, thereby promoting their migration, 
proliferation, and vascular channel formation (Brooks et al., 1994, Senger et al., 1996, 
Trochon et al., 1996, Griffioen et al., 1997, Arap et al., 1998, Scatena et al., 1998, Bayless 
et al., 2000, Savani et al., 2001). These binding and downstream signaling events leading to 
vascularization are permissive to tumor growth, and likely allowed for the observed 
exponential growth of tumors. Based on the kinetics of tumor growth which I reported in 
Chapter 4, as well as well as my findings of the pro-angiogenic function of TBX3iso1, the 
enhanced growth and tumorigenicity is likely due to the process of angiogenesis. This is in 
agreement with the findings of Shirinifard et al., who conducted 3D simulations of tumor 
growth, reporting that exponential growth of tumor cells at late stages of tumor development 
occurs only in vascularized tumors, whereas tumor growth in avascular tumors did not 
exceed linear growth values (Shirinifard et al., 2009). Further studies are required for 
elucidation of differential targets of TBX3iso1 and TBX3iso2, and assessment and validation 
of which direct targets downstream of TBX3iso1 may be responsible for up-regulation of pro-
angiogenic factors and thus vascular channel formation by endothelial cells. 
My mining of the TCGA breast cancer dataset has revealed a transcriptional shift in breast 
cancer progression, with increased TBX3iso1/TBX3iso2 expression in cancer tissues relative to 
normal breast tissue. This shift of increased TBX3iso1 expression was associated with several 
clinicopathological parameters, including high grade and more aggressive breast cancer 
subtypes. Interestingly, these are the opposite characteristics identified for TBX3 expression in 
breast cancer. I believe that this splice shift is due to changes in upstream splicing machinery, 
as several splice regulatory proteins are up-regulated in breast cancers (Watermann et al., 2006, 
Huang et al., 2007, Skotheim and Nees, 2007, Venables et al., 2008). Differences in breast 
cancer specific alternative splicing events have been observed between grade 1 and grade 3 
breast tumors as well, with a distinct trend towards exon loss of several transcripts in ER- tumors 
(Venables et al., 2008). These splicing changes were not associated with differences in combined 
expression of alternatively spliced transcripts (and as such TBX3 expression is low in ER- tumors) 
(Venables et al., 2008). It has been strongly suggested that functional selection for oncogenic 
splice variants occurs within tumors (Venables et al., 2008), and enhanced expression of 
TBX3iso1 may be an adaptive oncogenic mechanism. While the splice factors which are 
associated with an elevated TBX3iso1/TBX3iso2 ratio are unknown, they appear to be 
associated with aggressive breast tumors. 
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5.6 Future Studies 
To summarize, I have identified that the transcriptional regulator TBX3 is highly expressed in 
precursor lesions of the breast including CCLs and DCIS, in a manner similarly implicated in 
the context of other cancer types (Fan et al., 2004, Hansel et al., 2004, Lomnytska et al., 
2006, Lyng et al., 2006, Rodriguez et al., 2008, Yarosh et al., 2008, Cavard et al., 2009, 
Gudmundsson et al., 2010, Souter et al., 2010, Witte, 2010, Begum and Papaioannou, 2011, 
Miao et al., 2016). TBX3 expression is elevated in ER+, PR+, low-grade breast cancers, and 
is significantly associated with the degree of invasiveness in Stage I breast tumors. These 
studies have provided critical information regarding the stages in which expression of 
nuclear-localized TBX3 is up-regulated in cancer cells, and may be transcriptionally active in 
the promotion of tumorigenesis within the breast. Based on my IHC studies, TBX3 appears 
to be promoting progression of precursor lesions (CCLs, DCIS) through the low-grade 
molecular pathway.  
Further exploration of possible target genes that are regulated by and downstream of 
TBX3 isoforms should be conducted in order to identify and validate direct targets which are 
critical to cellular invasion. These gene products may themselves be potential targets for 
breast cancer therapy. This may include validation of identified cell-cycle proteins and/or 
mediators of EMT (such as SLUG) in other breast cancer cell lines, and further validation in 
cell lines representing other cancer subtypes. Initial validation in a breast cancer context is 
important, as functional effects mediated by TBX3, as well as direct transcriptional targets, 
are often described as context-dependent and may vary across cancer subtypes (Willmer et 
al., 2016a, Zhu et al., 2016, Willmer et al., 2017). 
An important follow-up experiment to my findings would be micro-dissection of the 
DCIS cross-sections (Stage 0 and Stage I) which express high vs. low TBX3 to assess for 
enrichment of transcripts associated with elevated TBX3 expression and invasiveness. 
Importantly, elevated TBX3 expression in DCIS of Stage I breast cancer samples is 
associated with the degree of invasiveness. Critical information may therefore be obtained 
through these transcriptional profiling experiments, which may link elevated and co-ordinate 
expression of TBX3 and another potential co-factor with invasiveness of breast cancers. 
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As I have reported significant differences between TBX3 isoforms in the promotion of 
angiogenesis and in vivo tumorigenesis, high-resolution analysis of differential transcriptional 
targets of TBX3iso1 and TBX3iso2 is required to elucidate which genes may be responsible 
for mediating this phenotype, with emphasis on genes involved in facilitating up-regulation of 
OPN (as TBX3iso1 does not directly bind the SPP1 gene). Additionally, as the T-box domain 
facilitates several protein-protein interactions (Hoogaars et al., 2008, Lu et al., 2010), there 
are likely differences in which proteins TBX3iso1 and TBX3iso2 interact with. This has been 
suggested by limited studies (Zhao et al., 2014), but would be interesting to explore further. 
While these studies likely do not possess immediate translatable findings, they would be 
important in fully understanding the functional differences between TBX3 isoforms.  
In conclusion, my thesis research has established that TBX3 is an important mediator 
of invasiveness in early-stage breast cancers. My proposed model is particularly relevant for 
luminal A breast cancers, which represents approximately 70% of all breast cancer 
diagnoses (Howlader et al., 2014). My findings will permit further understanding of expression 
profiles of precursor lesions, including CCLs and DCIS. An understanding of such molecular 
alterations and associated transcriptional profiles is essential in order to provide prognostic 
and predictive information regarding the propensity to progress to IDC, thereby avoiding 
progression to stages associated with reduced survival. Decisions regarding clinical 
management should be done on a per-patient basis based on the intrinsic characteristics of 
the tumor. Assessment of TBX3 expression, isoform ratios, and/or downstream signaling 
pathways in patients with low-grade DCIS may aid in this endeavor, although validation and 
follow-up studies are required. The validation cohort would be very important, as the single 
study which assessed the natural progression of LG DCIS across a median of 31 years 
highlighted that the risk of invasive recurrence is greatest within the first fifteen years after 
diagnosis (Sanders et al., 2005). Critical information may therefore be obtained through these 
profiling experiments, which may link elevated and co-ordinate expression of TBX3 and 
another potential co-factor with invasiveness of breast cancers. 
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 Appendices 
6.1 Chapter 3 – Supplementary Data 
 
 
 
 
 
Appendix 1 – TBX3 protein expression in 21NT transfectant and 21MT-1 transductant 
cell lines. 
 (A-C) Western blot analysis showing total TBX3 protein levels in generated stable cell lines. 21NT 
cells were transfected to overexpress TBX3iso1 or TBX3iso2, or transfected with an empty vector 
(EV) control. 21MT-1 cells were transduced with either shLUC (luciferase; off-target control) or 
shTBX3. Protein samples were separated by 10% SDS-PAGE and quantified by densitometry. 
Protein levels were normalized to Vinculin, which served as the loading control.  
*p<0.05, **p<0.01, ***p<0.001 by one-way ANOVA with Tukey post-hoc for comparison between 
three groups, and Student’s t-test for comparison between two groups.  
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Appendix 2 – Phenotypic assessment of TBX3 overexpressing cell lines. 
(A) Assessment of migration in 2D in 21NT transfectant cell lines. A scratch was produced in a 
confluent monolayer of cells, and migration of cells into the scratch area was monitored at 0, 12 and 
24 hours post-scratch. Migration was quantified as ratio of wound area filled at 0 and 12 hours, and 
normalized to the empty vector control. (B) Cell-cell adhesion assay. Cells were harvested and re-
suspended in media containing either 3mM EDTA or 1mM CaCl2 and incubated in a petri dish at 37ºC 
for 30 minutes with gentle agitation. Clusters containing over 4 cells were counted across 10 fields of 
view. (C) 21NT cells were transiently transfected with either a TBX3iso1 or TBX3iso2 plasmid 
containing a ZsGreen reporter, or empty vector control expressing ZsGreen. CDH1 was visualized 
using a red-fluorescently labeled antibody. CDH1 signal was quantified by counting pixels within the 
red channel of ZsGreen positive transfected cells. 
*p<0.05, **p<0.01, ***p<0.001 by one-way ANOVA with Tukey post-hoc for comparison between 
three groups. 
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Appendix 3 - Effect of TBX3 overexpression on invasiveness in cell lines representing 
other breast cancer molecular subtypes. 
The invasive ability of TBX3 transfectant lines was assessed using Matrigel-coated transwell inserts. 
(A-C) T-47D (luminal A), SKBR3 (HER2-enriched), and MDA-MB-468 (basal-like) cells were 
transfected with either an empty vector (EV), or TBX3iso1, or TBX3iso2 construct within the 
pZsGreen1-N1 vector containing a ZsGreen reporter. Twenty-four hours post-transfection, 50,000 
cells were added to the upper chamber of an 8.0µm pore transwell insert coated with Matrigel and 
allowed to invade for 18 hours. The number of green cells per field of view was used in the analysis. 
*p<0.05, **p<0.01, ***p<0.001 by one-way ANOVA with Tukey post-hoc for comparison between 
three groups. 
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Appendix 4 – Assessment of EMT markers in TBX3 overexpressing cell lines. 
(A) The mRNA expression of several EMT markers was evaluated by qRT-PCR. Expression 
was normalized to GAPDH expression levels, and depicted as fold change relative to the 
empty vector control. (B) Conditioned media was concentrated and resolved on a 10% 
zymogram gelatin gel. The gel was renatured and developed, and size of the proteolyzed 
bands was quantified by densitometry using the reverse image (as shown). Active (82 kDa) 
vs. inactive (pro-) MMP9 (92 kDa), and active (63 kDa) vs. inactive (pro-) MMP2 (72 kDa) 
were identified by molecular weight. 
*p<0.05, **p<0.01, ***p<0.001 by one-way ANOVA with Tukey post-hoc for comparison 
between three groups. 
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Appendix 5 – Protein class analysis of direct transcriptional targets of TBX3. 
The 194 genes directly bound by both TBX3 isoforms in ChIP-array data and whose transcript 
levels were significantly altered in expression by RNA-Seq (>1.5 fold up or down, FDR<0.05) 
were analyzed using the PANTHER database, conducting over-representation analysis and 
focusing on protein class. Protein classes with the lowest p-values are shown. P-values were 
calculated by comparing expected numbers compared to input numbers in the gene list.  
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6.2 Chapter 3 – Immunohistochemistry Quality Control 
As shown in Appendix 6-9, stringent quality control measures were used for all IHC-based 
quantifications. For TBX3 expression specifically, I conducted cell fractionation experiments 
through isolation of cytoplasmic and nuclear fractions by ultracentrifugation, followed by 
immunoblotting cellular fractions of 21PT and 21NT transfectants, and 21MT-1 transductants 
(Appendix 6). Although these examples represent isogenic cell lines and cellular fractionation 
was not conducted on other cell lines representing different molecular subtypes from different 
patients, we observed exclusive nuclear localization of TBX3 in cell fractionation experiments 
as well as in IHC. While TBX3 is a transcription factor and is expected to be located to the 
nucleus, a few studies have reported cytoplasmic expression of TBX3 by IHC in colorectal 
cancer, pancreatic cancer, and HNSCC (Burgucu et al., 2012, Shan et al., 2015, Wang et 
al., 2015). Lomnytska et al. reported elevated levels of truncated TBX3 protein in the plasma 
of breast cancer and ovarian cancer patients, in which they suggested that TBX3 is mis-
localized in cancer tissues and leaks out of cells and into plasma (Lomnytska et al., 2006).  
One of the most important aspects of reliable IHC staining is antibody selection, 
requiring new optimization depending on each new batch or clone, and selecting conditions 
that offers the highest contrast of true positive signal over background (Yaziji and Barry, 
2006, Matos et al., 2010). We have conducted thorough optimization of TBX3 IHC protocols, 
utilizing several commercially-available antibodies (Abcam, ab99302, rabbit polyclonal (used 
for study); Abcam, 154828, rabbit monoclonal; Invitrogen, 42-4800, rabbit polyclonal; Sigma, 
HPA005799, rabbit polyclonal). Several parameters have been considered, including antigen 
retrieval time and buffer components, antibody and concentration, blocking steps, etc. until a 
clean staining pattern with minimal background was achieved. Unfortunately, IHC staining 
patterns observed are a direct result of the staining optimization process, and improper 
localization can be observed without thorough optimization and proper positive and negative 
controls (Matos et al., 2010). Several of the aforementioned conditions (and remaining 
antibodies) gave high levels of background staining along with a consistent brown ‘blush’ in 
carcinoma cells, the extent which I believe is artifactual. It is a common rule that when the 
subcellular and micro-anatomical location of the protein of interest is known, the 
immunoreactivity pattern obtained for IHC studies should follow this distribution (Seidal et al., 
2001). While I cannot exclude that cytoplasmic TBX3 expression is not associated with any 
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clinicopathological parameters, we focused exclusively on nuclear-localized TBX3 for 
quantification purposes, as this is where TBX3 is active in regulating transcription. SLUG and 
TWIST1 IHC optimization and quantification of expression was conducted in the same 
manner as TBX3. 
Expression of TBX3, SLUG and TWIST1 was assessed in the same area across serial 
sections in a control slide (Appendix 7, Appendix 8), and expression was assessed for each 
run to ensure reproducible results and therefore eliminate potential confounding variables 
(Appendix 9). For each of the markers, I quantified expression in benign non-columnar 
epithelial cells, CCLs, DCIS, and in the invasive carcinoma. This mode of assessment is 
particularly strong and enhances our understanding of distribution of markers in a cell-
specific context. Additionally, the use of full slides allows for observation of expression 
patterns along a larger area and therefore minimizes sampling bias associated with tumor 
heterogeneity which is inherent in the use of tissue microarrays (Rubin et al., 2002, 
Besusparis et al., 2016). Lastly, I used semi-automated computer-assisted image analysis 
for my quantification of biomarker expression due to the ease and efficiency of use, as well 
as its documented association with increased accuracy and reproducibility when compared 
to manual quantification methods (Cross, 2001, Lehr et al., 2001, Umemura et al., 2004, Diaz 
and Sneige, 2005, Matos et al., 2010).  
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Appendix 6 – TBX3 expression in nuclear and cytoplasmic fractions of 21T cells. 
Cellular fractionation and analysis of TBX3 expression in nuclear and cytoplasmic 
compartments of (A) 21PT, (B) 21NT, and (C) MT-1 cell lines. The 21PT and 21NT cell lines 
were stably transfected with either an empty vector (EV), TBX3iso1 or TBX3iso2 
overexpressing plasmid. Total TBX3 expression was knocked down in 21MT-1 
transductants; the shTBX3 clone with highest knockdown is shown. Nuclear fractions are 
shown by histone H4 expression, and cytoplasmic fractions are shown by vinculin. 
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Appendix 7 – ImmunoRatio analysis of TBX3 expression in benign and columnar 
breast epithelium. 
Scanned digital slides of TBX3, SLUG and TWIST1 immunohistochemically stained slides 
were quantified for nuclear expression of each marker using ImmunoRatio. TBX3 expression 
by IHC in benign and columnar breast epithelial cells, and the associated quantification 
process is shown. The process consisted of four major steps: (1) Images of tissue 
compartments were acquired, and included benign non-columnar cells, benign columnar cell 
lesions (CCLs; includes columnar cell change, columnar cell hyperplasia or flat epithelial 
atypia), DCIS and invasive cancer. (2) Stromal cells, necrotic areas, and cells outside of the 
compartment in question were cropped out using ImageJ in order to solely analyze 
expression of markers in the cell type of interest. (3) The faint background signal was 
removed using ImageJ in order to bring out blue hematoxylin stain of negative nuclei. (4) The 
ImmunoRatio plugin for ImageJ was used to quantify percentage of nuclei positive for each 
marker. A control slide representing serial sections was included for each run (with 
quantification and statistical analysis) to ensure identical and reproducible staining for each 
run. 
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Appendix 8 – ImmunoRatio analysis of TBX3 expression in DCIS and IDC. 
Scanned digital slides of TBX3, SLUG and TWIST1 immunohistochemically stained slides 
were quantified for nuclear expression of each marker using ImmunoRatio. TBX3 expression 
by IHC in DCIS and IDC, and the associated quantification process is shown. The process 
consisted of four major steps: (1) Images of tissue compartments were acquired, and 
included benign non-columnar cells, benign columnar cell lesions (CCLs; includes columnar 
cell change, columnar cell hyperplasia or flat epithelial atypia), DCIS and invasive cancer.  
(2) Stromal cells, necrotic areas, and cells outside of the compartment in question were 
cropped out using ImageJ in order to solely analyze expression of markers in the cell type of 
interest. (3) Faint background signal was removed using ImageJ in order to bring out blue 
hematoxylin stain of negative nuclei. (4) The ImmunoRatio plugin for ImageJ was used to 
quantify percentage of nuclei positive for each marker. A control slide representing serial 
sections was included for each run (with quantification and statistical analysis) to ensure 
identical and reproducible staining for each run. 
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Appendix 9 – Quality control of TBX3 staining by immunohistochemistry. 
A control slide representing serial sections was included for each IHC run. Images were 
acquired of the same DCIS across serial section, and quantification was conducted as 
described in Materials and Methods (Chapter 3) and shown in Appendix 8. Expression of 
markers was graphed, and statistical analysis were conducted in order to ensure identical 
and reproducible staining for each run. If expression of markers was statistically different in 
the control slide, quantification was not conducted, and the batch of slides was re-stained 
until a similar staining pattern was observed. 
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6.3 Chapter 4 – Supplementary Data 
 
 
 
Appendix 10 – Expression of VEGFR2 by qRT-PCR. 
The mRNA expression of VEGFR2 was assessed across 21NT transfectant cell lines by 
qRT-PCR, normalized to GAPDH expression levels, and depicted as fold change relative to 
the empty vector control. 
*p<0.05, **p<0.01, ***p<0.001 by one way ANOVA with Tukey post-hoc for comparison 
between three groups. Error bars represent standard deviation. 
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Appendix 11 – TBX3 expression in stable transfectant cell lines. 
(A) Total TBX3, TBX3iso1 and TBX3iso2 expression was assessed by qRT-PCR in 21PT 
stable transfectant cell lines, normalized to GAPDH expression levels, and depicted as fold 
change relative to the empty vector control. (B) Total TBX3, TBX3iso1 and TBX3iso2 
expression was assessed by qRT-PCR in MCF7 stable transfectant cell lines, normalized to 
GAPDH expression levels, and depicted as fold change relative to the empty vector control. 
*p<0.05, **p<0.01, ***p<0.001 by one way ANOVA with Tukey post-hoc for comparison 
between three groups. Error bars represent standard deviation. 
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Appendix 12 – Assessment of TBX3 isoform expression in TCGA and GTEx datasets. 
TBX3iso1 and TBX3iso2 expression levels were assessed across tumor types in which TBX3 
overexpression has been documented (breast cancer, melanoma, colon, and pancreatic 
cancer). Isoform percentage is shown along the top axis, with TBX3 isoform expression 
shown in tumors (The Cancer Genome Atlas, TCGA; purple hills) and normal tissues 
(Genotype Tissue Expression Project, GTEx; blue hills). Data was assessed using 
XenaBrowser (www.xenabrowser.net). 
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